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Methamphetamine is a psychomotor stimulant that produces hyperactivity and euphoria and can 
lead to drug-seeking and abuse. An estimate from 2005 put the cost of methamphetamine 
abuse to society at an estimated 23.4 billion dollars. One of methamphetamine's effects is 
activation of glial cells and associated neuroinflammatory activity in the periphery and CNS.  
Glia are responsible for maintaining calcium homeostasis, neuroplasticity, immune activity, and 
cell signaling. Activation of glia and neuroinflammation are becoming recognized as links in drug 
abuse-related behavior. The goal of the present work was to assess the ability of ibudilast, 
AV1013, and minocycline, three glial cell modulating compounds, to attenuate responding in 
rodent procedures that model different aspects of methamphetamine abuse-related behavior.  
First, Ibudilast (1.8, 7.5, 13 mg/kg) and AV1013 (10, 30, 56 mg/kg) were examined for their 
effects on methamphetamine-induced (3 mg/kg) locomotor activity and sensitization in mice, the 
xiii 
 
 
 
latter thought to involve neurocircuitry common with drug relapse. Ibudilast and AV1013 dose-
dependently attenuated methamphetamine-induced locomotor activity and its sensitization. 
Second, ibudilast (1, 7.5, 10 mg/kg), AV1013 (1, 10, 30 mg/kg), and minocycline (10, 30, 60 
mg/kg) were examined for their effects on methamphetamine self-administration (0.001, 0.03, 
and 0.1 mg/kg/inf) in rats.  All three compounds significantly reduced methamphetamine (0.03 
mg/kg/inf) self-administration. Results suggested baseline self-administration rate as a possible 
determinant of these effects; however, follow-up tests with ibudilast while controlling for baseline 
response rate dismissed this possibility. Additional follow-up tests identified whether the 
attenuation of operant response rates was specific to methamphetamine-maintained behavior. 
Using a behavioral economic approach, all three test compounds were determined to also affect 
non-nutritive banana pellet-maintained responding when the baseline strengths maintained by 
methamphetamine and banana pellet delivery were matched.  Finally, ibudilast was evaluated 
for its effects on methamphetamine discrimination in rats, a procedure thought to model clinical 
subjective effects. Ibudilast (1, 7.5, 10 mg/kg) did not significantly modify methamphetamine’s 
discriminative stimulus effects when trained at either 1 or 0.56 mg/kg. These results support the 
hypothesis that attenuation of glial cell activity and neuroinflammation may be linked to some 
abuse-related behaviors of methamphetamine, reinforcing their examination as novel targets for 
treating methamphetamine abuse. 
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Chapter I: INTRODUCTION 
 
Background and Significance 
Methamphetamine abuse 
Methamphetamine is a psychomotor stimulant and is classified as a Schedule II 
controlled substance in the United States (Control, 2012). Methamphetamine abuse is 
widespread and detrimental to both society and the individual. In 2010, amphetamine type 
stimulant abuse prevalence was ranked second only to cannabis worldwide with an estimated 
14.3 to 52.5 million users (Crime, 2012). Methamphetamine use continues to be consistently 
high in Asia and the market for methamphetamine is increasing in parts of Europe (Norway, 
Germany, Sweden, Finland, and other Scandinavian countries) (Crime, 2012). Although 
estimates for current users in the United States were down from 731,000 in 2006 to 353,000 in 
2010, there still were approximately 105,000 young users who reportedly tried 
methamphetamine for the first time (SAMHSA, 2010).  Additionally, with the increase in 
methamphetamine seizures in the US, new methods for methamphetamine production by 
clandestine laboratories has been increasing rapidly (Crime, 2012). Geographically, 
methamphetamine abuse in the US is most prevalent in the western states in country/farm 
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regions (Johnston, 2011), whereas methamphetamine clandestine laboratory incidents almost 
exclusively occur in Midwestern states (i.e. Kentucky, Tennessee, Missouri, Indiana) (DEA, 
2012).  In 2005, methamphetamine abuse cost society an estimated 23.4 billion dollars, largely 
due to premature death and productivity losses, drug treatment and health care, criminal justice, 
and cleanup of toxic chemicals from methamphetamine production (Nicosia et al., 2009; 
Watanabe-Galloway et al., 2009) 
Centrally, methamphetamine increases motor activity, libido, alertness, and feelings of 
euphoria (Peachey et al., 1976; MacKenzie & Heischober, 1997; Winslow et al., 2007) by 
interacting with the monoaminergic dopamine, serotonin, and norepinephrine neurotransmitter 
systems (Creese, 1983; Cho & Segal, 1994). Peripherally, dopaminergic, alpha- and beta-
adrenergic stimulation leads to increased heart rate, blood pressure, force contraction, and 
arterial and venous vasoconstriction (Lynch & House, 1992; MacKenzie & Heischober, 1997).  
The perceived positive effects of elevated mood states and increased physical output, can lead 
to drug-seeking and chronic abuse (Everitt & Robbins, 2005; Vanderschuren & Everitt, 2005).  
Chronic methamphetamine abuse is associated with a range of centrally and peripherally 
mediated toxicities (Lynch & House, 1992; Chuck et al., 1996; MacKenzie & Heischober, 1997; 
Hamamoto & Rhodus, 2009).  
Central nervous system (CNS) toxicity associated with chronic methamphetamine use 
include agitation, insomnia, psychosis, paranoia, and visual and tactile hallucinations 
(MacKenzie & Heischober, 1997).  Also, the spontaneous recovery of methamphetamine 
psychosis and paranoid hallucinatory states (i.e. flashbacks) in the absence of drug, can be 
elicited by mild stressors and are associated with increased plasma norepinephrine levels 
underscoring methamphetamine’s ability to sensitize noradrenergic hyperactivity (Yui et al., 
1997; Yui et al., 2000).  
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Peripherally, cardiac problems as a result of chronic methamphetamine abuse are wide-
ranging.  Dysrhythmias, myocardial infarcts, hypertension, congestive heart failure, vasculitis, 
cardiomyopathy, and cardiac muscle lesions have all been cited as outcomes of chronic use 
(Lynch & House, 1992; He et al., 1996). Dental disease is also a significant outcome, as 
methamphetamine abusers commonly have tooth decay, wear from grinding, and decreased 
salivary flow (Hamamoto & Rhodus, 2009). Interestingly, dental disease is not a product of 
smoking the drug because intravenous methamphetamine users are more likely to have missing 
teeth than users who smoked (Shetty et al., 2010). Corneal ulceration, known as keratitis, has 
been associated with chronic methamphetamine usage as well (Chuck et al., 1996; Poulsen et 
al., 1996). Finally, methamphetamine’s immune suppression peripherally increases abusers’ 
vulnerability to pathogens and infection (Harms et al., 2012). Methamphetamine-related 
hepatitis has been reported although most cases of hepatitis observed in methamphetamine 
users are contracted virally (Davis et al., 1970).  Similarly, methamphetamine abuse has high 
rates of co-morbidity with human immunodeficiency virus (HIV) and an exacerbation of its 
effects, including increasing viral load and neurocognitive impairment (Carey et al., 2006; 
Theodore et al., 2006; Toussi et al., 2009; Wang et al., 2012b; Wires et al., 2012; Blackstone et 
al., 2013).  
Methamphetamine-related deaths are most often caused by coronary heart disease and 
subarachnoid hemorrhage (Karch et al., 1999), but may also be caused by seizure, stroke, liver 
or lung disease (MacKenzie & Heischober, 1997; Karch et al., 1999). Thus, it is clear that 
methamphetamine’s widespread abuse is costly to both society and to the user’s health 
underscoring the need for a treatment approach for methamphetamine stimulant abuse.      
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Current treatments 
Some behavioral intervention programs can reduce methamphetamine abuse. The 
Matrix Model integrates a variety of treatment approaches including individual therapy, relapse 
prevention and family education groups, urine testing, and participation in a 12-step program 
(Rawson et al., 1995) and is successful in reducing methamphetamine usage and sustaining 
abstinence for up to two years (Obert et al., 2000). Contingency Management (CM) programs in 
which the participant receives monetary or prize rewards for sustained abstinence also 
decreases positive methamphetamine urine samples from methamphetamine abusers (Roll et 
al., 2006).  Furthermore, CM alone and in combination with cognitive behavioral therapy (CBT) 
significantly reduces methamphetamine use and sexual behaviors in gay and bi-sexual men 
when compared to standard CBT or gay-specific social support therapy alone (Shoptaw et al., 
2005; Shoptaw et al., 2008). Other interventions such as Acceptance and Commitment 
Therapy, which emphasizes observation, thinking, and mindfulness/acceptance exercises, as 
opposed to avoidance, reduce methamphetamine abuse to a similar degree as CBT (Smout et 
al., 2010) and presenting repeated within-session multi-modal (picture, video, in-vivo) drug-
related cues diminish methamphetamine cue-elicited craving (Price et al., 2010). While these 
treatments can be successful in time, they require individualized therapy and close monitoring 
by the counselor as well as knowledgeable personnel and adequate funding (Rawson et al., 
2002; Kay-Lambkin, 2008). As such, discovering an effective pharmacotherapy to reduce 
methamphetamine abuse may serve as a vital complement to behavioral interventions to 
increase methamphetamine abstinence.  
In order to identify potential targets for an effective pharmacotherapy, a close 
examination of methamphetamine’s neurochemical effects is required. While most research 
efforts have focused on targeting the bioamine receptors to develop pharmacotherapeutic 
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agents, for they are the direct mediators of methamphetamine's abuse-related effects (see 
below), those efforts have not been successful (Karila et al., 2010). For instance, compounds 
involving varied bioamine receptor activity such as bupropion, modafinil, and aripiprazole, have 
had poor efficacy (Brackins et al., 2011). Thus, while an understanding of methamphetamine’s 
classical neuro-receptor mechanisms is important, an expanded examination of its non-receptor 
targets, such as the neuroglia, and how that interaction affects behavior may lead to fresh 
approaches in drug development. 
 
Methamphetamine’s Neurochemical Effects 
Monoamines 
Methamphetamine is best known for interacting with the monoaminergic dopamine, 
serotonin, and norepinephrine neurotransmitter systems (Creese, 1983; Cho & Segal, 1994). 
Amphetamine and methamphetamine work in several ways to increase the concentration of 
monoamines in the synapse promoting increased signaling. First, amphetamines cause a 
reversal of vesicular dopamine and monoamine transporter systems causing non-exocytotic (i.e. 
calcium independent) efflux of dopamine and other monoamines out of vesicles and then out of 
the cell (Liang & Rutledge, 1982; Creese, 1983; Cho & Segal, 1994; Brown et al., 2001; Schmitz 
et al., 2001; Khoshbouei et al., 2003). Amphetamines also reduce dopamine transporter 
function (Fleckenstein et al., 2000) and cause cell-surface dopamine transporter endocytosis, 
likely through a clathrin-mediated pathway (Saunders et al., 2000), which impedes dopamine re-
uptake. Serotonin (5-HT) transporter function is rapidly decreased following acute 
methamphetamine exposure as well, likely through a similar mechanism to dopamine 
transporter down-regulation (Fleckenstein et al., 1999). Conversely, while the norepinephrine 
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transporter is structurally similar to the other two, it is less vulnerable to oxidative inactivation via 
reactive oxygen species (Haughey et al., 1999); instead the norepinephrine transporter’s 
reduction in re-uptake activity is a proposed to be a direct effect of methamphetamine’s (or its 
metabolites’) action on the transporter itself (Haughey et al., 2000). However, the result is 
similar in that there is decreased uptake.    
Under normal physiological conditions, dopamine (D2) auto-receptors, located extra-
synaptically, sense dopamine and its metabolites (i.e. DOPAC and homovanillic acid) and 
decrease dopamine production and release (Cooper et al., 2003). Amphetamines interrupt this 
negative feedback mechanism and enhance dopamine synthesis (Cooper et al., 2003). 
Enhanced dopamine synthesis occurs via methamphetamine-induced increases in tyrosine 
hydroxylase activity to promote the production of dopamine (Mandell & Morgan, 1970; Cooper 
et al., 2003), while concurrently inhibiting monoamine oxidase (MAO), the enzyme that 
degrades monoamines (Green & El Hait, 1980). Thus, methamphetamine’s neurochemical 
actions promote the release of monoamines, prolong the time they are present in the synapse 
by inhibiting re-uptake, and stimulate continued synthesis which results in increased excitation 
and signaling. 
Repeated administrations and/or high doses of methamphetamine are neurotoxic to the 
same monoaminergic systems.  At high doses, methamphetamine decreases tyrosine 
hydroxylase and tryptophan hydroxylase activity, 5-HT concentrations, and dopamine and 5-HT 
transporter function (Buening & Gibb, 1974; Hotchkiss et al., 1979), which is likely due to axonal 
and/or terminal injury (Kogan et al., 1976; Fleckenstein et al., 2000). While the primary 
mechanism of methamphetamine-induced neurotoxicity is still unclear, the presence of 
excessive cytoplasmic and extracellular dopamine levels appears to be necessary to induce 
neurotoxicity (Wagner et al., 1983). Dopamine metabolism produces reactive oxygen species 
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and dopamine quinones which can cause detrimental effects to the nerve terminals (Cadet & 
Brannock, 1998; Yamamoto & Zhu, 1998), inactivate the dopamine transporters (Fleckenstein et 
al., 2000), and induce distinct behavioral responses (Kita et al., 2009). Oxidative inactivation of 
transporters and subsequent nerve injury is also exacerbated by methamphetamine-induced 
hyperthermic effects produced by the drug alone and in conjunction with environmental 
conditions like ambient temperature (Fleckenstein et al., 2000; Kiyatkin & Sharma, 2012). In 
sum, methamphetamine causes a profound effect on the monoaminergic system both acutely 
and chronically, and following repeated or high dose administration methamphetamine can 
cause severe terminal damage and neurotoxicity.  
While most pharmacotherapeutic approaches have focused on these direct mechanisms 
affecting bioamine receptor activity, methamphetamine also has additional, less understood, 
neurochemical effects including those on intracellular cAMP levels and of glial cell activation 
that have both been suggested to play a role in modulating methamphetamine-induced 
behavior.  
Cyclic adenosine monophosphate (cAMP, cyclic AMP or 3'-5'-cyclic adenosine 
monophosphate) 
Methamphetamine-induced increases in synapse monoamine neurotransmitters lead to 
dopamine D1 receptor (D1R) and D2 receptor (D2R) activation. D1R activation is associated 
with an increase in adenylyl cyclase activity, which catalyzes the conversion of ATP to cAMP, 
producing a subsequent increase in cAMP levels; whereas, activation of D2R is associated with 
a decrease in cAMP (Kebabian et al., 1984). As cAMP is a second messenger molecule, these 
alterations in cAMP levels may lead to modulations of downstream signal transmission and 
behavioral effects. Although the activation of the two dopamine receptors work in apparently 
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opposing directions, it has been hypothesized that activation of both D1R and D2R are required 
to produce methamphetamine sensitization and reinforcing effects (Kelly et al., 2008).  
Specifically, with an increase in cAMP levels (through D1R), cAMP-dependent protein 
kinase (PKA) phosphorylates dopamine- and cAMP-regulated neuronal phosphoprotein 
(DARPP-32) at one of several phosphorylation sites (Hemmings et al., 1984) .  Phosphorylation 
of DARPP-32 at the Thr34 residue converts DARPP-32 into a potent inhibitor of another protein 
inhibitor, protein phosphatase-1 (PP-1) (Hemmings et al., 1984). Phosphorylated Thr34-
DARPP-32 dependent signaling is associated with modulating many drug-induced actions 
including behavioral responses mediated through the dopaminergic pathways (Svenningsson et 
al., 2005).  For example, DARPP-32 knockout mice have an attenuated response to 
amphetamine-induced increases in repetitive movements and pre-pulse inhibition 
(Svenningsson et al., 2003) suggesting that DARPP-32 is partially responsible for these 
behaviors. Interestingly, acute administration of amphetamine upregulates Thr34-DARPP-32 
phosphorylation (Svenningsson et al., 2003), while repeated administration of 
methamphetamine produces sensitization and a decrease in Thr34-DARPP-32 phosphorylation 
(Chen & Chen, 2005; Borgkvist & Fisone, 2007).  Methamphetamine also induces an increase 
in the phosphorylation of the transcription factor cAMP response element-binding protein 
(CREB). While CREB plays several roles in behavioral activity as well, an enhancement of 
CREB seems to play a protective role against addiction-like behaviors (Carlezon et al., 2005). 
For example, cocaine-induced up-regulation of CREB in the nucleus accumbens is suggested to 
counter-act the primary effects of cocaine and limit sensitization (Carlezon et al., 2005; Dong et 
al., 2006).  
Because PP-1, the enzyme inhibited by phosphorylated Thr34-DARPP-32, inhibits 
CREB, Thr-34-DARPP-32 and CREB seem to be linked. Furthermore, the previously mentioned 
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studies showing a decrease in Thr34-DARPP-32 phosphorylation following methamphetamine 
sensitization are consistent with CREB’s protective activity role.  That is, with repeated 
administration of methamphetamine, the decrease in phosphorylated Thr34 DARPP-32 
increases PP-1 inhibition activity, thus decreasing CREB’s protective activity to counter-act 
sensitization.   
While the D2R works in the opposite direction at adenylyl cyclase to decrease cAMP 
concentration, D2R stimulation also leads to activation of phospholipase Cβ (PLCβ) via its 
coupling to Gq protein (Yan et al., 1999).  PLC promotes the production of IP3 which in turn 
releases Ca+2 stores (Yan et al., 1999; Hernandez-Lopez et al., 2000) to excite downstream 
targets, suggesting a mechanism for D2R activation to affect behavioral activity. 
Finally, D1R and D2R activation are both necessary to alter synaptic plasticity in the 
striatum which can affect behavioral outcomes such as locomotor activity (Calabresi et al., 
1992; Pollack, 2004).  In fact, heteromerization of D1R and D2R has been shown to lead to the 
activation of Gq protein, PLC, and IP3 inducing a Ca+2 signal (Hasbi et al., 2010).  Ca+2 
signaling activates CaMKII in the rat striatum contributing to synaptic plasticity (Rashid et al., 
2007), and potentiating amphetamine self-administration (Loweth et al., 2008).  Interestingly, 
psychostimulants’ up-regulation of medium spiney neuron spine density in the nucleus 
accumbens is more stable and sustained longer in the D1 receptors over the D2 receptors (Lee 
et al., 2006) implying the downstream effects of D1 activation may be longer lasting. Thus, 
modulation of cAMP levels may be sufficient to attenuate methamphetamine-induced abuse-like 
behaviors through D1’s DARPP-32 and CREB protective actions.  
In addition to its effects on cAMP, methamphetamine also induces glial cell activation 
and pro-inflammatory responses.   
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Glial Cells 
While neuroinflammation is commonly associated with neurodegenerative conditions, 
decades of evidence indicate that some CNS-active drugs can induce neuroinflammatory 
processes via activation of glial cells as well. Glial cells can be separated into two main groups, 
macroglia and microglia. One sub-type of macroglia, astrocytes, are the most prevalent cell type 
in the CNS and have a variety of functions including the response to injury by stimulating pro-
inflammatory cytokine release and immune function activity (Benveniste, 1992). Microglia work 
as macrophages to degrade foreign debris and are also associated with immune response by 
responding to and secreting inflammatory cytokines (Benveniste, 1992). Following 
methamphetamine administration, activated microglia and astrocytes release pro-inflammatory 
cytokines (Yamaguchi et al., 1991; Nakajima et al., 2004a; Goncalves et al., 2008; Loftis et al., 
2011). Methamphetamine increases levels of cytokines and inflammatory factors, such as tumor 
necrosis factor (TNFα), interleukin 6 (IL-6), interleukin 1β (IL-1β) mRNA levels, monocyte 
chemo-attractant protein 1 (MCP-1), and cellular adhesion molecule (ICAM-1) (Yamaguchi et 
al., 1991; Nakajima et al., 2004b; Goncalves et al., 2008).  
How methamphetamine promotes neuroinflammation is not yet known.  As mentioned 
above, dopamine quinones and reactive oxygen species contribute to methamphetamine-
induced cellular damage and apoptosis (Fleckenstein et al., 1997; Zhu et al., 2006). As a result 
of the damaged cells and neurotoxicity, astrocytes and microglia become activated and elicit an 
immune response and increase pro-inflammatory cytokine production (Kita et al., 2008; Clark et 
al., 2012). Environmental factors such as ambient temperature and hyperthermic state of the 
subject can exacerbate the methamphetamine-induced effects of glial activation and damage to 
the blood-brain barrier (Kiyatkin & Sharma, 2012; Kousik et al., 2012). 
  
11 
 
While cell damage and death is a common catalyst for inflammation induction, 
methamphetamine’s effects on inflammatory pathways can also temporally occur before 
dopamine cell terminal pathology (LaVoie et al., 2004).  Thus, methamphetamine-induced 
inflammation can occur at non-neurotoxic levels and independently of cell damage. A 
mechanism has been proposed for methamphetamine-induced inflammation via the nuclear 
transcription factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Shah et al., 2012).  
Methamphetamine’s release of excitatory neurotransmitters activates the metabotropic 
glutamate receptor, mGluR5. The mGluR5 receptor is described to activate the intracellular 
signaling pathway, AKT/PI3K, that downstream induces the release of NF-κB, which, in turn, 
translocates to the nucleus to promote transcription of inflammatory cytokine proteins such as 
TNFα, IL-6 and IL-8 (Shah et al., 2012). 
Interestingly, cAMP levels also modulate microglial cell activation (Ghosh et al., 2012), 
and glutamate derived from glial cells preferentially can act on NMDA extrasynaptic receptors to 
de-phosphorylate CREB and inhibit its protective action (Hardingham et al., 2002).  These 
reports indicate the potential for these two methamphetamine-induced mechanisms (i.e. glial 
cell activation and cAMP modulation) to be associated with one another providing our first links 
among cAMP, glial cell signaling, and drug abuse behavior (D'Ascenzo et al., 2007). 
In sum, methamphetamine’s effects on classic neuronal signaling systems has been well 
defined, however, methamphetamine also causes other neurochemical effects including those 
on cAMP and glial cell activation. While the importance of glial cells in the CNS may have been 
initially overlooked by the scientific community, there is recent evidence to suggest that glia and 
their activation play a significant role in neurotransmission and drug-induced behavior. 
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Importance of Glia 
Nervenkitt  or neuroglia, literally “nerve-glue” in English, were merely considered 
connective tissue that served only as scaffolding between neurons when first identified in the 
early 1900s (Somjen, 1988).  However, in the 1980s one subtype of glial cells, astrocytes, were 
shown to exhibit voltage-gated channels and neurotransmitter receptors leading to increased 
interest in their function (Volterra & Meldolesi, 2005).  Glial cells, specifically astrocytes and 
microglia, are now described as having a significant role in homeostatic processes, 
synaptogenesis and guiding neuronal development, neuroplasticity, and regulating the immune 
responses in the CNS by releasing pro-inflammatory cytokines and chemokines (Volterra & 
Meldolesi, 2005). Glial cells can elicit their own signals, termed gliotransmission, and regulate 
synapse formation and strength via the release of pro-inflammatory cytokines by astrocytes and 
microglia (Lawrence et al., 2007). Activated glial cells have been correlated with altering 
synaptic transmission and drug abuse behavior (Haydon et al., 2009) and an examination of 
glial cell function should highlight the importance of glial cell activity in behavior and suggest a 
unique target for novel drug abuse pharmacotherapies.   
Gliotransmission   
Glial cells can elicit both excitatory and inhibitory signals, known as gliotransmission, 
giving rise to the idea of the tripartite synapse (Araque et al., 1999) in which neurotransmitters 
released from the pre-synaptic neuron not only bind and affect the post-synaptic neuron, but 
also glial cells, which in turn can release their own gliotransmitters or neutralize synaptic 
neurotransmitters.  First, glial cells are activated as they exhibit many ionic and metabotropic 
receptor complexes on their membranes such as those for norepinephrine, glutamate, GABA, 
acetylcholine, histamine, adenosine, and ATP (Haydon & Carmignoto, 2006).  They do not 
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produce action potentials, but rather signal via oscillations in intracellular Ca+2 (Volterra & 
Meldolesi, 2005).  Following activation, glial cells may also release neurotransmitters, known as 
gliotransmitters, glutamate, D-serine, and ATP which may modulate synaptic transmission and 
neuronal excitability (Haydon & Carmignoto, 2006).  For example, release of glutamate from 
glial cells can excite glutamatergic NMDA and AMPA receptors on the post-synaptic neuron 
(Haydon & Carmignoto, 2006; Eroglu & Barres, 2010).  Furthermore, glial cells also play an 
active role in maintaining the extracellular glutamate concentration to prevent excitotoxicity to 
the neurons (Barbour et al., 1988). Thus, neurotransmitter signaling is no longer isolated to 
neuronal receptors.  Further, as a function of chronic gliotransmission signaling, glial cells also 
have the capability to modulate synapses. 
Regulation of synaptic strength by cytokines 
The main processes thought to regulate synaptic plasticity are the cell surface delivery 
and retention of the glutamatergic receptors, NMDA and AMPA (Eroglu & Barres, 2010).  
Interestingly, an up-regulation of the pro-inflammatory cytokine tumor necrosis factor (TNFα) 
elicited from activated astrocytes increases the expression of AMPA receptors on the cell 
surface and increases NMDA receptor and AMPA receptor mediated synaptic currents (Beattie 
et al., 2002; Stellwagen & Malenka, 2006) which subsequently improves synaptic efficacy and 
signal strength.  Conversely, the blockade of TNFα and an increase in brain-derived 
neurotrophic factor (BDNF) will have the opposite effect (Beattie et al., 2002).  A prolonged 
change in this synaptic regulation is known as synaptic scaling which involves changes in the 
synaptic strength based on activity levels.  Importantly, these mechanisms in which 
AMPA/NMDA ratios induce synaptic plasticity are important because they are associated with 
stimulant-induced behavioral responses such as sensitization (Wolf, 1998).  
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Thus, glial cells are capable of much more than providing scaffolding and debris 
removal. Activated glial cells may transmit their own signals as well as regulate synaptic 
strength suggesting that the innate immune system can modulate behaviors that define 
addiction (Crews et al., 2011). While methamphetamine’s effects on glial cells were mentioned 
above, it is not the only drug of abuse that does affect the glia.  
Effects of other drugs on glia 
Of the 12 most widely recognized classes of abused drugs worldwide, half can be 
categorized as producing an anti-inflammatory and the other half an inflammatory profile in the 
CNS (see Table 1). Inflammation is operationally defined here as the induction of CNS 
microglial and/or astrocyte activation as well as the production and release of pro-inflammatory 
cytokines or chemokines. While it cannot be concluded that neuroinflammation is a global 
indicator of drug abuse behavior, an in depth examination of the mechanism by which these 
drugs affect glial activity may reveal a pattern and potentially a mechanistic target. 
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Table 1.  Effects of common abused drugs on glial cell activity and inflammatory markers 
Drug of Abuse Effect on Glial Cells Cytokines/Chemokines Affected 
 
Inflammatory 
 
 
Methamphetamine 
 
 
 
 
Increases 
astrocyte/microglia 
activation  
(Orio et al., 2004; Gekker et 
al., 2006; Bruce-Keller et 
al., 2008; Kita et al., 2008; 
Sharma & Ali, 2008; Yao et 
al., 2010; Clark et al., 2012; 
Zhang et al., 2012; Frau et 
al., 2013) 
 
↑ TNF-a, IL-6, IL-1b, MCP-1, ICAM-1                     
↓ IL-2, IFN-y  
(Yamaguchi et al., 1991; Nakajima et 
al., 2004b; Goncalves et al., 2008; 
Loftis et al., 2011) 
 
MDMA 
 
↑ IL-1b  
(Thomas et al., 2004b; Orio et al., 
2010) 
 
Morphine 
↑ TNFa, IL-1b                                                      
LPS-induced ↑ in TNFa, IL-6, iNOS, 
and NO 
(Sawaya et al., 2009; Berta et al., 
2012; Chen et al., 2012) 
 
Cocaine 
 
↑ TNFa, IL-6, IL-1b, MCP-1 
                              ↓IL-10  
(Gan et al., 1999; Lin et al., 2011; 
Fox et al., 2012) 
 
Ethanol 
 
Increases astrocyte 
activation  
(Miguel-Hidalgo, 2005; 
2006) 
↑ TNFa, IL-6, IL-1b, MCP-1, IFN-y, 
TGF-b, IL-8, IL-10, IL-12, iNOS, 
COX2  
(Blanco et al., 2004; Laso et al., 
2007; He & Crews, 2008)                                                 
↓ GDNF in dependent users 
(Heberlein et al., 2010) 
 
PCP 
Induces microglia  (only 
because high doses are 
neurotoxic)  
(Nakki et al., 1996a; 
Fattorini et al., 2008) 
 
↑ TNFa (with non-toxic PCP doses) 
(Paterson et al., 2006)  
 
Anti-inflammatory 
 
THC 
Activates CB2 receptors on 
microglia  
(Puffenbarger et al., 2000; 
Chung et al., 2011) 
↓ LPS-induced TNFa, IL-6, IL-1b,   
IL-1a  
(Puffenbarger et al., 2000) 
 
LSD 
Suppresses proliferation of 
B-and T-lymphocytes 
↓ IL-2, IL-4, IL-6  
(House et al., 1994) 
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(House et al., 1994; Yu et 
al., 2008) 
 
Benzodiazepines 
Decreases proliferation of 
activated microglia                                               
Increases neuroprotection 
(Wilms et al., 2003) 
↓ TNFa and NO  
(Wilms et al., 2003) 
 
Nicotine 
Inhibits microglial and 
astrocyte activation and 
inflammation                
Increases neuroprotection 
(Ohnishi et al., 2009; Liu et 
al., 2012b) 
↓ TNFa and iNOS  
(De Simone et al., 2005; Ohnishi et 
al., 2009) 
Pentobarbital 
 
↓  TNFa mRNA  
(Yang et al., 2007) 
 
Caffeine 
Inhibits LPS- and ageing- 
induced microglia activation 
(Brothers et al., 2010) 
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Anti-inflammatory Drugs of Abuse 
Δ9-tetrahydrocannabinol (THC)  
THC, an agonist at CB1 and CB2 receptors, has several reported anti-inflammatory 
mechanisms. CB1 and CB2 receptor activation both work to reduce inflammation. A specific 
CB1 agonist (WIN55, 212-2) protects against MPTP-induced dopamine neurotoxicity, microglial 
activation, cytokine release, and oxidative damage (Chung et al., 2011) and CB2 receptors on 
microglia inhibit inflammatory processes downstream (Puffenbarger et al., 2000). THC can also 
bind to peroxisome proliferated activated receptor (PPAR) receptors, nuclear receptors which 
act as transcription factors to affect gene expression which could potentially affect inflammation 
(Granja et al., 2012).  Agonists of PPAR-y reduce lipopolysaccharide (LPS)-induced microglial 
activation, cytokine, and prostaglandin E2 (PGE2) release that would activate astrocytes for a 
secondary reaction (Granja et al., 2012). Furthermore, THC can directly affect transcription 
factors and genes, such as STAT1, STAT3, and Socs3 to cause even more anti-inflammatory 
signal (Kozela et al., 2010).  Finally, because THC is highly lipophilic, THC is hypothesized to 
inhibit LPS-induced inflammation and cytokine release by disrupting the plasma membrane 
fluidity and thereby inhibiting the activation of TLR-4 receptor by LPS (Puffenbarger et al., 
2000). Thus, THC’s anti-inflammatory activity is multi-modal and works at several levels of the 
cell to inhibit the glial activation.     
Nicotine 
Nicotine’s effects are also anti-inflammatory. Nicotine decreases immune cell responses 
both peripherally and centrally (Shi et al., 2009). Peripherally, nicotine decreases inflammation 
by altering the activity of T-cells (Shi et al., 2009). Centrally, neurons, astrocytes, and microglia 
have all been shown to exhibit nicotinic acetylcholine receptors (Shi et al., 2009), and activation 
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by nicotine can suppress TNFα production by microglia and exert a neuroprotective role against 
thrombin cytotoxicity (Ohnishi et al., 2009). Similarly, nicotine pretreatment significantly 
suppresses LPS-induced microglial activation and TNFα mRNA expression in vivo and in vitro 
through α7 nicotinic receptors and protects dopamine neurons (De Simone et al., 2005; Park et 
al., 2007). Nicotine also suppresses LPS and MPP+- induced astrocyte activation in vitro via a 
reduction in TNFα release, extracellular regulated kinase 1/2 (Erk1/2) and p38 activation (Liu et 
al., 2012b).     
As far as mechanism, nicotine is proposed to attenuate CNS inflammation by reducing 
NF-κB and c-myc activation by inhibiting MAP kinases through the α7 nAChR (Liu et al., 2007), 
and that stimulation of the α7 nAChR is necessary for the inhibition of astrocytes and 
inflammation by cholinergic agonists (Liu et al., 2012b). 
Benzodiazepines 
The translocator protein (18 kDa)(TSPO), also known as peripheral benzodiazepine 
receptor, is present in the CNS and its expression increases upon injury or inflammation (Chen 
& Guilarte, 2008). Specific ligands for TSPO (Ro-5-4864 and R-PK11195) increase reactive 
oxygen species (ROS) and  IL-1β production, however both ligands inhibit ATP-induced 
inflammation indicating that TSPO ligands have anti-inflammatory properties in the presence of 
activated microglia (Choi et al., 2011).  Bezodiazepines bind to TSPO and decrease the 
proliferation of activated microglia, the release of NO, and TNFα in vitro which is thought to also 
increase neuroprotection (Wilms et al., 2003).  
Barbiturates 
While there is an apparent absence of reports regarding the barbiturates’ direct effects 
on astrocytes and microglia activation, pentobarbital has been shown to suppress TNFα mRNA 
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expression in vivo and protect cells from TNFα-induced apoptosis in vitro (Yang et al., 2007).  
Additionally, thiopental inhibits NF-kB by suppressing IkB kinase activity (Loop et al., 2003), 
however the “thio” group (sulfur atom at the C2 position) was likely a structural requirement for 
NF-kB inhibition (Loop et al., 2003) qualifying the potential for a common effect among all 
barbiturates.   
Lysergic acid diethylamide (LSD) 
As a strong partial agonist at the 5-HT2A receptor, LSD suppresses proliferation of B-
lymphocytes, production of IL-2, IL-4, and IL-6 cytokines, and the induction of cytotoxic T-
lymphocytes in vitro (House et al., 1994).  Similarly, activating the 5-HT2A receptor with the 
receptor-specific agonist, (R)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane ((R)-DOI) 
inhibits TNFα and its pro-inflammatory markers ICAM-1, VCAM-1, IL-6, NO synthase, and NF-
κB (Yu et al., 2008) indicating that 5-HT2A receptors are involved in an anti-inflammatory 
response.  However, these reports are limited to peripheral inflammation, and LSD has not yet 
been linked to microglial or neuroinflammatory signaling. 
Caffeine 
Caffeine antagonizes both the adenosine A1 and A2A receptors pre-synaptically, which 
increases glutamate signaling (Solinas et al., 2002), and attenuates LPS- and aging-induced 
microglial activation (Brothers et al., 2010).  Caffeine enhances astrocyte and microglial 
reactivity following exposure to MDMA, however it was proposed that the gliosis was likely due 
to hyperthermia as a result of MDMA neurotoxicity that was exacerbated by caffeine (Khairnar 
et al., 2010).  
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In sum, while it seems THC, nicotine, benzodiazepines, barbiturates, LSD, and caffeine 
all exhibit some anti-inflammatory effects and most attenuate glial activation, there is currently 
not a common mechanism by which these drugs work.  Conversely, there are a number of 
drugs that cause inflammatory effects similar to methamphetamine’s effects on glial cells.  
Inflammatory Drugs of Abuse 
 The following drugs of abuse all exhibit neuroinflammatory profiles as reported in the 
literature, and the body of evidence to support the hypothesis that glial cell activation and 
inflammation play a role in addiction-like behaviors is growing rapidly (Miguel-Hidalgo, 2009; 
Coller & Hutchinson, 2012).  Thus, an examination of the effects on CNS inflammation induced 
by these drugs, as well as the potential mechanisms involved, may provide insight for common 
targets for potential pharmacotherapies. 
MDMA (3, 4-methylenedioxy-N-methylamphetamine) 
MDMA induces microglial activation and the release of IL-1β (Orio et al., 2004; Thomas 
et al., 2004a; Orio et al., 2010; Frau et al., 2013). MDMA has also been shown to induce 
astrocyte activation, however, this was only after MDMA first induced hyperthermia, cellular 
injury, and disruption of the blood-brain barrier (BBB), suggesting that astrocyte activation is a 
consequence of earlier MDMA induced toxic events (Sharma & Ali, 2008).  Conversely, while 
microglial activation was correlated with MDMA hyperthermia (Frau et al., 2013), it was not 
dependent upon it, indicating independent mechanisms (Orio et al., 2004).   
MDMA’s potential mechanism may be linked to the A2A adenosine receptor system. The 
A2A receptor antagonist, SCH 58261, attenuates MDMA-induced increases in NF-κB mRNA and 
protein levels (Kermanian et al., 2013) indicating an anti-inflammatory effect. Furthermore, A2A 
receptor knock-out mice exhibit decreases in microglial and astrocyte activation following 
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MDMA administration and less MDMA self-administration compared to their wild-type littermates 
(Ruiz-Medina et al., 2011). Interestingly, CB1 and CB2 receptor systems have also been shown 
to modulate MDMA-induced microglia and astrocytes and protect against MDMA neurotoxicity. 
For example, a CB2 agonist as well as THC significantly inhibits MDMA-induced microglial 
activation and IL-1β release (Torres et al., 2010; Tourino et al., 2010). THC’s neuroprotective 
role against MDMA requires both CB1 and CB2 receptors to be present (Tourino et al., 2010), 
as CB1 receptors attenuate MDMA hyperthermia and CB2 receptors attenuate the inflammatory 
response (Tourino et al., 2010).    
Phencyclidine (PCP) 
Acute, non-neurotoxic doses of PCP produce a regionally specific (prefrontal cortex 
only) decrease in TNFα levels (Paterson et al., 2006). In contrast, high doses of ketamine (80 
mg/kg), PCP (10 and 50 mg/kg), and MK-801 (5-10 mg/kg) all induce microglial activation, 
however this effect is likely due to neuronal injury, damage, and cell death (Nakki et al., 1995; 
Nakki et al., 1996b; Nakki et al., 1996c). Glutamatergic NMDA receptors are present on 
microglial cells and which can be activated with kainic acid (Eriksson et al., 2000). Further, the 
resulting cytokine mRNA production may be attenuated by MK-801 (Eriksson et al., 2000) 
suggesting that NMDA receptor activation may be an important player in glial cell activation and 
inflammatory actvity.   
Ethanol 
Chronic ethanol up-regulates iNOS, COX2, and IL-1β in cultured astrocytes, and up-
regulates NF-κB and AP-1 signaling (Blanco et al., 2004; Valles et al., 2004).  In humans, 
ethanol produces increases in IL-1β, IL-6, TNFα, and IFN-γ cytokine levels (Laso et al., 2007), 
and elevation of MCP-1 levels in the VTA, substantia nigra, hippocampus, and amygdala were 
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found in post-mortem alcoholics’ brain tissue (He & Crews, 2008) indicative of increased pro-
inflammatory signaling. Alcohol’s major metabolite, acetaldehyde, also induces NF-κB mediated 
IL-1β and TNFα expression indicating that the pro-inflammatory response is most likely a 
combined effect of ethanol and its metabolites (Hsiang et al., 2005).  Furthermore, serum levels 
of the neurotrophic factor GDNF are decreased in alcohol dependent subjects (Heberlein et al., 
2010), reducing neuroprotection.  
While ethanol withdrawal increases astrocyte proliferation in the prefrontal cortex 
(Miguel-Hidalgo, 2005; 2006), some neuroprotective factors are also up-regulated. In humans 
GDNF and BDNF serum levels become escalated in early withdrawal and are associated with 
lower withdrawal scores and lower alcohol tolerance scores (Heberlein et al., 2010) indicative of 
some recovery.  
Ethanol-induced inflammatory signaling in astrocytes is a consequence of up-regulating 
p65 activity, a transcription factor involved in the NF-κB signaling pathway (Davis & Syapin, 
2004). Ethanol also activates the TLR4 receptor by inducing its translocation to lipid rafts in 
astrocytes, which enhances the same NF-κB signaling pathway downstream (Blanco & Guerri, 
2007; Szabo et al., 2007; Blanco et al., 2008). In microglia, ethanol induces this activation and 
translocation of TLR4 as well as TLR2 receptors to lipid rafts (Fernandez-Lizarbe et al., 2013). 
The hetero-dimerization of TLR4 to TLR2 potentiates ethanol’s inflammatory effect (Fernandez-
Lizarbe et al., 2013) suggesting that microglia enhance the inflammatory signal induced by 
astrocytes. 
Finally, LPS-induced inflammation, via TLR4 receptor activation, increases alcohol 
consumption in mice (Blednov et al., 2011). Genetic knockouts of the TLR4 receptor, on the 
other hand, are protected against ethanol-induced inflammation, locomotor activity, memory and 
anxiety, and epigenetic changes (Pascual et al., 2011), indicating that the TLR4 receptor and its 
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downstream signaling pathways are vital components of ethanol’s inflammatory and behavioral 
effects.   
Cocaine 
 Cocaine’s inflammatory profile does not seem to be nearly as extensive as the other 
drugs of abuse.  Cocaine up-regulates IL-1β from astrocytes, IL-6, and TNFα expression, and 
down-regulates IL-10 (Gan et al., 1999; Cearley et al., 2011; Lin et al., 2011; Fox et al., 2012).  
Cocaine also increases BBB permeability, enhancing monocyte migration across the barrier 
inducing ICAM-1 and VCAM-1 expression (Fiala et al., 1998).  Cocaine’s induction of MCP-1 
and enhancement of HIV are regulated through the sigma-1 receptor which is present on 
microglia (Gekker et al., 2006; Yao et al., 2010).  Also, withdrawal from cocaine has an effect on 
astrocytes themselves as suggested by the induction of GFAP following three weeks of 
abstinence, indicative of astroglial plasticity (Bowers & Kalivas, 2003).   
 Mechanistically, there is no direct evidence linking cocaine’s effect on glial cells or 
inflammation and the TLR4 receptor as with alcohol and morphine.  However, chronic cocaine 
increases NF-κB induction in the nucleus accumbens (Ang et al., 2001) and has been 
implicated in playing a direct role in cocaine’s abuse and sensitization by inducing increases in 
dendritic spine densities to alter neuronal plasticity (Russo et al., 2009). Another proposed 
mechanism for cocaine’s effect on glial cells involves the glutamatergic systems.  mGluR5 
receptors, which are present on astrocytes, become activated by extracellular glutamate 
released by cocaine administration. Then, astrocytes generate Ca+2 signaling cascades 
inducing a prolonged stimulus associated with selectively activated NR2B-containing 
extrasynaptic neuronal NMDA receptors (D'Ascenzo et al., 2007; Fellin et al., 2007) implicating 
gliotransmission’s role in altering cocaine-induced behaviors.  Furthermore, mice lacking the 
mGluR5 gene do not exhibit cocaine-induced locomotor activity increases nor do they reliably 
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self-administer cocaine (Chiamulera et al., 2001).  Interestingly, the activation of astrocytic 
mGluR5 receptors and of NF-kB pathways is similar to the proposed mechanism of 
methamphetamine’s action and it is linked to abuse-like behaviors.   
Morphine 
Similar in breadth to methamphetamine's neuroinflammatory activity, morphine activates 
astrocytes and microglia and up-regulates the production of many pro-inflammatory cytokines in 
the CNS (Bruce-Keller et al., 2008; Zhang et al., 2012).  Morphine up-regulates cytokines such 
as TNF-α, IL-1β, IL-6 mRNA levels in the nucleus accumbens, medial pre-frontal cortex, and 
dorsal root ganglia (Sawaya et al., 2009; Berta et al., 2012; Chen et al., 2012) and increases 
LPS-induced expression of the same cytokines via the mu opioid receptor located on microglial 
cells and the protein kinase C (PKC) pathway (Merighi et al., 2013).  Furthermore, one of 
morphine’s metabolite’s, morphine-3-glucoronide, activates TLR4 and causes microglial 
activation and the release of IL-1β (Lewis et al., 2010) indicating that opioids’ metabolites 
contribute to their inflammatory action as well.   
Mechanistically, similar to ethanol, morphine has been suggested to require TLR2 
receptors for its inflammatory action, as TLR2 receptor knock-out mice do not exhibit morphine-
induced microglial activation, cytokine release, and have attenuated morphine withdrawal 
symptoms relative to wild types (Zhang et al., 2011).  Also, a study utilizing a small interfering 
RNA (siRNA) directed against p65, an element of the NF-kB signaling pathway, indicated that 
morphine-induced TNFα release was NF-κB pathway dependent (Sawaya et al., 2009).  
Activation of the PKC pathway stimulates AKT upstream of ERK 1/2 and iNOS (Merighi et al., 
2013) which is the same AKT pathway that stimulates NF-kB induction in the proposed 
mechanism of methamphetamine-induced glial cell activation (Shah et al., 2012; see 
discussion). Interestingly, CB2 receptor activation attenuates morphine-induced inflammation by 
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interfering with the AKT-ERK 1/2 pathway suggesting that activation of CB2, and the inhibition 
of microglial activation and subsequent downstream inflammatory effects, may increase the 
clinical efficacy of opioids (Merighi et al., 2013).   
Also similar to methamphetamine’s effects, opioids are also involved in increasing the 
phosphorylation of DARPP-32 and DARPP-32’s link to behavioral effects and synaptic plasticity 
(Mahajan et al., 2009). Finally, morphine’s glial cell activation and pro-inflammatory action is 
also associated with its behavioral effects.  Astrocyte-conditioned medium (i.e. activated 
astrocytes) increases morphine-induced CPP when injected into the nucleus accumbens (Narita 
et al., 2006).  
In sum, the drugs of abuse that have exhibited neuroinflammatory profiles share some 
aspects of their proposed mechanisms of action.  For example, both ethanol and morphine have 
been shown to require both TLR2 and TLR4 receptor activation to induce NF-kB to promote 
cytokine production (Zhang et al., 2011; Fernandez-Lizarbe et al., 2013), and cocaine, 
morphine, and methamphetamine have all been linked to activation of mGluR5 receptor and 
AKT pathway activation to induce NF-kB (D'Ascenzo et al., 2007; Shah et al., 2012; Merighi et 
al., 2013).  Thus, perhaps a common mechanism of action preludes a common mechanistic 
target for attenuating the downstream effects of these drugs and the behaviors they induce.  
 
Novel approaches to attenuate drug abuse-like behavior 
As mentioned above, methamphetamine’s regulation of cAMP levels in the brain are 
implicated in mediating many of its behavioral effects such as methamphetamine-induced 
hyperactivity, sensitization, and drug discrimination. Phosphodiesterase (PDE) degrades cAMP 
(Beavo, 1995); so compounds that block PDE, will increase cAMP levels and could, 
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consequentially, cause a change in methamphetamine-induced behaviors. Rolipram (a PDE 
inhibitor) increases cAMP levels in the brain and dose dependently attenuates 
methamphetamine-induced hyperlocomotion (Iyo et al., 1995; Iyo et al., 1996a; Iyo et al., 1996b; 
Mori et al., 2000). In addition, rolipram and nifiracetam (another PDE inhibitor) attenuate 
methamphetamine discrimination in mice (Yan et al., 2004; Yan et al., 2006). Thus, compounds 
that influence cAMP levels may be potential methamphetamine pharmacotherapies that should 
be tested in animal models. Methamphetamine also influences glial cells, suggesting another 
therapeutic target. 
Glial cell attenuating compounds have been shown to prevent increases or cause 
decreases in up-regulated cytokines and chemokines in brain regions associated with opioid 
withdrawal such as the ventral tagmental area and nucleus accumbens (Hutchinson et al., 
2009a), block morphine-induced CPP (Narita et al., 2006; Hutchinson et al., 2009a; Hutchinson 
et al., 2009b), and block morphine and oxycodone spontaneous and precipitated withdrawal 
signs (Hutchinson et al., 2009a).  Developing evidence indicates that attenuating glial activation 
can reduce methamphetamine-induced behavioral effects (Narita et al., 2006; Zhang et al., 
2006; Fujita et al., 2012).  Correspondingly, an enhancement of neuroprotective growth factors, 
like glial cell derived neurotrophic factor (GDNF), blocks cocaine (Green-Sadan et al., 2003; 
Green-Sadan et al., 2005) and methamphetamine self-administration and vulnerability towards 
reinstatement and sensitization (Niwa et al., 2007c; Yan et al., 2007) and attenuates morphine 
CPP and morphine sensitization (Niwa et al., 2007a; Niwa et al., 2007b).  
Finally, the initial component of methamphetamine’s proposed mechanism of glial cell 
activation is the activation of the mGluR5 receptor. Activation of mGluR5 receptors, which are 
present on glial cells (Miller et al., 1995), can lead to inflammatory downstream processes 
(Shah et al., 2012), while mGluR5 antagonism attenuates on-going cocaine and 
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methamphetamine self-administration as well as cue-and drug-induced reinstatement 
(Chiamulera et al., 2001; Gass et al., 2009). Thus, both PDE inhibition, up-regulation of 
neuroprotective neurotrophic factors, and anti-inflammatory activity all attenuate 
methamphetamine-induced abuse-like behaviors.  
Compounds of Interest 
Ibudilast (AV411) 
Ibudilast (3-isobutyryl-2-isopropylpyrazolo-[1, 5-a] pyridine) is a pyrazole-pyridine small 
molecule which has a broad range of functions. Ibudilast is approved clinically to treat asthma 
and post-stroke dizziness in Japan and is well tolerated in humans (Rolan et al., 2008; Rolan et 
al., 2009).  Ibudilast is a non-selective phosphodiesterase (PDE) inhibitor for PDEs 3, 4, 10, and 
11 (Kishi et al., 2001; Gibson et al., 2006) and is a glial cell modulator and anti-inflammatory 
agent which attenuates LPS-induced nitric oxide release, reactive oxygen species, TNF-a, IL-
1b, and IL-6 production (Suzumura et al., 1999; Mizuno et al., 2004; Rolan et al., 2009). 
Ibudilast is also a potent inhibitor of macrophage migration inhibitory factor (MIF) (Cho et al., 
2010) and it attenuates LPS-induced microglial production of the chemokine MCP-1 (Ledeboer 
et al., 2007).  
Ibudilast enhances neuroprotective function by increasing the production of the anti-
inflammatory cytokine, IL-10, and neurotrophic factors such as GDNF, nerve growth factor 
(NGF), and neurotrophin (NT-4) (Mizuno et al., 2004).  Ibudilast is also neuroprotective against 
glutamate toxicity by reducing Ca+2 influx (Tominaga et al., 1996). Separately, PDE inhibition 
and glial cell modulation have already been reported to reduce drug abuse activity, as described 
above. Thus, ibudilast’s effects could be a result of any or a combination of all these 
mechanisms. Ibudilast has been reported to decrease opioid dependence and withdrawal signs 
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(Ledeboer et al., 2007; Hutchinson et al., 2009a), attenuate morphine-induced dopamine 
release in the nucleus accumbens (Bland et al., 2009), and CPP reinstatement in rats (Schwarz 
et al., 2011). Importantly, ibudilast attenuates prime- and cue-induced reinstatement of 
methamphetamine-maintained responding (Beardsley et al., 2010) further supporting the 
hypothesis that PDE inhibition and/or glial cell modulation can alter methamphetamine-induce 
behaviors.  
AV1013 
AV1013 ((R)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one 
hydrochloride) is an amino analogue of ibudilast which exhibits similar glial attenuating actions 
as ibudilast, but is impotent at inhibiting PDE (Cho et al., 2010). A characterization of AV1013’s 
effects on methamphetamine-induced behaviors could suggest whether modulation of glial cell 
activity is sufficient to have target effects without PDE inhibition. 
Minocycline Hydrochloride 
Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline), a second generation, 
semi-synthetic tetracycline derivative, is indicated as a treatment for numerous infections due to 
gram-positive and gram-negative micro-organisms including severe acne, some sexually 
transmitted diseases, respiratory tract infections as well as some more serious conditions 
including syphilis, anthrax, and plague (FDA, 2010).  In addition to minocycline’s anti-microbial 
action, its anti-inflammatory and neuroprotective functionality have implicated it as a potential 
therapeutic for disorders including dermatitis, periodontal disease, rheumatoid arthritis, CNS 
pathologies, neuropathic pain, inflammatory bowel disease, and allergic asthma (Garrido-Mesa 
et al., 2013).  Minocycline significantly attenuates microglial activation (Sriram et al., 2006; 
Zhang et al., 2006) and suppresses LPS-induced TNFα, IL-6, IFN-γ  and chemokines such as 
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IL-8, MCP-1, and interferon inducible protein (IP)-10 via inhibition of IKKα/β phosphorylation, a 
component of the NF-κB signaling cascade (Tai et al., 2013).  Minocycline also attenuates the 
biochemical effects of some drugs of abuse as it decreases NF-κB, IL-1β, and microglial 
activation induced by MDMA (Orio et al., 2010) and significantly attenuates ethanol-induced up-
regulation of IκBα protein levels (Wu et al., 2011).   
Minocycline attenuates drug-induced behavioral effects as well.  Minocycline suppresses 
methamphetamine and cocaine-induced hyperlocomotion and sensitization (Zhang et al., 2006; 
Chen et al., 2009a) and prevents methamphetamine conditioned place preference (CPP) (Fujita 
et al., 2012). Minocycline reduces morphine-induced respiratory suppression, attenuates 
morphine CPP, enhances morphine analgesia (Hutchinson et al., 2008; Zhang et al., 2012), 
attenuates tolerance to morphine analgesia (Cui et al., 2008) and decreases alcohol 
consumption in mice (Agrawal et al., 2011).  Finally, psychotic symptoms following 
methamphetamine use are improved by minocycline in humans (Tanibuchi et al., 2010). Thus, 
there is some previous evidence that PDE inhibition and glial cell modulation is related to drug 
abuse-related behavior.  Given that ibudilast, AV1013, and minocycline alter several of these 
novel molecular targets, it is important to assess whether they could attenuate 
methamphetamine induced abuse-like behaviors in several animal models of drug abuse.  
Animal Models of Drug Abuse 
There are a number of laboratory animal procedures that have face and/or predictive 
validity for clinical drug abuse disorders that can be useful when evaluating potential 
pharmacotherapies. While there is not one model that alone predicts drug abuse or its blockade 
by a compound, studying the effects of compounds on several animals models of 
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methamphetamine abuse provides a fuller profile of their ability to attenuate abuse-like 
behaviors.  
Locomotor Activity 
First, methamphetamine, as a stimulant, elicits hyperactivity following administration 
(Peachey et al., 1977). There are several ways to measure methamphetamine-induced 
hyperactivity in rodents. Methods include recording stereotypies such as repeated rearing, 
continuous sniffing or head bobbing, or tracking ambulatory behavior by measuring an animal’s 
total distance traveled in an open field (Hall, 1934; Iyo et al., 1995; Kuribara, 1997; Buccafusco, 
2001; Tatsuta et al., 2006). For example, acute methamphetamine-induces hyperactivity.  When 
wistar rats are administered 4 mg/kg methamphetamine (i.p.) it produces a significant increase 
of distance traveled measured by almost 40,000 locomotor counts/hr  compared to less than 
300 counts/hr in the vehicle group (Iyo et al., 1995). Importantly, following repeated 
methamphetamine administration its hyperlocomotion effect becomes more pronounced (i.e. 
sensitized) (Nishikawa et al., 1983; Hirabayasi et al., 1991; Iyo et al., 1996b). For example, 
animals challenged with 2 mg/kg methamphetamine following once-daily injections of 4 mg/kg 
methamphetamine for 5 days show twice as great an increase in locomotor activity counts 
compared to those who had received saline vehicle for the 5 days (Iyo et al., 1996a; Iyo et al., 
1996b). 
Sensitization has been postulated to play a key role in drug addiction in humans 
(Strakowski & Sax, 1998; Sax & Strakowski, 2001; Chen et al., 2009b), and the adaptations of 
specific brain regions implicated in the process of sensitization have been associated with 
reward pathways linked to drug-seeking and addiction (Robinson & Berridge, 1993). 
Furthermore, sensitization phenomena interacts with similar neurocircuitry, neurotransmitter and 
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receptor systems as those activated during reinstatement in models of drug abuse (Steketee & 
Kalivas, 2011) implicating its association with craving and drug relapse. Thus, perhaps if 
sensitization may be attenuated pharmacologically, the potential for relapse may been 
attenuated as well. In sum, hyperactivity after acute methamphetamine administration and 
sensitization after repeated administration can be modeled in rodents, and provide a valuable 
tool for the study of drug addiction. 
Self-administration 
Drug use may be generated in laboratory animals using drug self-administration 
procedures in which responses (such as lever pressing) result in drug administration (Schuster 
& Thompson, 1969; Thompson & Pickens, 1970). Intravenous (i.v.) methamphetamine self-
administration in rats is well-established in our laboratory (e.g. Shelton & Beardsley, 2008; 
Beardsley et al., 2010). Aside from the assay’s strong face validity for modeling drug-taking 
behavior, self-administration procedures may be used to measure the ability of test compounds 
to alter the reinforcing efficacy of an abused drug (Mello & Negus, 1996). In fact, several 
compounds have been reported to reduce methamphetamine self-administration in rats (Ranaldi 
& Poeggel, 2002; Neugebauer et al., 2007; Reichel et al., 2009).  Thus, methamphetamine i.v. 
self-administration is a well-established model of drug-taking behavior in rats, and should 
provide a strong model of drug abuse-related behavior to test the effects of glial cell modulators. 
Given the results obtained with self-administration studies alone, sometimes the 
identification of the determinants and range of conditions for observing self-administration 
effects is also important. Two potential variables that may influence the effects of test 
compounds on drug self-administration are the response rate and response strength of the 
drug-maintained baselines. 
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Response Rate 
Response rate dependency holds that a drug’s effects may differentially affect behavior 
based on initial baseline rates of behavior. For example, Dews (1955) reported that a dose of 
pentobarbital can increase low rates, but the same dose can decrease high rates of schedule 
controlled behavior. Thus, a drug’s effect on behavior is a function of the control response rate. 
A response rate control procedure controls for and determines whether a treatment compound’s 
effects are rate dependent by maintaining the response rate for all conditions equal to determine 
a change in behavior following test compound administration.   
Behavioral Economics 
The behavioral economic approach applies consumer demand theory to behavioral 
psychology (Hursh, 1984). Consumer demand theory examines the relationship between price 
and demand for a commodity, while behavioral economics examines the relationship between 
an operant, such as lever presses, and total consumption of a reinforcer. The equation log Q= 
log Q0 + k(e
-αP – 1) developed by Hursh (1984) includes several variables, Q, Q0, k, P, and α, 
used to generate a demand curve.  Variable Q indicates total or normalized consumption of the 
reinforcer, Q0 is consumption of the reinforcer when the price is set to zero, k is a constant that 
specifies the range of the dependent variable in logarithmic units, P is the price of the 
commodity, and α is a rate constant indicating the rate of change in elasticity of the demand 
curve (Hursh & Silberberg, 2008). The demand curve itself indicates total consumption of a 
particular reinforcer as a function of increasing price.  The elasticity of the curve’s descent with 
increasing price indicates the amount to which the subject will defend responding for the 
particular reinforcer at higher prices (Hursh, 1984). Thus, when examining the demand curve for 
a particular reinforcer, the rate of change in elasticity of the demand curve (α level) becomes an 
important dependent variable.  “Less elasticity”, and a small α level, can be interpreted as “more 
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reinforcing” per this approach because consumption behavior continues even at high prices 
(Hursh, 1984; Hursh & Winger, 1995; Hursh et al., 2005; Hursh & Silberberg, 2008). In order 
measure and compare the reinforcing efficacy of several reinforcers to one another, the 
behavioral economic approach engenders several advantages over response rate, behavioral 
momentum, choice, and breakpoint methodologies.  
Why behavioral economics? 
In contrast to measuring response rates for a self-administration of a commodity to 
assess its reinforcing strength, the dependent measure of behavioral economics is total 
consumption.  While response rate analyses are conventionally used in self-administration 
studies, the inverted U-shaped curve in which response rates decline at higher doses of self-
administered drugs inhibits a comparison or reinforcing efficacies between different reinforcers 
(Hursh et al., 2005). Furthermore, response rate measures are incapable of comparing 
reinforcing strengths because the behavioral schedules and local contingencies set by the 
experimenter can affect response rate responding (Hursh & Silberberg, 2008). There are other 
approaches to measuring reinforcing strength. Behavioral momentum, the notion that the 
relative strength of reinforcers may be measured by their relative resistance to change 
responding following an experimenter-introduced disruption (Nevin, 1992), is again not 
completely independent of schedule effects on rate of responding (Hursh & Silberberg, 2008). 
Choice tasks maintain face-validity, but they are not independent of environmental factors such 
as income and price (Hursh & Silberberg, 2008). Finally, many researchers employ progressive 
ratio schedules to obtain a breakpoint measure of reinforcing strength. To obtain a breakpoint, 
the ratio size incrementally increases with every reinforcer delivery during the session until the 
subject no longer earns reinforcement.  While breakpoints could be informative, they omit 
information regarding behavior that occurs at different ratio sizes (Hursh & Silberberg, 2008), 
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and the breakpoint may co-vary with experimenter set criteria (Stafford & Branch, 1998). 
Breakpoints determined via within session progressive ratio tests are also vulnerable to satiation 
effects (Giordano et al., 2001).   
Hursh and others have effectively argued that traditional measures of reinforcement (i.e. 
peak response rate, breakpoint, and preference) are all encompassed by and represented in 
different portions of the demand curve (Bickel et al., 2000; Hursh & Silberberg, 2008) and that 
measuring unit price is the most parsimonious method to studying reinforcing strength 
(DeGrandpre et al., 1993).  Thus, the demand curve and the behavioral economic approach is 
currently the most appropriate method of comparing the reinforcing efficacy of different 
reinforcers.          
Drug Discrimination 
Drug discrimination using laboratory animals is a procedure that is used to model the 
subjective effects of a drug experienced by humans (Schuster, 1976; Brady & Balster, 1981). A 
discrimination procedure reinforces a response dependent upon the stimulus conditions 
prevailing during training sessions (Overton, 1979). In a drug discrimination procedure, the 
discriminative stimuli are the interoceptive effects that occur following drug and saline 
administration, and reinforcement is typically a food pellet delivery, access to sweetened milk, or 
avoidance of shock reinforced by pressing a lever or a nose poke. The drug discrimination 
procedure is viewed as a valuable method for studying the abuse liability of drugs of abuse 
(Berkley & Stebbins, 1990) as it may be used to assess the extent to which a novel test drug 
reproduces the "subjective effects" of a drug of abuse used as the training drug, or whether the 
test drug attenuates those subjective effects when the two drugs are given concurrently 
(Schuster, 1976; Solinas et al., 2006). Methamphetamine drug discrimination is well 
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established, and methamphetamine is known to substitute for other stimulants such as 
ephedrine, cocaine, methylphenidate, and d-amphetamine (Schechter, 1997b; Bondareva et al., 
2002; Sevak et al., 2009). In sum, a methamphetamine drug discrimination assay can determine 
whether the interoceptive stimuli produced by methamphetamine administration are attenuated 
when a potential pharmacotherapy is administered, and by inference, whether the subjective 
effects of methamphetamine and the control they exert on behavior is weakened. 
Rationale  
Locomotor activity and its sensitization, self-administration, and drug discrimination each 
are related to different aspects of drug abuse-like behavior as modeled in rodents. Thus, 
utilizing all three of these assays in combination to assess the effects of the glial cell modulators 
would help identify their effectiveness in attenuating different aspects of methamphetamine 
abuse. First, examining effects on locomotor activity in mice allows for a measure of drug effects 
on methamphetamine-induced acute hyperactivity and the development of sensitization, which 
potentially tracks the effects of methamphetamine-induced synaptic plasticity as well as the 
likelihood of relapse. Comparing ibudilast’s effects to those of AV1013 on methamphetamine-
induced locomotor activity also helps identify whether glial cell modulation alone, without 
inhibition of PDE, is sufficient to affect this behavior and its sensitization. 
Second, assessing ibudilast, AV1013, and minocycline’s effects on self-administration 
behavior in rats determines whether PDE inhibition and/or glial cell modulation can attenuate 
on-going drug-taking behavior and again allows for a comparison between these drugs’ effects. 
If the test compounds did effect on-going methamphetamine self-administration, identification of 
the behavioral determinants and range of conditions for observing these effects would be 
important. Two potential variables that may influence the effects of test compounds on drug self-
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administration are the response rate and strength of the drug-maintained baselines. Controlling 
for potential response rate determinants of ibudilast's effects is crucial to ensure that the drug’s 
effects are not exclusively rate dependent. Behavioral economics can be used to help in the 
evaluation of the non-specific effects of the test compounds, such as testing for reductions in 
responding maintained by alternate reinforcers (i.e. food pellets) when baseline strength is 
equated.  
Finally, drug discrimination is thought to model the subjective effects of a drug. Thus, 
evaluating a compound's effects on methamphetamine’s discriminative stimulus effects would 
help identify the importance of its mechanism(s) as involved in occasioning episodes of drug 
taking in human abusers. In summary, examining the test compounds ibudilast, AV1013, and 
minocycline in these behavioral assays, accompanied by control procedures, clarify their ability 
to attenuate different components of methamphetamine abuse-related behaviors, as well as the 
underlying mechanisms of those behaviors.       
Hypothesis 
Previous literature suggests that inhibiting PDE function and modulating glial cell activity 
can alter drug abuse-related behavior (Iyo et al., 1995; Yan et al., 2006; Miguel-Hidalgo, 2009; 
Crews et al., 2011). Ibudilast, AV1013 and minocycline all modulate glial cell activation and 
reduce inflammatory processes (Kishi et al., 2001; Mizuno et al., 2004; Cho et al., 2010; Tai et 
al., 2013). Furthermore ibudilast and minocycline have been reported to attenuate some drug-
induced behavioral effects including those of methamphetamine (Zhang et al., 2006; Hutchinson 
et al., 2009a; Beardsley et al., 2010; Agrawal et al., 2011; Schwarz et al., 2011; Fujita et al., 
2012). Thus, the present study hypothesizes that ibudilast, AV1013 and minocycline will 
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attenuate the locomotor activity and sensitization, self-administration, and the discriminative 
stimulus effects of methamphetamine.  
Research Approach 
1) Determine ibudilast and AV1013’s effects on the locomotor activity and its sensitization 
induced by methamphetamine in mice 
2) Evaluate ibudilast, AV1013, and minocycline’s ability to modulate methamphetamine 
self-administration in rats 
a. Control for rate-dependent effects 
b. Control for methamphetamine-specific effects using a behavioral economic 
approach 
3) Determine if the discriminative stimulus effects of methamphetamine are modulated by 
ibudilast 
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Chapter II: The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate 
methamphetamine locomotor activity and its sensitization in mice1                                 
 
Introduction 
This purpose of the following study was to examine the ability of ibudilast to attenuate 
the acute and chronic effects of methamphetamine-induced hyperactivity and sensitization in 
mice. Additionally, the amino analog of ibudilast, AV1013, which retains ibudilast's ability to 
inhibit glial cell activation but has minimal PDE inhibitory effects (Cho et al., 2010), was also 
tested to determine whether PDE inhibition was essential for the initial effects observed with 
ibudilast. 
 
Methods 
Subjects 
Male adult C57BL/6J mice were obtained at approximately 8 weeks of age (The Jackson 
Laboratory, Bar Harbor, ME) and were allowed to acclimate to the vivarium for approximately 
one week prior to commencement of testing. The mice were housed at a maximum of four per 
                                               
1 Some content of Chapter II is adapted from Euro. J. Pharmacol, 2012, 679: 75-80 
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cage in an Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) International-accredited animal facility with food (7012 Teklad LM-485 Mouse/Rat 
Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN) and water available ad libitum under 
a 12-h/12-h light/dark cycle (lights illuminated from 0600-h to 1800-h) with all testing occurring 
during the light phase. All procedures were carried out in accordance with the “Guide for the 
Care and Use of Laboratory Animals” (Institute of Laboratory Animal Resources, National 
Academy Press, 1996) and were approved by the Institutional Animal Care and Use Committee 
of Virginia Commonwealth University. 
Apparatus 
Locomotor activity tests were conducted in eight commercially obtained, automated 
activity monitoring devices each enclosed in sound- and light-attenuating chambers that 
recorded distance traveled in cm in 10-min bins via computer-controlled circuitry (AccuScan 
Instruments, Columbus OH). The interior of each device was divided into separate 20 × 20 × 30 
cm arenas permitting the independent and simultaneous measurement of two mice. Sixteen 
photobeam sensors per axis were spaced 2.5 cm apart along the walls of the chamber and 
were used to detect movement. 
Locomotor activity procedure 
One hundred and twenty-eight mice were randomly assigned into 16 groups of eight 
mice each. Eight groups were treated b.i.d. for 7 days with subcutaneous (s.c.) injections of 
either 0 (vehicle; VEH1), 1.8, 7.5, or 13 mg/kg ibudilast, with two groups of eight at each dose. 
Eight other groups were similarly treated but with 0 (vehicle; VEH2), 10, 30, or 56 mg/kg 
AV1013. Both ibudilast and AV1013 injections occurred twice daily separated approximately 7 
hours apart (0900-h and 1600-h). During the last five days of these seven-day regimens (Days 
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3–7), the mice were given locomotor activity tests. Two, 1-h locomotor activity sessions 
(Baseline and Test) were given on Days 1 and 5. Single locomotor activity sessions were given 
on Days 2–4 to minimize the occurrence of extinction of any conditioned locomotor activity 
effects in methamphetamine treated mice. On days when locomotor activity sessions were 
administered (Days 3–7), morning ibudilast and AV1013 injections were given 1 h prior to the 
first session. Immediately prior to Baseline and Test sessions on Days 1 and 5, all mice were 
injected intraperitoneally (i.p.) with saline or 3 mg/kg methamphetamine, respectively. On Days 
2–4, half of all mice in the ibudilast and AV1013 groups received 3 mg/kg i.p. methamphetamine 
(METH) before all locomotor activity sessions (IBUD + METH and AV1013 + METH groups), 
while the other half received saline injections (IBUD + SAL and AV1013 + SAL groups). Thus, 
the mice were distributed across groups as shown in Table 2 and treated as shown in Table 3. 
Drugs 
(±)-Methamphetamine (National Institute on Drug Abuse, Rockville, MD) was prepared in 
0.9% saline stock solutions sterilized by filtration through 0.2 μm filtration disks. Working 
methamphetamine solutions were dissolved in sterile 0.9% saline and injected i.p. Ibudilast (3-
isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and AV1013 ((R)-2-amino-1-(2-
isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one hydrochloride) were received as a gift from 
MediciNova, Inc., San Diego, CA). Ibudilast was prepared in 35% polyethylene glycol (PEG) in 
saline vehicle and administered s.c. (referred to below as “VEH1”). Doses of AV1013 were 
administered s.c. and prepared in sterile 0.9% saline (referred to below as “VEH2”), with the 
exception of the highest dose (56 mg/kg) that was solubilized in a 35% PEG in saline vehicle 
(i.e., VEH1) because of its incomplete dissolution in 0.9% saline. All injections were given in a 
volume equivalent to 10 ml/kg body weight. 
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Data analysis 
Distance traveled (cm) was subjected to analysis by a mixed-model ANOVA (repeated 
measures on Testday test and between comparisons on drug condition) for the chronically 
administered methamphetamine and vehicle groups separately for each drug (i.e., 2 drugs × 2 
methamphetamine treatment conditions = 4 ANOVAs). Comparisons between ibudilast or 
AV1013-treated mice to their respective vehicle condition were made using Bonferroni Multiple 
Comparisons Tests. AD50 (CI) values for attenuating methamphetamine hyperactivity by 50% 
relative to vehicle controls were estimated by first converting distance traveled scores for each 
mouse to percent of its respective mean vehicle control, logarithmically transforming dose, and 
using nonlinear regression assuming a normalized response. All statistical tests were conducted 
using computer software (Prism 5d for Macintosh, GraphPad Software, Inc., San Diego, CA), 
and all types of comparisons were considered statistically significant if P < 0.05. 
 
Results 
Ibudilast and chronic methamphetamine 
Fig. 1 shows the effects of ibudilast on chronic methamphetamine administration (upper 
frame) and on chronic vehicle administration (lower frame). ANOVA results indicated that drug 
[F (3, 28) = 7.093; p = 0.0011] and time [F (6,168) = 56.64; P < 0.0001] and their interaction [F 
(18,168) = 2.479; p = 0.0013] significantly affected activity. Methamphetamine induced a 
significant increase in total distance traveled of over 2900 cm during the Testday 1 test relative 
to Baseline 1 levels in the VEH1 + METH group (t = 3.735, df = 7, P < 0.05) (Fig. 1, upper 
frame; significance not indicated by asterisks). Methamphetamine also induced increases in 
distance traveled during the Testday 1 test from Baseline 1 levels in the IBUD + METH treated 
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groups, but their levels were non-significantly different, and increases were less than those of 
the VEH1 + METH group. Distance traveled progressively increased in the VEH1 + METH 
group following each subsequent day of methamphetamine administration and was significantly 
(t = 4.325, df = 7, P < 0.01) greater during the Testday 5 test relative to the Testday 1 test 
indicative of sensitization. Distance traveled on Testday 5 was significantly greater relative to 
Testday 1 in the 1.8 IBUD + METH (t = 6.316, df = 7, P < 0.0001) and 7.5 IBUD + METH (t = 
5.2000, df = 7, P < 0.0001) groups, but not the 13 IBUD + METH group, indicating that 13 mg/kg 
ibudilast blocked the induction of sensitization. Ibudilast reduced distance traveled during all test 
sessions following methamphetamine administration relative to the VEH1 + METH treatment 
group, and significantly so during Testday 2–5 tests at 13 mg/kg ibudilast and during Testday 3 
and 4 tests at 7.5 mg/kg ibudilast. 
Ibudilast and acute methamphetamine 
Distance traveled did not differ between the VEH1 + SAL group and any of the ibudilast 
groups following saline administration indicating that ibudilast did not affect locomotor behavior 
in mice without methamphetamine histories (Fig. 1, lower frame). However, ibudilast 
significantly reduced distance traveled following methamphetamine administration during the 
Testday 5 test, relative to the VEH1 + SAL group, at all doses of ibudilast (1.8 mg/kg ibudilast: t 
= 3.278, df = 7, P < 0.05; 7.5 mg/kg ibudilast: t = 6.944, df = 7, P < 0.0001; 13 mg/kg ibudilast: t 
= 6.374, df = 7, P < 0.0001) indicating its ability to blunt the acute challenge by 
methamphetamine. 
AV1013 and chronic methamphetamine 
Fig. 2 shows the effects of AV1013 on chronic methamphetamine administration (upper 
frame) and on chronic vehicle administration (lower frame). ANOVA indicated a significant effect 
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of drug [F (4, 34) = 5.947; p = 0.0010], time [F (6,204) = 92.28; P < 0.0001, and their interaction 
[F (24,204) = 2.282; p = 0.0010]. Methamphetamine induced a significant increase in total 
distance traveled during the Testday 1 test relative to Baseline 1 levels in the VEH1 + METH 
group (t = 4.341, df = 7, P < 0.001). Methamphetamine induced a non-significant mean increase 
in total distance traveled in the VEH2 + METH group during the Testday 1 test relative to 
Baseline 1 levels, which further increased to significant levels during Testday 2 tests (t = 4.530, 
df = 7, P < 0.001) (Fig. 2, upper frame). Methamphetamine induced increases in total distance 
traveled by all AV1013 treatment groups during the Testday 1 test relative to Baseline 1 levels; 
however, these were non-significant increases and were always less than respective control 
vehicle groups. Total distance traveled generally increased in all groups following each 
subsequent day of methamphetamine administration and were significantly greater during the 
Testday 5 test relative to the Testday 1 test in all chronically-treated methamphetamine groups 
(VEH2 + METH: t = 4.181, df = 7, P < 0.001; VEH1 + METH: t = 5.027, df = 7, P < 0.001, 10 
AV1013 + METH: t = 5.618, df = 7, P < 0.001; 30 AV1013 + METH: t = 8.095, df = 7, P < 0.001, 
56 AV1013 + METH: t = 4.154, df = 7, P < 0.001). Total distance traveled was significantly 
reduced following 56 mg/kg AV1013 administrations relative to its vehicle control group (VEH1 + 
METH) following methamphetamine treatment on all days. (Testday 1: t = 3.357, df = 7, P < 
0.01; Testday 2: t = 3.681, df = 7, P < 0.01; Testday 3: t = 5.089, df = 7, P < 0.001; Testday 4: t 
= 5.434, df = 7, P < 0.001; Testday5: t = 4.009, df = 7, P < 0.01). 
AV1013 and acute methamphetamine 
Total distance traveled did not differ between the VEH2 + SAL group and either the 10 
AV1013 + SAL or 30 AV1013 + SAL groups during all test sessions that were preceded by 
saline administration, indicating that AV1013 did not affect locomotor behavior on its own (Fig. 
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2, lower frame). Similarly, distance traveled did not differ between the VEH1 + SAL and 56 
AV1013 + SAL group indicating that 56 mg/kg AV1013 did not affect locomotor behavior in mice 
without a methamphetamine history. However, following methamphetamine challenge during 
Testday 5 tests, 30 mg/kg AV1013 significantly reduced levels of total distance traveled relative 
to its vehicle control group, VEH2 + SAL (t = 4.683, df = 7, P < 0.001), as did 56 mg/kg AV1013 
relative to its vehicle control group, VEH1 + SAL (t = 4.900, df = 7, P < 0.001). 
Ibudilast vs. AV1013 
The AD50 (CI) for ibudilast to reduce the hyperactivity effects of acute 
methamphetamine challenge on Testday 1 was 7.146 (3.763–13.57) mg/kg for groups 
chronically-treated with methamphetamine. By Testday 5 the AD50 (CI) increased to 23.23 
(9.660–55.86) mg/kg in these groups. In groups whose first exposure to methamphetamine was 
on Testday 5, but which had received chronic ibudilast up to Testday 5, the AD50 (CI) was 
7.092 (3.420–14.71) mg/kg. This AD50 value was non-significantly different from that on 
Testday 1 in the chronically treated methamphetamine group (i.e., vs. 7.146 mg/kg). 
AV1013 attenuated methamphetamine's effects with an AD50 (CI) of 43.88 (19.40–
99.27) mg/kg on Testday 1 that increased to 201.2 (51.49–786.0) mg/kg on Testday 5 in the 
chronically treated methamphetamine groups. In groups whose first exposure to 
methamphetamine was on Testday 5 but which had received chronic AV1013 up to Testday 5 
the AD50 (CI) was 48.13 (19.05–121.7) mg/kg. This AD50 value was non-significantly different 
from that on Testday 1 in the chronically treated methamphetamine group (i.e., vs. 43.88 
mg/kg). 
When compared to each other, ibudilast produced significantly lower AD50 values than 
AV1013 on both Testday 1 [F(1,61) = 11.32; p = 0.0013] and on Testday 5 [F(1,61) = 6.978; p = 
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0.0105] in groups chronically-treated with methamphetamine, as well when comparing groups 
chronically-treated with saline and challenged for the first time on Testday 5 [F(1,62) = 10.90; p 
= 0.0016]. 
 
Summary 
Ibudilast dose-dependently reduced both chronically and acutely administered 
methamphetamine-induced locomotor activity. Chronic treatment with methamphetamine 
provided evidence of sensitization as subsequent administrations elicited greater increases in 
distance traveled. The highest dose of ibudilast (13 mg/kg) tested significantly attenuated these 
methamphetamine-induced sensitization effects. Ibudilast's analog, AV1013, which lacks its 
potency for inhibiting PDE, but retains its ability to suppress activated glial activity, similarly 
dose-dependently attenuated methamphetamine's chronic and acute locomotor activity effects, 
but was ~ 6–9 fold less potent in doing so. These later observations suggest that the ability to 
modulate glial activity is sufficient to attenuate methamphetamine's locomotor activity effects, 
although PDE inhibition likely can additionally contribute if present. 
  
46 
 
Table 2. Distribution of mice in chronically and acutely treated methamphetamine (METH) 
groups. 
Chronic METH Acute METH 
Ibudilast Groups 
VEH1+METH VEH1+SAL 
1.8 IBUD+METH 1.8 IBUD+SAL 
7.5 IBUD+METH 7.5 IBUD+SAL 
13 IBUD+METH 13 IBUD+SAL 
AV1013 Groups 
VEH2+METH VEH2+SAL 
10 AV1013+METH 10 AV1013+SAL 
30 AV1013+METH 30 AV1013+SAL 
56 AV1013+METH 56 AV1013+SAL 
 
  
  
47 
 
Table 3. Treatment procedures  
 Day 1 Day 2 Day 3 Day 4 Day 5 
1Chronic METH groups     
Injection #1 Saline    Saline 
Session Baseline 1    Baseline 5 
      
Injection #2 METH METH METH METH METH 
Session Test 1 Test 2 Test 3 Test 4 Test 5 
2Acute METH groups     
Injection #1 Saline    Saline 
Session Baseline 1    Baseline 5 
      
Injection #2 Saline Saline Saline Saline METH 
Session Test 1 Test 2 Test 3 Test 4 Test 5 
 
1 Groups include: IBUD+METH, AV1013+METH, VEH1+METH, VEH2+METH 
2 Groups include: IBUD+SAL, AV1013+SAL, VEH1+SAL, VEH2+SAL 
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Chapter II: Figure Legends 
Fig. 1. Upper frame: Results on distance traveled (cm) by mice treated b.i.d. for seven days with 
ibudilast (IBUD) or its vehicle (VEH1), beginning two days before five days of treatment with 3 
mg/kg methamphetamine. Ibudilast was administered at 1.8, 7.5, or 13 mg/kg. Data points 
represent group means (± S.E.M.) obtained during 1-h experimental sessions. Filled data points 
represent sessions preceded by 3 mg/kg i.p. methamphetamine injections. Unfilled data points 
represent sessions preceded by i.p. saline injections. N = 8 for each treatment group. *P < 0.05 
with respect to mice treated with ibudilast's vehicle. Lower frame: Results on distance traveled 
(cm) by mice treated b.i.d. for seven days with ibudilast (IBUD) or its vehicle (VEH1), beginning 
two days before four days of saline administration and acute treatment with 3 mg/kg 
methamphetamine on the fifth day. Ibudilast was administered at 1.8, 7.5, or 13 mg/kg. Data 
points represent group means (± S.E.M.) obtained during 1-h experimental sessions. Other 
details are as in the upper frame. 
 
Fig. 2. Upper frame: Results on distance traveled (cm) by mice treated b.i.d. for seven days with 
AV1013 or its vehicle (VEH2 for 10 and 30 mg/kg and VEH1 for 56 mg/kg), beginning two days 
before five days of treatment with 3 mg/kg methamphetamine. AV1013 was administered at 10, 
30, or 56 mg/kg. *P < 0.05 with respect to mice treated with AV1013's vehicle. Other details are 
as in Fig. 1. Lower frame: Results on distance traveled (cm) by mice treated b.i.d. for seven 
days with AV1013 or its vehicle (VEH2 for 10 and 30 mg/kg and VEH1 for 56 mg/kg), beginning 
two days before four days of saline administration and acute treatment with 3 mg/kg 
methamphetamine on the fifth day. Other details are as in the upper frame. 
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Figure 1.  
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Figure 2. 
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Chapter III: Glial cell modulators attenuate methamphetamine self-administration in the rat 2 
 
 
Introduction 
 The purpose of this study was to ascertain the effects of ibudilast, AV1013, and 
minocycline on on-going self-administration of methamphetamine in rats.  It was previously 
reported that ibudilast attenuates stress- and prime-induced methamphetamine reinstatement in 
rats (Beardsley et al 2010), and the previously described locomotor activity study suggested that 
glial cell modulation and anti-inflammatory action is sufficient to attenuate methamphetamine 
locomotor activity in mice.  Thus, it was hypothesized that ibudilast, AV1013, and minocycline, 
another compound that attenuates microglial activation, would attenuate on-going 
methamphetamine self-administration.  
 
                                               
2 Some content of Chapter III is adapted from Eur. J. Pharmacol., 2013, 701: 124-130. 
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Methods 
Subjects 
Adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) weighing 275-300 g at the 
start of studies were acclimated to the vivarium for at least one week prior to catheter 
implantation. When not in testing, rats were individually housed in standard plastic rodent cages 
in a temperature-controlled (22o C), AAALAC International-accredited facility in which they had 
ad libitum access to water. The rats were allowed ad libitum rat chow (7012 Teklad LM-485 
Mouse/Rat Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN) for at least one week 
prior to commencement of training, after which they were maintained at 320 g by controlled 
feedings given after experimental sessions or at a comparable time of day if not tested. The rats 
were maintained on a reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) for the 
duration of the experiment, and they were trained and tested during the dark segment of this 
cycle. 
All procedures were carried out in accordance with the “Guide for the Care and Use of 
Laboratory Animals” (Institute of Laboratory Animal Resources, National Academy Press, 1996) 
and were approved by the Institutional Animal Care and Use Committee of Virginia 
Commonwealth University. 
Infusion assembly system 
Catheters were constructed from polyurethane tubing (Access Technologies, Skokie, IL; 
0.044” O.D. X 0.025” I.D.). The proximal 3.2 cm of the catheter was tapered by stretching 
following immersion in hot sesame oil. The catheters were prepared with a retaining cuff 
approximately 3 cm from the proximal end of the catheter. A second larger retaining cuff was 
positioned approximately 3.4 cm from the proximal end of the catheter. Mid-scapula cannula 
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connectors were obtained from Plastics One (Roanoke, VA). The cannula connectors consisted 
of a threaded plastic post through which passed an “L” shaped section of 22 gauge stainless 
steel needle tubing. The lower surface of the plastic post was affixed to a 2 cm diameter disc of 
Dacron mesh. During sessions the exposed threaded portion of the infusion cannula was 
connected to an infusion tether consisting of a 35 cm length of 0.40 mm i.d. polypropylene 
tubing encased within a 30 cm stainless steel spring to prevent damage. The upper portion of 
the 0.40 polypropylene tubing was connected to a fluid swivel (Lomir Biomedical, Inc, Quebec, 
Canada) that was, in turn, attached via 0.40 polypropylene tubing to the infusion syringe. 
Surgical procedure 
Following acclimation to the laboratory environment, indwelling venous catheters were 
implanted into the right external jugular vein. Rats were administered 5 mg/kg carprofen s.c. 
(Rimadyl, Pfizer Animal Health, New York, NY) before surgery. Surgical anesthesia was 
induced with a combination of 50 mg/kg ketamine (KetaThesia, Butler Animal Health Supply, 
Dublin, OH) and 8.7 mg/kg xylazine (X-Ject E, Butler Animal Health Supply, Dublin, OH). The 
ventral neck area and back of the rat were shaved and wiped with povidone-iodine, 7.5% 
(Betadine, Purdue Products L.P., Stamford, CT) and isopropyl alcohol. The rat was placed 
ventral side down on the surgical table and a 3 cm incision was made 1 cm lateral from mid-
scapula. A second 0.5 cm incision was then made mid-scapula. The rat was then placed dorsal 
side down on the operating table and a 2.5 cm incision was made longitudinally through the skin 
above the jugular area. The underlying fascia was bluntly dissected and the right external 
jugular vein isolated and ligated. A small cut was made into the vein using an iris scissors and 
the catheter was introduced into the vein and inserted up to the level of the larger retaining cuff. 
The vein encircling the catheter between the two cuffs was then tied with silk suture. A second 
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suture was then used to anchor the catheter to surrounding fascia. The distal end of the 
catheter was passed subcutaneously and attached to the cannula connector that was then 
inserted subcutaneously through the larger incision. The upper post portion of the cannula 
connector exited through the smaller mid-scapula incision. All incisions were then sprayed with 
a gentamicin sulfate/betamethasone valerate topical antibiotic (Betagen, Med-Pharmex, Inc., 
Pomona, CA) and the incisions were closed with Michel wound clips. Five mg/kg oral carprofen 
(Rimadyl, Bio-Serv, Frenchtown, NJ) was administered 24 h after surgery, and 8 mg/kg oral 
enrofloxacin (Baytril, Bio-Serv, Frenchtown, NJ) was administered daily for three days following 
surgery. 
Rats were allowed to recover from surgery for at least 5 days before self-administration 
training began. Periodically throughout training, ketamine (5 mg/kg) (KetaThesia, Butler Animal 
Health Supply, Dublin, OH) was infused through the catheters to determine patency as inferred 
when immediate anesthesia was induced. Between sessions the catheters were flushed and 
filled with 0.1 ml of a 25% glycerol (Acros, New Jersey)/75% sterile saline locking solution 
containing: 250 units/ml heparin (Abraxis Pharmaceutical Products, Schaumburg, IL) and 250 
mg/ml ticarcillin/9 mg/ml clavulanic acid (Timentin, GlaxoSmithKline, Research Triangle Park, 
NC). If during the experiment a catheter was determined to be in-patent, the left external jugular 
was then catheterized and the rat was returned to testing.  
Apparatus 
Commercially-obtained test chambers equipped with two retractable levers, a 5-w house 
light, and a Sonalert tone generator (MED Associates, Inc., St. Albans, VT) were used. 
Positioned above each lever was a white cue light. A syringe pump (Model PHS-100; MED 
Associates, Inc., St. Albans, VT) when activated, delivered a 6-sec, 0.2 ml infusion. Recording 
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of lever presses and activation of lights, shockers, pumps, and Sonalerts were accomplished by 
a microcomputer, interface, and associated software (MED-PC IV, MED Associates, Inc., St. 
Albans, VT). 
Self-administration procedure 
Methamphetamine self-administration training sessions were conducted seven days per 
week for 2 h daily. Each response (fixed ratio 1, FR1) on the right-side lever resulted in delivery 
of a 0.1 mg/kg methamphetamine infusion (0.2 ml/6 sec) followed by a 14-s timeout period. At 
the start of an infusion the house light was extinguished, the Sonalert was sounded, and the 
cue lights above each lever flashed at 3 Hz. The Sonalert and cue lights remained activated 
during the 6-s infusion. Twenty seconds following the onset of the infusion the house light was 
re-illuminated, and the opportunity to self-administer methamphetamine was again made 
available (i.e., each methamphetamine infusion initiated a 20 s period during which lever 
presses were recorded but were without scheduled consequences and further infusions could 
not be obtained). Active (right-side) lever presses during the infusions as well as all inactive 
(left-side) lever presses were recorded but were without scheduled consequences. 
Training sessions occurred until stability criteria were met.  Stability criteria were defined 
in which during the first and last session of at least 3 consecutive sessions neither the highest 
nor lowest number of infusions were obtained, and the number of infusions during each session 
was ±20% from the mean. Following training, ibudilast (1, 7.5 and 10 mg/kg) or AV1013 (1, 10 
and 30 mg/kg) was administered i.p. twice daily, or minocycline (10, 30 and 60 mg/kg) was 
administered i.p. once daily, or their corresponding vehicles were administered for three 
consecutive days during self-administration of each of three doses of methamphetamine (0.1, 
0.03, and 0.001 mg/kg/inf). Thus, a total of nine consecutive days of b.i.d. or once daily dosing 
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of vehicle or dose of test drug was necessary to complete testing at each self-administered 
dose of methamphetamine. Between tests of vehicle or dose of test drug, rats were maintained 
under 0.1 mg/kg methamphetamine self-administration conditions with i.p. injections of the test 
drug’s vehicle until training criteria were once again met.  
Rate Dependency Analysis 
Preliminary results had indicated that ibudilast reduced response rates maintained by 
0.03 mg/kg/inf but not by 0.1 mg/kg/inf methamphetamine. In order to determine if the higher 
baseline response rates maintained by 0.03 mg/kg/inf methamphetamine were the sole 
determinants for the greater ibudilast-induced response rate reductions, relative to those 
maintained at 0.1 mg/kg/inf methamphetamine, response rates were matched across the two 
methamphetamine doses. Fixed-ratio requirements reinforced by 0.1 mg/kg/inf 
methamphetamine were increased to increase response rates, and ibudilast was then re-tested 
at its most influential dose of 10 mg/kg. Rats were trained to self-administer 0.1 mg/kg/inf 
methamphetamine reinforced according to a FR1 schedule, and they were required to complete 
the previously described stability criteria before proceeding. The fixed ratio requirement was 
then adjusted to between FR2- FR4 in individual rats in order to increase response rates 
reinforced by 0.1 mg/kg/inf methamphetamine to approximate, as a group mean response rate, 
those maintained by 0.03 mg/kg/inf methamphetamine. Once the response rates were stably 
matched between 0.03 and 0.1 mg/kg/inf methamphetamine groups, ibudilast (10 mg/kg) or its 
vehicle was then administered b.i.d. i.p. for three consecutive days. Between three-day sets of 
testing, animals were returned to training conditions and were required to meet stability criteria 
once again.  
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Drugs 
(±)-Methamphetamine hydrochloride (National Institute on Drug Abuse, Rockville, MD) 
was prepared in sterile 0.9% saline. Methamphetamine stock solutions were sterilized by 
filtration through 0.2 µm filtration disks. Heparin (5 units/ml) was additionally added to 
methamphetamine and saline infusates. Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-
a]pyridine) and AV1013 ((R)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one 
hydrochloride) were received as a gift from MediciNova, Inc. (San Diego, CA) and were 
dissolved in a 35% PEG400, 10% Cremophor® RH40 (BASF, Ludwigshafen, Germany) 
aqueous vehicle. Minocycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in 
saline and a few drops of 1 M hydrochloric acid. Immediately prior administration, the 
minocycline solution was adjusted to pH 3-4 using a few drops of sodium hydroxide. Ibudilast, 
AV1013, and minocycline were all administered i.p. in 1 ml/kg body weight volume, except for 
60 mg/kg minocycline that was given at 2 ml/kg body weight volume due to insolubility at the 
lower volume.  
Data Analysis 
The number of infusions obtained on the third (and final) day of testing at each condition 
was used for data analysis because it was assumed it would most likely represent terminal 
behavior. Numbers of infusions comparing methamphetamine dose to saline under vehicle-
treatment conditions were made with Dunnett’s Multiple Comparison posttests following a one-
way within-subjects ANOVA to determine if a dose of methamphetamine served as a reinforcer.  
Additionally, infusion numbers were analyzed using a two-way repeated measures ANOVA 
(repeated measures on treatment dose and between comparisons on methamphetamine dose), 
and comparisons of ibudilast, AV1013, or minocycline treatment on methamphetamine self-
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administration were assessed using Bonferroni Multiple Comparisons tests. AD50 (CI) values 
for attenuating methamphetamine self-administration by 50% relative to vehicle control 
conditions were estimated by first converting total infusions obtained to percent of their 
respective vehicle control infusions, logarithmically transforming dose, and using nonlinear 
regression assuming a normalized response.  
For Rate Dependency Analysis, "response rate" was defined as the: (number of presses 
of the right-side lever - those occurring during time-out periods) ÷ (total session duration in sec - 
cumulative duration of all time-out periods). Response rates maintained by 0.03 mg/kg/inf 
methamphetamine at FR1 were considered matched to response rates for 0.1 mg/kg/inf 
methamphetamine at FR2-4 when there were no significant differences between group mean 
rates when compared by an unpaired t-test. During 10 mg/kg ibudilast and vehicle treatment, 
response rates at 0.03 mg/kg/inf methamphetamine administration were compared to those at 
0.1 mg/kg/inf methamphetamine using a two-way analysis of variance (ANOVA) with repeated 
measures on ibudilast "dose" (i.e., 10 mg/kg or vehicle) followed by Sidak's Multiple 
Comparisons tests.     
All statistical tests were conducted using commercial computer software (Prism 5d for 
Macintosh, GraphPad Software, Inc., San Diego, CA), and all types of comparisons were 
considered statistically significant if p < 0.05.  
Results 
Figure 3 illustrates the effects of ibudilast on methamphetamine self-administration. 
Under b.i.d. vehicle conditions, methamphetamine was self-administered characterized by an 
inverted U-shaped curve relating infusion numbers to dose, and the one-way within-subjects 
ANOVA on infusion numbers was significant [F (3, 15) =32.75; p<0.001]. Dunnett’s posttests 
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revealed that infusions of 0.03 and 0.1 mg/kg/inf methamphetamine were self-administered 
significantly greater than those of saline (p<0.05) indicating that these doses were serving as 
positive reinforcers under baseline conditions.  
There was a significant effect of methamphetamine dose [F (2, 27) =19.90; p= 0.0005] 
and ibudilast dose [F (3, 27) =3.44; p=0.0308]. Ibudilast did not systematically affect the number 
of 0.001 mg/kg methamphetamine infusions, which had not served as a positive reinforcer 
under vehicle conditions, nor the number 0.1 mg/kg methamphetamine infusions, which did 
serve as a positive reinforcer. At its two highest doses (7.5 and 10 mg/kg), ibudilast reduced the 
number of 0.03 mg/kg methamphetamine infusions, the methamphetamine dose that had 
maintained the greatest number of infusions above those of saline under baseline conditions, 
and significantly so at the 10 mg/kg ibudilast dose (p<0.05).  
Response Rate Dependency analysis indicated that group mean response rate 
maintained by 0.03 mg/kg/inf methamphetamine at FR1 was not significantly different from the 
group mean response rate maintained by 0.1 mg/kg/inf methamphetamine in the matched 
response rate group (FR2-4) (t=0.1591, df=6, p=0.8788)(Fig. 4). Although 10 mg/kg ibudilast 
reduced infusion levels of 0.03 mg/kg/inf methamphetamine relative to vehicle control (t=3.998, 
df=6, p<0.05), and as described above, infusion rates of 0.01 mg/kg/inf methamphetamine in 
the matched response rate group were unaffected (t=1.324, df=6, p>0.05).   
Figure 5 shows AV1013’s effects on methamphetamine self-administration.  Under b.i.d. 
vehicle conditions, methamphetamine was self-administered characterized by an inverted U-
shaped curve relating infusion numbers to dose. The one-way within subjects ANOVA on 
infusion numbers was significant [F (3, 19) =214.9; p<0.0001].  Dunnett’s posttest results 
indicated that 0.03 and 0.1 mg/kg/inf methamphetamine doses were self-administered 
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significantly above those of saline (p<0.05) indicating that these doses were serving as positive 
reinforcers.  
There was a significant effect of methamphetamine dose [F (2, 36) =62.59; p<0.0001] 
and AV1013 dose [F (3, 36) =10.59; p<0.0001].  As with ibudilast, AV1013 did not 
systematically affect the number of 0.001 mg/kg methamphetamine infusions, which had not 
served as a positive reinforcer under vehicle conditions, nor the number 0.1 mg/kg 
methamphetamine infusions, which had served as a positive reinforcer. AV1013 did, however, 
significantly reduce the number of 0.03 mg/kg methamphetamine infusions at the 10 and 30 
mg/kg AV1013 doses (p<0.05). 
Minocycline’s effects on methamphetamine self-administration are shown in Figure 6. 
During daily dosing conditions with minocycline’s vehicle (saline), methamphetamine self-
administration was characterized by an inverted U-shaped curve relating infusion numbers to 
dose. The one-way ANOVA on infusion numbers was significant [F (3, 19) =34.07; p<0.0001]. 
Dunnett’s posttests indicated that the 0.03 mg/kg/inf methamphetamine dose (p<0.05), but 
neither the 0.001 mg/kg/inf nor the 0.1 mg/kg/inf methamphetamine doses, were self-
administered significantly above those of saline (although the level of 0.1 mg/kg/inf 
methamphetamine self-administration infusions was similar to those obtained under baseline 
conditions during tests with ibudilast and AV1013, self-administered saline infusions were 
greater during minocycline testing).  
There was a significant effect of methamphetamine dose [F (2, 36) =23.09; p<0.0001] 
and minocycline dose [F (3, 36) =6.907; p=0.0009]. Minocycline reduced infusion numbers of 
0.03 mg/kg/inf methamphetamine, significantly so at the 60 mg/kg dose of minocycline (p<0.05), 
while infusion numbers of other self-administered doses of methamphetamine were non-
systematically affected. 
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The potency (AD50 value) relationship amongst the drugs for reducing total infusions 
obtained during 0.03 mg/kg/inf methamphetamine self-administration differed [F(2,53)=7.909; 
p=0.001], and resulted in ibudilast being the most potent, followed by AV1013, and then 
minocycline with respective AD50 (CI) values of 10.67 (3.86-29.47), 60.80 (23.26-158.9) and 
128.8 (57.14-290.3) mg/kg.   
 
Summary 
Methamphetamine was established as a positive reinforcer and was self-administered 
under vehicle pretreatment conditions characterized by an inverted U-shaped curve relating 
infusion numbers to dose, with significantly more methamphetamine infusions being obtained at 
the intermediate dose (0.03 mg/kg/inf) during testing of all drugs, and at the highest dose (0.1 
mg/kg/inf) during testing of ibudilast and AV1013, relative to those obtained of saline. Ibudilast 
(10 mg/kg), AV1013 (10 and 30 mg/kg) and minocycline (60 mg/kg) significantly reduced total 
0.03 mg/kg/inf methamphetamine infusions compared to vehicle pretreatment conditions. These 
results suggest that modulating glial cell activity and consequent neuroinflammatory processes, 
can, in turn, modulate abuse-related effects of methamphetamine.  
 
Controlling for methamphetamine-specific effects  
 The purpose of this control study was to assess whether the test compounds' effects 
were specific to attenuating methamphetamine-induced behaviors. Knowing the degree of 
specificity of the effects of these glial modulators would better profile the freedom with which 
they could be used therapeutically, without affecting other behaviors. Relaxed specificity 
suggests that non-target behaviors could also be affected. Incomplete specificity, however, 
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should not preclude a test compound as a possible therapeutic, just as a potential cancer 
chemotherapeutic shouldn't be automatically excluded from clinical use if it affects some non-
cancerous cells in addition to cancerous cells. Ibudilast, AV1013, and minocycline all reduced 
methamphetamine self-administration, however will these compounds reduce responding for 
another reinforcer such as food? It was hypothesized that in order to properly determine a test 
compound's effects on food- and drug-maintained behavior, that both food and 
methamphetamine should first be matched in terms of their relative reinforcing strength, 
otherwise effects might be seen on a weak baseline but not on a stronger baseline regardless if 
food or drug was the maintaining event. In order to match food- and methamphetamine-
maintained baselines, a behavioral economics approach was used to ensure similar demand 
curves obtained by both reinforcers before testing. One assumption of a behavioral economic 
approach is that demand is calculated when the commodity in question is only available during 
the testing session, that is, provided within a closed economy (Hursh, 1984).  Hursh (1984) 
showed that demand for a commodity is more elastic if it is available at alternative times outside 
the testing procedure, and in an open economy, as compared to a closed economy. Thus, 
controlling for this variable was an important component to consider prior to testing with a food-
like reinforcer given animals must be maintained at healthy body weights throughout the study. 
Thus, non-nutritive banana flavored cellulose pellets were the closest approximation to a food-
like reinforcer while avoiding open economy confounds during testing. Ibudilast, AV1013, and 
minocycline's effects on methamphetamine and non-nutritive banana pellet-maintained 
responding and consumption were then assessed under the conditions in which both reinforcers 
were inferred to have equal reinforcing strength. 
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Methods 
Subjects  
Adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) with a history of 
methamphetamine self-administration were allowed to acclimate to the vivarium for at least one 
week before training began. When not in testing, rats were individually housed in standard 
plastic rodent cages in a temperature-controlled (22°C), AAALAC International-accredited 
facility in which they had ad libitum access to water. Rats were assigned to one of two groups, 
to assess the demand for self-administration of either methamphetamine (METH group) or 45 
mg calorie-free (non-nutritive) banana flavored cellulose pellets (TestDiet) (BANANA group). 
METH rats were maintained at 320 g by controlled feedings of rat chow (7012 Teklad LM-485 
Mouse/Rat Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN) after daily sessions. 
Before training, BANANA rats were allowed ad libitum rat chow for at least six days in order to 
calculate each individual’s free feeding body weight to be used throughout the study.  BANANA 
rats were then maintained at 85% of their own free feeding body weight for remainder of the 
study. All rats were maintained on a reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) 
for the duration of the experiment, and they were trained and tested during the dark segment of 
this cycle. All procedures were carried out in accordance with the “Guide for the Care and Use 
of Laboratory Animals” (Institute of Laboratory Animal Resources, National Academy Press, 
1996) and were approved by the Institutional Animal Care and Use Committee of Virginia 
Commonwealth University. 
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Procedure 
Methamphetamine training  
Methamphetamine self-administration training sessions were conducted seven days per 
week for 2 h daily. Each response (fixed ratio 1, FR1) on the right-side lever resulted in delivery 
of a 0.1 mg/kg methamphetamine infusion (0.2 ml/6 sec) followed by a 14-s timeout period. At 
the start of an infusion the house light was extinguished, the Sonalert was sounded, and the 
cue lights above each lever flashed at 3 Hz. The Sonalert and cue lights remained activated 
during the 6-s infusion. Twenty seconds following the onset of the infusion the house light was 
re-illuminated, and the opportunity to self-administer methamphetamine was again made 
available (i.e., each methamphetamine infusion initiated a 20-s period during which lever 
presses were recorded but were without scheduled consequences and further infusions could 
not be obtained). Active (right-side) lever presses during the infusions as well as all inactive 
(left-side) lever presses were recorded but were without scheduled consequences. Training 
sessions occurred until stability criteria were met.  Stability criteria were defined in which during 
the first and last session of3 consecutive sessions neither the highest nor lowest number of 
infusions were obtained, and the number of infusions during each session was ±20% from the 
mean.  
BANANA pellet Training 
Banana pellet training sessions occurred seven days a week for 15 min daily. Rats were 
trained to respond on a fixed ratio 10 (FR10) schedule in which 10 consecutive left-lever 
responses resulted in a banana pellet delivery.  Non-nutritive banana flavored cellulose pellets 
were used to best approximate a closed economy, in which the “food-like” reinforcer is only 
available during the session and caloric value does not influence total consumption. During the 
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session, the house light remained illuminated, and there were no scheduled light or tone stimuli 
presentations during food delivery. All inactive (right-side) lever presses were recorded but were 
without scheduled consequences. Because the subjects had a history of methamphetamine 
self-administration in which the right lever was active and upon infusion delivery both a stimulus 
light and tone were presented, the banana pellet protocol removed those stimuli and reversed 
the active lever position in order to avoid any confounding environmental conditioning. Following 
training, rats were required to meet stability criteria on a FR1 schedule for banana pellet 
delivery. Stability criteria were defined as the first and last session of three consecutive sessions 
had neither the highest nor lowest number of active lever responses, nor the number of 
responses during each session was more than ±20% from the mean. Additionally, rats did not 
always consume all of their earned banana pellets within the session so stability criteria were 
only met if <3 banana pellets remained following each of the three consecutive sessions.  
Demand curve analyses  
Following training, demand curve analyses were obtained for 0.1 and 0.03 mg/kg/inf 
methamphetamine and banana pellet self-administration. For each curve, the fixed ratio was 
increased daily in the following progression 1,3,6,9,13,19,26,35,47,62,82,108…using the 
formula (response ratio = [5e(injection number x j)] – 5, where j=0.26)) adapted from Richardson and 
Roberts (1996). Sessions continued until responding at a particular FR decreased to below that 
sufficient to earn a single reinforcer during the session.  Rats were then returned to FR1, and 
were required to meet stability criteria before progressing to the alternate methamphetamine 
infusion dose or banana pellet administration.   
  
67 
 
Methamphetamine-specific consumption effects analysis 
BANANA group rats were maintained at 85% of their individual free feeding body weight 
and were required to meet stability criteria at FR1 for banana pellet administration.  Once 
stability was reached, twice daily i.p. administration of ibudilast (10 mg/kg), AV1013 (10, 30 
mg/kg) 1-h prior to testing or once daily i.p. administration of minocycline (10, 30, 60 mg/kg) 67-
min prior to testing or their respective vehicles for three consecutive days under a FR1 
schedule. Minocycline was administered 67-min prior to the test session to allow for similar pre-
treatment, distribution, and absorption time to that of the self-administration tests. Between 
three-day sets of testing, rats were returned to FR1 training conditions and required to meet 
stability criteria. 
Drugs 
(±)-Methamphetamine hydrochloride (National Institute on Drug Abuse, Rockville, MD) 
was prepared in sterile 0.9% saline. Methamphetamine stock solutions were sterilized by 
filtration through 0.2 µm filtration disks. Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) 
and AV1013 ((R)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one hydrochloride) 
were received as a gift from MediciNova, Inc. (San Diego, CA) and were dissolved in a 35% 
PEG400, 10% Cremophor® RH40 (BASF, Ludwigshafen, Germany) aqueous vehicle. 
Minocycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and a few 
drops of 1 M hydrochloric acid. Immediately prior to administration, the minocycline solution was 
adjusted to pH 3-4 using a few drops of sodium hydroxide. Ibudilast, AV1013, and minocycline 
were all administered i.p. in 1 ml/kg body weight volume, except for 60 mg/kg minocycline that 
was given at 2 ml/kg body weight volume due to insolubility at the lower volume. Of note, two 
additional vehicles were tested during the minocycline banana pellet consumption assays. 
Veh30, a few drops of 1M hydrochloric acid added to sterile water to produce a vehicle with 
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equivalent pH to 30 mg/kg minocycline, and Veh60 similar vehicle to Veh30 which was 
administered at 2 ml/kg injection volume to control for injection volume at 60 mg/kg minocycline 
administration, were tested. Neither vehicle produced significantly different total banana pellet 
consumption compared to sterile water vehicle, so data is not shown. 
Data Analysis 
Demand curves were generated using the formula log Q = log Q0 + k (e
-αP – 1) from 
(Hursh & Silberberg, 2008). Non-linear regression best fit values for the alpha level parameter 
were compared between reinforcer types using an extra sum-of-squares F-test. When tested on 
a FR1 schedule, total consumption of METH (0.3 mg/kg/inf) or BANANA pellets was normalized 
by calculating the percentage of reinforcer consumption under test compound (ibudilast, 
AV1013 or minocycline) treatment compared to total consumption under vehicle conditions. 
Normalized consumption percentages were analyzed using a two-way repeated measures 
ANOVA (repeated measures on treatment dose and between comparisons on reinforcer type), 
and comparisons of ibudilast, AV1013, or minocycline treatment on consumption were assessed 
using Bonferroni Multiple Comparisons tests.  
Results 
 The α levels (95% CI), the behavioral economic variable indicative of reinforcing strength 
of a particular commodity, for (0.03 and 0.1 mg/kg/inf) methamphetamine self-administration 
and banana pellet-maintained responding were calculated as 0.00012 (0.000075-0.00016), 
0.000076 (0.000061-0.000090), 0.00013 (0.00011-0.00015) respectively.  When the α levels of 
0.3 and 0.1 mg/kg/inf methamphetamine were compared, the α level obtained under 0.1 
mg/kg/inf methamphetamine conditions was significantly lower [F (1, 101) = 5.2, p=0.0246] 
indicating that under these conditions, 0.1 mg/kg/inf methamphetamine had a stronger 
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reinforcing strength.  When 0.3 mg/kg/inf methamphetamine and banana pellets were 
compared, there was not a significant difference [F (1, 87) = 0.2, p=0.65] indicating that the 
baseline reinforcing strength of these two reinforcers, obtained under the specified conditions, 
was successfully matched (Fig. 7). Thus, all further methamphetamine demand analyses were 
performed using 0.03 mg/kg/inf methamphetamine.  
There was a significant effect of ibudilast treatment on normalized consumption [F (1, 7) 
=30.26; p= 0.0009]. Bonferroni multiple comparison’s indicated that 10 mg/kg ibudilast treatment 
significantly decreased normalized consumption of both 0.3 mg/kg methamphetamine self-
administration (p<0.05) and banana pellets (p<0.05) compared to vehicle (Fig 8).  
AV1013’s treatment effect on normalized consumption of 0.03 mg/kg/inf 
methamphetamine self-administration and banana pellets was significant [F (2, 12) =12.63; 
p=0.0011].  Normalized consumption of 0.03 mg/kg/inf methamphetamine was significantly 
reduced by 10 and 30 mg/kg AV1013 compared to vehicle conditions (p<0.05).  Banana pellet 
consumption, however, was only significantly decreased by 30 mg/kg AV1013 (p<0.05) (Fig. 9).    
Figure 10 illustrates minocycline’s effects on the normalized consumption of 
methamphetamine (0.03 mg/kg/inf) and banana pellet administration.  There was a significant 
main effect of reinforcer type [F (1, 8) =7.741; p=0.0238] and minocycline treatment on 
consumption [F (3, 24) =12.76; p<0.0001]. Normalized consumption of 0.03 mg/kg/inf 
methamphetamine was significantly reduced by 60 mg/kg minocycline (p<0.05) compared to 
vehicle conditions. Bonferroni multiple comparison’s also indicated that normalized consumption 
of banana pellets while the subjects were maintained at 85% of their free-feeding body weight 
was significantly decreased by 30 and 60 mg/kg minocycline (p<0.05).  
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Summary 
 In order to support whether ibudilast, AV1013, and minocycline’s effects on attenuating 
methamphetamine-induced behaviors are methamphetamine specific, the effects of the test 
compounds was measured on the total consumption of an alternative reinforcer, non-nutritive 
banana flavored cellulose pellets.  Using behavioral economics, demand curves were generated 
for methamphetamine (0.03 mg/kg/inf) and banana flavored pellets when the subjects were 
maintained at 85% of their free-feeding body weight.  Under those conditions, the reinforcing 
strength (α level) of the two different reinforcers was successfully matched.  All three test 
compounds, ibudilast, AV1013, and minocycline, significantly attenuated total consumption of 
banana pellets at the same doses that attenuated methamphetamine self-administration with 
the exception of 10 mg/kg AV1013.  This suggests that perhaps the intermediate dose of 
AV1013 (10 mg/kg) was specifically attenuating methamphetamine self-administration without 
affecting consumption of a non-nutritive food-like reinforcer.  
Controlling for differential drug effects on differing reinforcing baselines 
 An assumption was made prior to initiating the previous studies involving the behavioral 
economic analysis of test drug effects on banana pellet and methamphetamine-maintained 
responding that baseline strength could be a determinant of whether a test compound affected 
responding or not. The assumption was that baselines maintained by very weak reinforcers 
would be affected before baselines maintained by stronger reinforcers. The following study 
attempted to provide a proof-of-concept to support this assumption. The present study 
examined food-maintained behavior while its baseline strength (α level) was manipulated by 
altering the subject’s percentage of free feeding body weight.  Test compounds were then 
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evaluated to assess the extent to which baseline strength (i.e., efficacy of the food reinforcers) 
determined the magnitude of their effects.  
 
Methods 
Subjects 
Adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) with a history of 
methamphetamine self-administration were allowed to acclimate to the vivarium for at least one 
week before training began. When not in testing, rats were individually housed in standard 
plastic rodent cages in a temperature-controlled (22°C), AAALAC International-accredited 
facility in which they had ad libitum access to water. Before training, FOOD rats were allowed ad 
libitum rat chow for at least six days in order to determine each individual’s free feeding body 
weight to be used throughout the study. FOOD rats were then maintained at a percentage of 
their own free feeding body weight for remainder of the study. All rats were maintained on a 
reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) for the duration of the experiment, 
and they were trained and tested during the dark phase of this cycle. All procedures were 
carried out in accordance with the “Guide for the Care and Use of Laboratory Animals” (Institute 
of Laboratory Animal Resources, National Academy Press, 1996) and were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University. 
Procedure 
Food Pellet Training 
Food pellet training was identical to banana pellet training as described above in which 
sessions occurred seven days a week for 15 min. Rats were trained to respond on a fixed ratio 
10 (FR10) schedule in which 10 consecutive left-lever responses resulted in delivery of a 45 mg 
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rodent purified diet dustless precision pellet (BioServ, Frenchtown, NJ).  During the session, the 
house light remained illuminated, and there were no scheduled light or tone stimuli 
presentations during food delivery. Because the subjects had a history of methamphetamine 
self-administration in which the right lever was active and upon infusion delivery both a stimulus 
light and tone were presented, the present protocol removed those stimuli and reversed the 
active lever position in order to avoid any confounding environmental conditioning. All inactive 
(right-side) lever presses were recorded but were without scheduled consequences. Following 
training, rats were required to meet stability criteria on a FR1 schedule for food pellet delivery. 
Stability criteria were defined as the first and last session of three consecutive sessions had 
neither the highest nor lowest number of active lever responses, nor the number of responses 
during each session was more than ±20% from the mean. 
Demand Curve Analyses 
The percent of ad libitum body weight was adjusted to vary the reinforcing efficacy 
(demand) of the food reinforcer. Rats were maintained at 85%, 90%, 100%, or 115% of their 
initial individual free feeding body weight by controlled feedings of rat chow following each daily 
session.  Initial individual body weights were determined by averaging daily weights from six 
consecutive days of ad libitum feeding prior to initiation of weight maintenance and test 
sessions. Because Long-Evans hooded rats’ growth and body weight continues to increase over 
time (Harlan Laboratories, 2006), maintaining the animals at 115% of their body weight was 
possible in later studies to introduce an even further reduction in the strength for food demand. 
Immediately following meeting criteria at FR1, the fixed ratio was increased daily in the following 
progression 1,3,6,9,13,19,26,35,47,62,82,108…using the formula (response ratio = [5e(injection 
number x j)] – 5, where j=0.26)) adapted from Richardson and Roberts (1996). Sessions continued 
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until responding at a particular FR decreased to below that sufficient to earn a single reinforcer 
during the session. 
Drug Administration 
Test compounds were administered acutely to determine their effects on food 
maintained responding under a FR10 schedule.  A FR10 schedule was implemented in order to 
best maintain the rats’ target body weight percentage because some animals were earning 
more nutritive food pellets under the FR1 schedule during the session than their daily food 
ration would allow.  Administration of i.p. minocycline (0, 10, 30, 60 mg/kg) 67 minutes prior or 
i.p. buspirone (0, 1, 3, 10 mg/kg) was given 30 minutes prior to the test session.  Minocycline’s 
effects on differential reinforcing baselines of food-maintained behavior was examined given its 
effects on the previous self-administration studies as well as it’s known reduction of other 
stimulant-induced behavioral outcomes (Zhang et al., 2006; Chen et al., 2009a; Fujita et al., 
2012). Buspirone, a partial 5-HT1A agonist with some dopaminergic antagonist activity, is an 
approved for treatment of anxiety. Buspirone was examined in the present study due to its 
ability to attenuate other psychostimulant-induced behaviors such as self-administration and re-
instatement (Gold & Balster, 1992; Bergman et al., 2013; Shelton et al., 2013).  Furthermore, 
the literature remains unclear as to whether buspirone significantly affects food-maintained 
behavior because significant rate decreasing were observed in a drug discrimination paradigm 
under buspirone treatment (Ator, 1991) but no significant decrease was observed in a self-
administration procedure (Bergman et al., 2013). Thus, buspirone provided a test compound 
which may or may not have significant effects on food-maintained behavior and significantly 
affected drug abuse-related behaviors. Between all test sessions with either minocycline or 
buspirone, rats were required to meet stability criteria on a FR10 schedule before moving to the 
next dose.   
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Preliminary results suggested that while statistically significant, 85 and 100% BW 
conditions displayed a narrow window in demand between which to see differential effects of 
drug on food-maintained responding. Thus, widening the window between the initial demand 
conditions was hypothesized to allow for a better evaluation of differential drug effects. Thus, 
buspirone rats’ percent body weight was increased to 115%, and they were re-tested under two 
intermediate doses of buspirone (1.3 and 1.8 mg/kg). 
Drugs 
Minocycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and a 
few drops of 1 M hydrochloric acid. Immediately prior administration, the minocycline solution 
was adjusted to pH 3-4 using a few drops of sodium hydroxide. Buspirone was dissolved in 
saline. Minocycline and buspirone were both administered i.p. in 1 ml/kg body weight volume, 
except for 60 mg/kg minocycline that was given at 2 ml/kg body weight volume due to 
insolubility at the lower volume.  
Data Analysis 
Demand curves were generated using the formula log Q = log Q0 + k (e
-αP – 1) from 
Hursh and Silberberg (2008). Non-linear regression best fit values for the alpha level parameter 
were compared between body weight conditions for each group (85%, 90%, 100%) or (85%, 
100%, 115%) using an extra sum-of-squares F-test. When tested on a FR10 schedule, total 
consumption of food pellets was normalized by calculating the percentage of reinforcer 
consumption under test compound (minocycline or buspirone) treatment compared to total 
consumption under vehicle conditions. Normalized consumption percentages were analyzed 
using a two-way within subjects repeated measures ANOVA (repeated measures on treatment 
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dose and body weight condition), and comparisons of minocycline and buspirone treatment on 
consumption were assessed using Sidak’s Multiple Comparisons tests.  
 
Results 
 The group α levels (95% CI) for each body weight condition (85%, 90%, 100%) were 
calculated as 0.000041 (0.000036-0.000045), 0.000058 (0.000052-0.000064), 0.000081 
(0.000071-0.000092), respectively and were significantly different from one another [F (2, 178) 
= 35, p<0.0001] (Fig. 11). Responding by rats when maintained at 85% of their free-feeding 
body weight had a significantly smaller α level and a less elastic demand curve compared to 
animals maintained at 100% body weight [F(1,122)= 63, p<0.0001].    
 Figure 12 illustrates a significant main effect of minocycline on normalized consumption 
of the FOOD pellet reinforcer as compared to FOOD consumption under vehicle conditions 
[F(3,15)= 24.98, p<0.0001], however there was no main effect of body weight condition nor a 
significant interaction between the two variables. Multiple comparisons revealed that 30 and 60 
mg/kg minocycline significantly attenuated FOOD consumption when it was normalized to its 
corresponding vehicle condition in both body weight conditions (p<0.05).  
Similarly, there was a significant difference in α levels between body weights tested for 
the buspirone group [F (2,173) = 108, p<0.0001] (Fig. 13). The α levels for 85%, 100%, and 
115% body weight were 0.000051 (0.000044-0.000057), 0.00025 (0.00019-0.00031), 0.00014 
(0.00011-0.00017), respectively. Buspirone (1, 3, 10 mg/kg) produced a significant main effect 
on normalize FOOD consumption [(F (3, 36) = 26.20, p<0.0001], however there was no main 
effect of body weight condition nor a significant interaction.  Buspirone (10 mg/kg) significantly 
  
76 
 
reduced FOOD consumption when it was normalized to its corresponding vehicle and body 
weight conditions (p<0.05) (Fig. 14).  
Buspirone at 1.3 and 1.8 mg/kg produced a significant main effect [F (2, 8) = 14.33 p= 
0.0023] on normalized FOOD consumption, while there was no main effect of body weight 
condition when consumption was compared between animals maintained at 85% and 115% of 
their free-feeding body weight. Multiple comparisons analyses revealed that 1.8 mg/kg 
buspirone significantly attenuated FOOD consumption in both body weight conditions when 
normalized to its appropriate vehicle treated condition (p<0.05) (Fig. 15).  
Summary 
Given the results obtained from the methamphetamine self-administration studies, 
ibudilast, AV1013, and minocycline were all examined for their specificity of effect on 
methamphetamine-maintained relative to behavior maintained by a non-drug reinforcer, banana 
pellets.  A behavioral economics analysis was applied to assess the baseline strengths 
maintained by methamphetamine and banana pellet delivery. This approach was based on the 
assumption that the most legitimate comparison of the effects of test drugs on 
methamphetamine-specific behavior would be obtained when baseline strengths of food and 
methamphetamine reinforcement were at similar levels. A follow-up study was conducted to 
demonstrate "proof of concept" that baseline strength can be a determinant of whether or not an 
effect by a challenge drug occurs. The baseline strengths utilizing the same reinforcer, food 
pellets, were altered by manipulating the percentage of the free feeding body weight of the 
subjects. Then, test compounds (minocycline and buspirone) were evaluated for their effects on 
food-maintained responding at differing levels of baseline strength. The results obtained 
indicated that there were not differential drug effects as a function of baseline strength under the 
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conditions tested. However, there are several considerations of this study that limit the 
conclusions that can be drawn from it that are discussed in the Discussion.   
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Chapter III: Figure Legends  
Fig. 3. Effects of ibudilast or its vehicle on group mean infusions of methamphetamine (0.001, 
0.03, and 0.1 mg/kg/inf) obtained during daily 2-h self-administration sessions. Ibudilast was 
administered at 1, 7.5, or 10 mg/kg i.p. b.i.d. for three consecutive days at each 
methamphetamine self-administered dose. Data points represent the group means of total 
infusions obtained during the third day of testing at each ibudilast dose. Bars through symbols 
indicate ±S.E.M. Data point above “S” on the abscissa indicates results when saline was self-
administered when ibudilast's vehicle was given b.i.d. N=4 rats. *p<0.05 with respect to 
infusions obtained under ibudilast's vehicle condition.  
 
Fig. 4. Response Rate Dependency analysis of effects of 10 mg/kg ibudilast on 
methamphetamine (0.03 mg/kg/inf or 0.1 mg/kg/inf) response rates when response rates were 
approximately matched under vehicle conditions. Under ibudilast’s vehicle conditions the 
response rate maintained by 0.1 mg/kg/inf methamphetamine were altered by increasing the FR 
requirement (FR2-4). Ibudilast (10 mg/kg) was administered i.p. b.i.d. for three consecutive 
days.  Data represent the group means (±S.E.M.) of response rate maintained by both 
methamphetamine infusion doses. N=4 rats. *p<0.05 with respect to response rate obtained 
under ibudilast’s vehicle condition.  
 
Fig. 5. Effects of AV1013 or its vehicle on group mean infusions of methamphetamine (0.001, 
0.03, and 0.1 mg/kg/inf) obtained during daily 2-h self-administration sessions. AV1013 was 
administered at 1, 10, or 30 mg/kg i.p. b.i.d. for three consecutive days at each 
methamphetamine self-administered dose. Data points represent the group means of total 
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infusions obtained during the third day of testing at each AV1013 dose. Bars through symbols 
indicate ±S.E.M. Data point above “S” on the abscissa indicates results when saline was self-
administered when AV1013s vehicle was given b.i.d. N=5 rats. *p<0.05 with respect to infusions 
obtained under AV1013s vehicle condition.  
 
Fig. 6. Effects of minocycline or its vehicle on group mean infusions of methamphetamine 
(0.001, 0.03, and 0.1 mg/kg/inf) obtained during daily 2-h self-administration sessions. 
Minocycline was administered at 10, 30, or 60 mg/kg i.p once daily for three consecutive days at 
each methamphetamine self-administered dose. Data points represent the group means of total 
infusions obtained during the third day of testing at each minocycline dose. Bars through 
symbols indicate ±S.E.M. Data point above “S” on the abscissa indicates results when saline 
was self-administered when minocycline's vehicle (saline) was given daily. N=5 rats. *p<0.05 
with respect to infusions obtained under minocycline's vehicle condition.  
 
Fig. 7. Total demand for 0.1, 0.03 mg/kg/inf methamphetamine and banana pellets when rats 
were maintained at 85% of their free-feeding body weight.  Methamphetamine demand was 
generated during daily 2-h self-administration session and banana pellet demand was 
generated during daily 15-min sessions.  Data points represent the group means of total log of 
consumption of the reinforcing commodity (methamphetamine or banana pellets) as a function 
of unit price (FR value).  Brackets through the symbols indicate ±S.E.M.  Solid line curves 
represent the best non-linear fits for each reinforcer.  N=5-6 rats.   
 
Fig. 8. Effects of ibudilast (10mg/kg) on normalized consumption of 0.03 mg/kg/inf 
methamphetamine self-administration and banana pellets under a FR1 schedule.  Data were 
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collected during daily 2-h methamphetamine self-administration sessions or daily 15-min 
banana pellet sessions. Ibudilast (vehicle or 10 mg/kg) was administered i.p. b.i.d. for three 
consecutive days 1-h before testing.  Bars represent group means of normalized consumption 
of either reinforcer obtained on the third day of testing ±S.E.M.   N=4-5 rats. *p<0.05 with 
respect to normalized consumption of either reinforcer under vehicle conditions.   
 
Fig. 9. Effects of AV1013 (10, 30 mg/kg) on normalized consumption of 0.03 mg/kg/inf 
methamphetamine self-administration and banana pellets under a FR1 schedule.  Data were 
collected during daily 2-h methamphetamine self-administration sessions or daily 15-min 
banana pellet sessions. AV1013 (vehicle, 10, 30 mg/kg) was administered i.p. b.i.d. for three 
consecutive days 1-h before testing.  Bars represent group means of normalized consumption 
of either reinforcer obtained on the third day of testing. Brackets through bars represent ±S.E.M.   
N=3-5 rats. *p<0.05 with respect to normalized consumption of either reinforcer under vehicle 
conditions.   
 
Fig. 10. Effects of minocycline (10, 30, 60 mg/kg) on normalized consumption of 0.03 mg/kg/inf 
methamphetamine self-administration and banana pellets under a FR1 schedule.  Data were 
collected during daily 2-h methamphetamine self-administration sessions or daily 15-min 
banana pellet sessions. Minocycline (vehicle, 10, 30, 60 mg/kg) was administered i.p. once daily 
for three consecutive days 67-min before testing.  Bars represent group means of normalized 
consumption of either reinforcer obtained on the third day of testing. Brackets through bars 
represent ±S.E.M.  N=5 rats. *p<0.05 with respect to normalized consumption of either 
reinforcer under vehicle conditions.   
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Fig. 11. Total demand for 45 mg nutritive FOOD pellets when rats were maintained at 85%, 
90%, and 100% of their individual free-feeding body weight. FOOD pellet demand was 
generated during daily 15-min sessions. As a within subject study, all animals were assessed 
under all three body weight conditions. Data points represent the group means of total log of 
consumption of the reinforcing commodity (FOOD) as a function of unit price (FR value).  
Brackets through the symbols indicate ±S.E.M.  Solid line curves represent the best non-linear 
fits for each body weight condition.  N=5 rats.   
 
Fig. 12.  Effects of minocycline (10, 30, 60 mg/kg) on normalized consumption of FOOD pellets 
under a FR10 schedule.  Total consumption under minocycline treatment was normalized to 
total consumption of FOOD pellets following vehicle administration for each body weight 
condition.  Data was collected during daily 15-min sessions.  Data points represent the group 
mean of total normalized consumption as a function of minocycline dose in both body weight 
conditions. Brackets through symbols represent ±S.E.M.   N=6 rats. * and # indicate p<0.05 with 
respect to normalized consumption of FOOD under vehicle conditions at 100% and 85% BW, 
respectively. 
 
 Fig. 13. Total demand for 45 mg nutritive FOOD pellets when rats were maintained at 85%, 
100%, and 115% of their individual free-feeding body weight. FOOD pellet demand was 
generated during daily 15-min sessions. As a within subject study, all animals were assessed 
under all three body weight conditions. Data points represent the group means of total log of 
consumption of the reinforcing commodity (FOOD) as a function of unit price (FR value).  
Brackets through the symbols indicate ±S.E.M.  Solid line curves represent the best non-linear 
fits for each body weight condition.  N=5 rats.   
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Fig. 14.  Effects of buspirone (1, 3, 10 mg/kg) on normalized consumption of FOOD pellets 
under a FR10 schedule.  Total consumption under buspirone treatment was normalized to total 
consumption of FOOD pellets following vehicle administration for each body weight condition.  
Data were collected during daily 15-min sessions.  Data points represent the group mean of 
total normalized consumption as a function of buspirone dose in two body weight conditions 
(85% and 100%). Brackets through symbols represent ±S.E.M.   N=13 rats. * and # indicate 
p<0.05 with respect to normalized consumption of FOOD under vehicle conditions at 100% and 
85% BW, respectively. 
 
Fig. 15.  Effects of buspirone (1.3, 1.8 mg/kg) on normalized consumption of FOOD pellets 
under a FR10 schedule.  Total consumption under buspirone treatment was normalized to total 
consumption of FOOD pellets following vehicle administration for each body weight condition.  
Data was collected during daily 15-min sessions.  Data points represent the group mean of total 
normalized consumption as a function of buspirone dose in two body weight conditions (85% 
and 115%). Brackets through symbols represent ±S.E.M.   N=5 rats. * and # indicate p<0.05 
with respect to normalized consumption of FOOD under vehicle conditions at 115% and 85% 
BW, respectively. 
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Chapter IV: Ibudilast’s effects on methamphetamine drug discrimination in the rat 
 
Introduction 
 The purpose of the final research aim of this dissertation was to determine whether the 
discriminative stimuli produced by methamphetamine administration are attenuated by ibudilast 
administration. Others have reported that the PDE inhibitors, rolipram and nefiracetam, 
significantly attenuate methamphetamine (0.2 and 0.5 mg/kg) drug discrimination in rats (Yan et 
al., 2004; Yan et al., 2006).  Given that we have shown ibudilast, which exhibits PDE inhibitory 
activity, significantly attenuates methamphetamine-induced locomotor activity, sensitization, and 
self-administration (above), ibudilast was hypothesized to significantly attenuate 
methamphetamine’s discriminative stimulus effects.   
 
Methods 
Subjects 
Ten adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) were allowed to 
acclimate to the vivarium for at least one week before training began. When not in testing, rats 
were individually housed in standard plastic rodent cages in a temperature-controlled (22°C), 
Association for the AAALAC International-accredited facility in which they had ad libitum access 
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to water. Rats were allowed ad libitum rat chow (7012 Teklad LM-485 Mouse/Rat Sterilizable 
Diet, Harlan Laboratories, Inc., Indianapolis, IN) for at least ten days in order to calculate each 
individual’s free feeding body weight. Individual body weights were determined by averaging 
daily weights from six consecutive days of ad libitum feeding prior to initiation of weight 
maintenance and test sessions Rats were then maintained at 85% of their free-feeding body 
weight by controlled feedings of rat chow after daily sessions and once daily over the weekend. 
All rats were maintained on a reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) for the 
duration of the experiment, and they were trained and tested during the dark segment of this 
cycle. All procedures were carried out in accordance with the “Guide for the Care and Use of 
Laboratory Animals” (Institute of Laboratory Animal Resources, National Academy Press, 1996) 
and were approved by the Institutional Animal Care and Use Committee of Virginia 
Commonwealth University. 
Apparatus 
Commercially-obtained test chambers equipped with two retractable levers, a 5-w 
houselight, a Sonalert tone generator, and a food pellet dispenser (MED Associates, Inc., St. 
Albans, VT) were used. Recording of lever presses and food dispenser activation was 
accomplished by a microcomputer, interface, and associated software (MED-PCs IV, MED 
Associates, Inc., St. Albans, VT). 
Procedure 
Discrimination Training 
Rats were initially trained to lever press for 45 mg rodent purified diet dustless precision 
pellet (BioServ, Frenchtown, NJ) delivery according to a FR10 schedule during daily 15-min 
sessions (Mon-Fri). Five rats were trained to respond on the left lever and five rats on the right 
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lever for food pellet delivery.  This initially active lever eventually became the vehicle-designated 
lever. Rats were then trained to respond on the opposite lever for food pellet delivery under a 
FR10 schedule, which eventually became the drug-designated lever. During training sessions, 
either 1 mg/kg methamphetamine or saline i.p. injection was administered 15 min pre-session 
and the appropriately paired lever produced food pellets under a FR10 schedule. Training 
sessions occurred using the following sequence which renewed bi-monthly. 
(1) D-V-V-D-V 
V-D-D-V-D 
V-D-V-D-V 
D-V-D-V-D 
 
(2) V-D-D-V-V 
D-V-D-V-D 
D-V-V-D-D 
V-D-V-D-V 
 
 
Acute Tues/Fri Discrimination Testing  
Testing commenced once the rats met training criteria in which the first fixed ratio (FFR) 
was completed on the appropriate lever during at least 8 out of 10 consecutive sessions, and 
80% of total responses had been emitted on the appropriate lever during these 8 sessions. Test 
sessions subsequently occurred if the FFR was correct on both the most recent 
methamphetamine and saline training sessions, otherwise additional training sessions were 
given. During test sessions, which occurred on Tuesdays and Fridays, responding at either 
lever was reinforced according to a FR10 schedule. Initially, methamphetamine (0.1, 0.3, 0.56, 
1, and 3 mg/kg) was tested to obtain a generalization curve for the training dose (1 mg/kg). 
Methamphetamine dose testing order was randomized across subjects. 
Cumulative Dosing Training  
An objective during testing was to rapidly obtain a complete dose-effect curve for 
methamphetamine at each ibudilast dose tested. To do so, training under cumulative dosing 
conditions was necessary before testing could begin to ensure that the procedure produced a 
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generalization curve similar to that obtained under acute dosing conditions. After the acute 
dose-effect curve for methamphetamine was obtained, cumulative dosing pilot training sessions 
began. The pilot training sessions consisted of five 3-min reinforcement periods each preceded 
by 10-min TO periods during which the test chambers darkened and response levers retracted. 
Having five, 3-min food-reinforcement components preceded by 10-min TO periods ensured 
that total food pellet availability remained constant at 15 min (similar to preceding training and 
testing conditions) and that overall session duration did not exceed methamphetamine’s 
approximate elimination half-life of 70-min (Cho et al., 2001). During pilot sessions, subjects 
were administered saline 10-min prior to the first 3-min reinforcement period, methamphetamine 
(1 mg/kg) at the commencement of the first TO period, and sham injections at the 
commencement of the TO periods prior to the remaining reinforcement components. During 
each reinforcement component, only the lever associated with the most recent injection 
produced food reinforcement under a FR10 schedule. Pilot sessions were utilized to allow the 
subjects to acclimate to the multi-component, multi-injection procedure, and to determine that 
the pre-session injections controlled consistent lever selection for the 55 min session. 
Cumulative dosing training was complete if subjects completed the FFR on the correct lever and 
>80% of responding was emitted on the correct lever during all five food reinforcement periods.  
Following pilot sessions, regular training with continuous 15-min training sessions resumed until 
testing criteria were again met (i.e., correct FFR during the most recent drug and vehicle training 
sessions).  
Cumulative Dosing Testing 
Once a subject met testing criteria, training was suspended for two full days (Sat-Sun) 
during which ibudilast was administered b.i.d (see below) and the cumulative dosing testdays 
occurred on the subsequent days (Mon-Tues). Beginning b.i.d. ibudilast dosing two days prior to 
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the test sessions maintained consistency with the previously described behavioral protocols.   
Multiple treatments (i.e. b.i.d. dosing) prior to beginning and throughout testing are necessary to 
obtain steady-state drug levels of ibudilast in various tissue compartments and to enable 
minimally sufficient glial attenuation that relates to the onset of other effects (Ledeboer et al., 
2006; Hutchinson et al., 2009a; Beardsley et al., 2010). Furthermore, dosing over weekends 
avoided disruption of regularly scheduled training sessions (Mon-Fri). Cumulative dosing 
testdays consisted of five, 3-min food availability periods each but the first proceeded by 10-min 
TO periods. A methamphetamine (0, 0.1, 0.3, 0.56, 1, 3 mg/kg) dose effect curve was obtained 
by combining results from two testdays in which cumulative doses of 0 (saline), 0 (sham), 0.1, 
0.56 and 1, and 0 (saline), 0 (sham), 0.3, 1, and 3 mg/kg were obtained (in which acute doses of 
0 (saline), 0 (sham), .1, .46, and .44 mg/kg, and 0 (saline), 0 (sham), 0.3, 0.7, and 2 mg/kg were 
administered).  
Ibudilast (0, 1, 7.5, 10 mg/kg) was administered b.i.d. beginning two days prior to the test 
days and 1-h prior to testing on both test days. Between Testdays, subjects returned to daily 
acute dosing 15-min session training and were required to meet test criteria before advancing. 
Tested ibudilast doses were randomized between individual rats. 
Testing and Training Lower Methamphetamine Doses (1 mg/kg vs. 0.56 or 0.3 mg/kg) 
The literature suggests that the training dose utilized during a drug discrimination 
procedure can be a pivotal component of the assay.  For example, progressively lowering a 
PCP training dose produces marked decreases in the ED50 for stimulus generalization and 
parallel leftward shifts of the dose response curves indicative of greater stimulus generalization 
at lower training doses (Beardsley et al., 1987). Further, an antagonist can more readily disrupt 
discrimination of a particular drug when trained at a low training dose (Picker et al., 1993). Yan 
et al (2006) first trained animals to discriminate 0.5 mg/kg methamphetamine and tested PDE 
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inhibitors’ effects under 0.2 mg/kg methamphetamine conditions. Thus, in order to better 
compare ibudilast’s effects as a PDE inhibitor and glial cell modulator to rolipram and 
nefiracetam’s effects on methamphetamine drug discrimination, the subjects were re-trained at 
a lower methamphetamine training doses (0.56 and 0.3 mg/kg).  
Animals were re-trained to discriminate 0.56 mg/kg methamphetamine using the 
procedures described above that involved only a single injection prior to each 15-min session 
until training criteria were again met. As a probe to determine if even the high dose of ibudilast 
(10 mg/kg)  would now have effects different from those following discrimination training at the 1 
mg/kg dose, the effects of 10 mg/kg ibudilast were tested on discrimination performance. To do 
so, training was suspended for two full days during which (10 mg/kg) ibudilast was administered 
b.i.d and then ibudilast was administered 1-h prior to a 15-min 0.56 mg/kg methamphetamine 
testing session on the third day. The results from the probe were compared to the %DLR for 
0.56 mg/kg methamphetamine obtained during a non ibudilast pre-treated 15-min control test 
session.   
 Following this initial probe, the group was divided in two. Five of the 10 animals 
remained at the 0.56 mg/kg methamphetamine training dose and underwent the cumulative 
dosing procedure in order to obtain a full dose response curve for the 0.56 mg/kg training dose 
and determine whether there was a leftward shift of the curve and reduction of the ED50 for 
methamphetamine generalization. Further, the cumulative dosing procedure allowed for the 
potential to examine ibudilast’s effects on methamphetamine discrimination at all doses of 
methamphetamine, not just the training dose (0.56 mg/kg methamphetamine). Second, to better 
approximate the training and testing conditions previously reported to result in antagonism of 
the methamphetamine discriminative stimulus by other PDE inhibitors (Yan et al., 2004; Yan et 
al., 2006), the methamphetamine training dose was further decreased to 0.3 mg/kg for the 
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remaining five animals.  Subjects were re-trained, as before, and required to meet training and 
testing criteria at the 0.3 mg/kg methamphetamine training dose.  A methamphetamine dose 
response curve (0, 0.1, 0.3, 0.56, 1, 3 mg/kg) was obtained using the acute Tues/Fri testing 
procedure where dose order was randomized between subjects. The acute procedure was 
utilized here because initial acquisition to the lower training dose took much longer and stability 
of discrimination performance was unstable.  
Drugs 
(±)-Methamphetamine hydrochloride (National Institute on Drug Abuse, Rockville, MD) 
was prepared in sterile 0.9% saline. Methamphetamine stock solutions were sterilized by 
filtration through 0.2 mm filtration disks. Ibudilast (3-isobutyryl-2-isopropylpyrazolo [1, 5-a] 
pyridine) was received as a gift from MediciNova, Inc. (San Diego, CA) and was dissolved in a 
35% PEG400, 10%Cremophor® RH40 (BASF, Ludwigshafen, Germany) aqueous vehicle. 
Ibudilast was administered i.p.in 1 ml/kg body weight volume. 
Data Analysis 
The percentage of methamphetamine-lever presses (%DLR) was calculated for each 
subject by dividing the number of lever presses emitted upon the methamphetamine-designated 
lever by the total number of presses emitted, and multiplying this quotient by 100. Individual 
values of %DLR were then averaged (±SEM). Complete generalization to the 
methamphetamine discriminative stimulus was inferred when %DLR ≥80%. If a rat failed to 
make at least 10 lever presses during a test session, its data were excluded from calculations of 
%DLR but were included for mean response rate determinations. This exclusion was made to 
prevent near-zero rates of responding from disproportionately influencing estimates of %DLR. 
ED50 values and their confidence intervals (CI) were calculated for %DLR and for reducing 
  
97 
 
response rates after a log-dose transformation using a variable slope, nonlinear regression 
analysis. Methamphetamine slopes with and without co-administration of the test drug were 
then determined parallel or not using the F test, and if parallel, intercepts were determined equal 
or not as a measure of potency. Average ED50s from each condition were analyzed using an 
un-paired t-test (in comparing acute vs. cumulative dosing procedures) or a one-way ANOVA 
with Dunnett’s multiple comparisons post hoc tests (in ibudilast treatment conditions). Response 
rates were calculated for each drug condition by dividing the total number of lever presses 
emitted during the session by the number of seconds in the acute 15-min session (900-sec) or 
for each individual 3-min test bin during the cumulative testing procedure (180-sec).  Calculated 
response rates under acute Tues/Fri methamphetamine conditions were compared using a one-
way ANOVA with Dunnett’s multiple comparison’s post hoc tests.  Calculated response rates for 
acute vs. cumulative dosing procedures and ibudilast treated conditions were analyzed with a 
two-way ANOVA (repeated measures on methamphetamine dose and between dosing 
procedure or ibudilast condition). Differences in response rates from saline vehicle conditions 
and/or compared to PEG/crem veh response rates were assessed using Bonferroni post hoc 
analyses.  All statistical tests were conducted using commercial computer software (Prism5d for 
Macintosh, GraphPad Software, Inc., San Diego, CA), and all types of comparisons were 
considered statistically significant if p<0.05. 
 
Results 
 The upper frame of Figure 15 shows the percentage of methamphetamine lever presses 
obtained during acute Tues/Fri tests when the rats were trained to discriminate 1 mg/kg 
methamphetamine from saline. Complete generalization (>80% DLR) occurred at 1 and 3 mg/kg 
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methamphetamine, while saline produced near-zero drug lever presses.  The ED50 (CI) 
obtained was 0.53 (0.46-0.58) mg/kg methamphetamine for occasioning the 1 mg/kg 
methamphetamine stimulus. There were no statistically significant effects of methamphetamine 
on response rates at any dose compared to vehicle conditions (Fig. 15; lower frame).  
 Results from the cumulative dosing discrimination procedure produced similar results in 
that both 1 and 3 mg/kg produced complete generalization to the 1 mg/kg methamphetamine 
training stimulus, while saline and sham injections produced near-zero %DLR (Fig. 16; upper 
frame). The ED50 for methamphetamine to occasion its 1 mg/kg discriminative stimulus was 
0.58 (0.51-0.65) mg/kg. There was a significant main effect of methamphetamine dose on 
response rates [F (5, 35) = 5.326, p=0.001] and interaction between methamphetamine dose 
and the dosing procedure used [F (5, 35) = 3.982, p=0.0058]. Bonferroni post hoc analyses 
indicated that in the cumulative dosing procedure there was a significant decrease in response 
rates at 3 mg/kg methamphetamine compared to the saline condition (p<0.05). There were no 
significant differences in the ED50s for %DLR or for suppressing response rates (Fig. 16; lower 
frame) between the acute Tues/Fri and the cumulative dosing procedures.  
 During cumulative doing testing, complete generalization occurred at 1 and 3 mg/kg 
methamphetamine with near-zero %DLR following saline and sham injections under PEG/crem 
vehicle, 7.5, and 10 mg/kg ibudilast pre-treatment conditions (Fig. 17; upper frame).  Complete 
generalization occurred at 3 mg/kg of methamphetamine; however 1 mg/kg methamphetamine 
fell just short of full generalization with an average of 79 %DLR for methamphetamine under 1 
mg/kg ibudilast pre-treatment conditions. The calculated ED50s (CI) were 0.49 (0.42-0.56), 
0.711 (0.62-0.82), 0.49 (0.42-0.57), and 0.50 (0.37-0.67) mg/kg for occasioning the 1 mg/kg 
methamphetamine training dose under PEG/crem vehicle, 1, 7.5, and 10 mg/kg ibudilast pre-
treatment conditions, respectively. Further, there were no significant differences in ED50s for 
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occasioning the 1 mg/kg methamphetamine stimulus following any ibudilast pretreatment 
condition compared to pretreatment with PEG/crem vehicle. Methamphetamine [F (6, 54) = 
16.18, p<0.0001] and ibudilast [F (3, 27) =14.71, p<0.0001] both had a significant main effects 
on response rates in the cumulative dosing procedure (Fig. 17; lower frame).  The high dose of 
methamphetamine (3 mg/kg) significantly depressed response rates compared to saline and 
sham conditions regardless of ibudilast pre-treatment dose (p<0.05).  Ibudilast (7.5 mg/kg) pre-
treatment significantly decreased response rates at all methamphetamine doses compared to 
PEG/crem vehicle and 10 mg/kg ibudilast pre-treatment decreased response rates at all the 
methamphetamine doses with the exception of the high dose of methamphetamine (3 mg/kg) 
(p<0.05).  
 Figure 18 illustrates the %DLR for methamphetamine obtained when the training dose 
was lowered to 0.56 mg/kg. Unlike results when trained at 1 mg/kg methamphetamine, lowering 
the training dose to 0.56 mg/kg methamphetamine now resulted with 0.56 mg/kg 
methamphetamine completely occasioning methamphetamine lever pressing.  A probe (n=7) to 
determine  the effects of 10 mg/kg ibudilast pretreatment on methamphetamine discrimination at 
the new training dose (0.56 mg/kg) indicated no significant attenuation in %DLR for 
methamphetamine compared to non-treated control test sessions.  
 When the rats were sub-divided into groups of five, subjects whose training dose 
remained at 0.56 mg/kg methamphetamine were tested under cumulative dosing conditions in 
order to characterize a complete dose-effect curve. Under ibudilast's vehicle (PEG/crem) pre-
treatment conditions, methamphetamine produced increasingly more methamphetamine 
appropriate responding with increasing cumulative dose, with complete generalization at 0.56, 1 
and 3 mg/kg methamphetamine. Although ibudilast was planned to be tested under these 
conditions, proceeding forward with these tests seemed unwarranted and were not conducted 
  
100 
 
considering that 0.3 mg/kg methamphetamine elicited near zero methamphetamine appropriate 
responding and the probe analysis indicated that 10 mg/kg ibudilast does not affect % DLR 
even at 0.56 mg/kg methamphetamine.  
 The remaining five animals were re-trained to discriminate 0.3 mg/kg methamphetamine 
from saline. Although the subjects reached both training and testing criteria, their discrimination 
behavior was not consistently stable from week to week thus promoting the use of the acute 
Tues/Fri testing procedure. For example, it took an average of 16 training days to complete the 
methamphetamine dose response curve when animals were trained at 1 mg/kg.  Conversely, 
the same five animals required an average of 28.8 training days to complete the entire dose 
response curve when trained at 0.3 mg/kg methamphetamine. Further, while the training dose 
(0.3 mg/kg) produced full generalization, both 0.56 and 1 mg/kg methamphetamine failed to 
produce greater than 80% of methamphetamine appropriate lever responding. Thus, these 
inconsistencies in discrimination at 0.3 mg/kg precluded further testing with ibudilast or its 
vehicle.  
  
Summary 
 The results from drug discrimination tests indicated that when trained to discriminate 1 
mg/kg methamphetamine, increasingly greater proportions of % DLR occurred.  There was not 
a significant difference in the ED50s for %DLR or response rates when tested under the acute 
or in a two-day cumulative dosing procedure.  When ibudilast was administered as a 
pretreatment following drug discrimination training at 1 mg/kg methamphetamine, there were no 
significant differences in ED50 for methamphetamine at any ibudilast dose tested. However, 7.5 
and 10 mg/kg ibudilast significantly attenuated session response rates compared to vehicle 
  
101 
 
conditions. These results suggest that ibudilast was ineffective at attenuating 
methamphetamine’s discriminative stimulus effects following training at 1 mg/kg 
methamphetamine.  
When animals were re-trained to discriminate methamphetamine at lower doses, a 
training dose of 0.56 mg/kg methamphetamine was still not affected by 10 mg/kg ibudilast. 
Finally, training at the 0.3 mg/kg methamphetamine training dose resulted in inconsistent 
discriminative performance, which was considered too unreliable to permit subsequent tests 
with ibudilast. 
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Table 4. Number of rats included in each condition based on session response criteria 
Tues/Fri Acute Vs. Cumulative Dosing Procedure 
Meth Dose Procedure 
 Tues/Fri Acute Response Rate Cumulative 
Dosing 
Response Rate 
0.1 mg/kg n=10 n=10 n=8 n=8 
0.3 mg/kg n=10 n=10 n=8 n=8 
0.56 mg/kg n=10 n=10 n=8 n=8 
1 mg/kg n=10 n=10 n=8 n=8 
3 mg/kg n=9 n=10 n=7 n=8 
 
2-Day Cumulative Dosing Procedure 
Meth Dose Ibudilast Dose (b.i.d.) Response 
Rate  
 PEG/crem veh 1 mg/kg 7.5 mg/kg 10 mg/kg  
0.1 mg/kg n=10 n=10 n=10 n=9 n=10 
0.3 mg/kg n=10 n=9 n=10 n=10 n=10 
0.56 mg/kg n=10 n=10 n=8 n=9 n=10 
1 mg/kg n=10 n=10 n=9 n=10 n=10 
3 mg/kg n=7 n=8 n=9 n=7 n=10 
 
Methamphetamine Probe Analysis (0.56 mg/kg Training Dose) 
Meth Dose Treatment Condition 
 No Pre-treatment Response Rate  10 mg/kg 
ibudilast  
Response Rate 
0.56 mg/kg n=8 n=8 n=7 n=8 
 
1 vs 0.56 mg/kg Training Dose Comparison (Cumulative Dosing) 
Meth Dose PEG/crem veh 
 1 mg/kg Training 0.56 mg/kg Training 
0.1 mg/kg n=10 n=3 
0.3 mg/kg n=10 n=3 
0.56 mg/kg n=10 n=3 
1 mg/kg n=10 n=3 
3 mg/kg n=7 n=2 
 
1 vs 0.3 mg/kg Training Dose Comparison (Tues/Fri Acute Dosing) 
Meth Dose PEG/crem veh 
 1 mg/kg Training 0.3 mg/kg Training 
0.1 mg/kg n=10 n=5 
0.3 mg/kg n=10 n=5 
0.56 mg/kg n=10 n=5 
1 mg/kg n=10 n=5 
3 mg/kg n=9 n=5 
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Chapter V: Figure Legends  
Fig. 15. Upper Frame: Methamphetamine %DLR during acute Tues/Fri tests.  Discrimination 
sessions were 15-min in duration. Data points represent the group means of %DLR ± S.E.M. for 
each dosing procedure. “S” indicates results with saline vehicle. “Sh” indicates results following 
sham injections. See Table 4 for groups sizes for each methamphetamine dose. Lower Frame: 
Response rates during acute dosing tests. Data points represent the group means of response 
rates ± S.E.M. for each dosing procedure. Other details identical to those described in the upper 
frame. N=10 rats. 
 
Fig. 16. Upper Frame: Comparison of %DLR of methamphetamine between acute Tues/Fri 
dosing and cumulative dosing tests. Acute Tues/Fri dosing sessions were 15-min in duration.  
Cumulative dosing data are a compilation of two consecutive days of testing in which five 3-min 
active reinforcement periods were separated by 10-min TO periods to allow for injections and 
drug absorption. Data points represent the group means of %DLR ± S.E.M. for each dosing 
procedure. “S” indicates discrimination of saline vehicle. See Table 4 for group sizes for each 
methamphetamine dose. Lower Frame: Response rates between acute Tues/Fri dosing and 
cumulative dosing tests. Data points represent the group means of response rates ± S.E.M. for 
each dosing procedure. Other details identical to those described in the upper frame. *p<0.05 
with respect to saline response rates. N=10 rats. 
 
Fig. 17. Upper Frame: Ibudilast’s effects on %DLR of methamphetamine during cumulative 
dosing tests. Cumulative dosing data are a compilation of two consecutive days of testing in 
which five 3-min active reinforcement periods were separated by 10-min TO periods to allow for 
injections and drug absorption. Data points represent the group means of %DLR ± S.E.M. for 
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each dosing procedure. “S” indicates results with saline vehicle. “Sh” indicates results following 
sham injections. See Table 4 for groups sizes for each ibudilast dose. Lower Frame: Ibudilast’s 
effects on responses rate during cumulative dosing tests. Data points represent the group 
means of response rates ± S.E.M. for each dosing procedure. Other details identical to those 
described in the upper frame. *p<0.05 with respect to PEG/crem vehicle response rates. 
#p<0.05 with respect to saline and sham condition response rates. N=10 rats. 
 
Fig. 18. Ibudilast’s (10 mg/kg) effects on %DLR for methamphetamine training dose (0.56 
mg/kg) tests.  Filled circle points represent %DLR ± S.E.M. from Tues/Fri acute dosing 
methamphetamine dosing procedure when the animals were trained to discriminate 1 mg/kg 
methamphetamine from saline.  The filled square represents %DLR ± S.E.M. of an acute dose 
of methamphetamine (0.56 mg/kg) training dose.  The filled triangle represents ibudilast (10 
mg/kg) treatment effects on 0.56 mg/kg methamphetamine %DLR ± S.E.M. “S” indicates results 
with saline vehicle. See Table 4 for group sizes for each condition. 
 
Fig. 19. Comparison of 1 vs. 0.56 mg/kg methamphetamine training dose effects on %DLR of 
methamphetamine during cumulative dose tests. Both curves generated following ibudilast’s 
vehicle (PEG/crem) pre-treatment. Cumulative dosing data is a compilation of two consecutive 
days of testing in which five 3-min active reinforcement periods were separated by 10-min TO 
periods to allow for dosing and absorption. Data points represent the group means of %DLR ± 
S.E.M. for each dosing procedure. “S” indicates results with saline vehicle. “Sh” indicates results 
following sham injections. See Table 4 for groups sizes for each methamphetamine dose. 
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Fig. 20. Comparison of 1 vs. 0.3 mg/kg methamphetamine training dose effects on %DLR of 
methamphetamine during acute Tues/Fri test sessions. Acute Tues/Fri sessions were 15-min in 
duration. Data points represent the group means of %DLR ± S.E.M. for each dosing procedure. 
“S” indicates results with saline vehicle. See Table 4 for group sizes for each methamphetamine 
dose. 
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Chapter V: DISCUSSION 
Introduction 
 The evidence provided above suggests that modulating glial cell activity, and 
consequently reducing glial cell associated neuroinflammation, and/or inhibiting PDE activity, 
may modulate behaviors in animal models presumably predictive of clinical behavior associated 
with drug abuse disorders.  More specifically, the evidence suggests that attenuating microglial 
and astrocyte activation and its subsequent inflammatory events elicited by methamphetamine 
administration can reduce methamphetamine locomotor activity and sensitization, self-
administration, but perhaps not drug discrimination.  Furthermore, given the control procedures 
performed as a result of the self-administration study results, the data suggests that the glial 
modulating compounds are not acting in a rate dependent manner, but may not be specific for 
only reducing methamphetamine-specific behavior.  Further studies are required in order to 
determine whether the initial reinforcing efficacy of alternative reinforcers is important in 
examining non-specific effects of potential pharmacotherapies. 
Chapter II 
Results from Chapter II indicated that ibudilast dose-dependently reduced the chronic 
and acute effects of methamphetamine on locomotor activity in the mouse. Chronic treatment 
with methamphetamine provided evidence of sensitization as subsequent administrations 
elicited greater increases in distance traveled. The highest dose of ibudilast (13 mg/kg) tested 
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significantly attenuated these methamphetamine-induced sensitization effects. Ibudilast's 
analog, AV1013, which lacks its potency for inhibiting PDE, but retains its ability to suppress 
activated glial activity, similarly dose-dependently attenuated methamphetamine's chronic and 
acute locomotor activity effects, although it was ~ 6–9 fold less potent in doing so. These later 
observations suggest that the ability to modulate glial activity is sufficient to attenuate 
methamphetamine's locomotor activity effects, although PDE inhibition likely can additionally 
contribute if present. 
Ibudilast is a non-selective PDE inhibitor (Kishi et al., 2001; Gibson et al., 2006), glial cell 
modulator and anti-inflammatory agent (Suzumura et al., 1999; Mizuno et al., 2004), and an 
inhibitor of macrophage migration inhibitory factor (Cho et al., 2010). As such, its effects could 
be a result of any or a combination of all these mechanisms. Some of these effects have 
already been reported to reduce methamphetamine activity (see below). It is unlikely ibudilast’s 
effects on methamphetamine are a result of directly affecting conventional mechanisms, for it 
doesn't have effective activity at ~100 other radioligand binding and enzyme targets (Ledeboer 
et al., 2006). 
PDE inhibition, by itself, significantly reduces some methamphetamine behaviors. PDE 
inhibitors, such as rolipram and nefiracetam, attenuate methamphetamine-induced locomotor 
activity, sensitization, and the discriminative stimulus effects of methamphetamine (Iyo et al., 
1995; Iyo et al., 1996a; Iyo et al., 1996b; Mori et al., 2000; Yan et al., 2004; Yan et al., 2006).  
Methamphetamine increases levels of cytokines and inflammatory factors, such as 
tumor necrosis factor (TNFα), interleukin 6 (IL-6), interleukin 1β (IL-1β) mRNA levels, monocyte 
chemo-attractant protein 1 (MCP-1), and intercellular adhesion molecule (ICAM-1) (Yamaguchi 
et al., 1991; Nakajima et al., 2004b; Goncalves et al., 2008). Attenuation of glial cell activation 
and pro-inflammatory signaling, and up-regulation of neuroprotective factors, activities of both 
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ibudilast and AV1013, have also been reported to attenuate some of methamphetamine's 
behavioral effects, including locomotor sensitization (Zhang et al., 2006; Niwa et al., 2007c). 
Conversely, reducing GDNF levels potentiates methamphetamine self-administration and 
reinstatement vulnerability (Yan et al., 2007). GDNF is a neurotrophic factor best known for its 
role in cell survival and re-growth, especially in dopamine neurons, that has been recently 
implicated negatively regulating drug abuse behaviors (Carnicella & Ron, 2009). Ibudilast’s anti-
inflammatory action reduces glial activation by suppressing TNFα, IL-6, IL-1β, MCP-1, and nitric 
oxide (NO), while also increasing production of GDNF (Suzumura et al., 1999; Mizuno et al., 
2004). Although AV1013 lacks the efficacy of PDE inhibition of ibudilast, it has similar glial cell 
modulatory activity (Cho et al., 2010). Both ibudilast and AV1013 reduce methamphetamine-
induced locomotor behavior, suggesting that AV1013’s modulation of glial cell activation is 
sufficient to attenuate methamphetamine effects.  
Lilius (2009) reported that ibudilast could induce decreases in spontaneous locomotor 
activity in rats following its acute administration. Although the Lilius study used rats, and the 
present study used mice, the possibility of direct locomotor decreasing effects needs to be 
considered in interpreting ibudilast's and AV1013's modulation of methamphetamine's locomotor 
activity effects. It is unlikely that these potential locomotor decreasing effects could explain the 
magnitude of their effects on methamphetamine's activity. Importantly, none of the dosage 
regimens of ibudilast or AV1013 produced statistically significant reductions in locomotor activity 
during either baseline test.  Perhaps if there had been important locomotor decreasing effects of 
these drugs initially, tolerance developed to them, for the drugs were given b.i.d beginning two 
days prior to the initiation of testing, whereas in the Lilius study ibudilast was given acutely. 
Additionally, acute tolerance may have occurred as well, for in the Lilius study, ibudilast was 
administered 15 min before testing, whereas in the present study it was given one hour prior to 
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locomotor tests, and sedative-like effects appear to wane within 30 min of its administration 
(Ledeboer et al., 2006).  
Both ibudilast and AV1013 attenuated methamphetamine-induced locomotor activity 
when administered concurrently with methamphetamine. These results suggest that these drugs 
potentially could blunt methamphetamine’s stimulatory effects or “value” to chronic users 
potentially facilitating the effectiveness of other interventions such as psychotherapy. 
Additionally, ibudilast and AV1013 significantly attenuated the hyperactivity effects following 
acute methamphetamine challenge. Considering that limited re-exposure to an abused drug can 
precipitate a longer-termed relapse in an abstinent abuser (Bigelow et al., 1977; Chornock et al., 
1992; de Wit, 1996), ibudilast and AV1013’s attenuation of an acute methamphetamine 
challenge suggests usefulness as a relapse prevention treatment in abstinent abusers, which is 
consistent with a previous report that ibudilast reduces reinstatement precipitated by 
methamphetamine primes in rats previously reinforced with methamphetamine (Beardsley et al., 
2010). The possibility of clinically useful relapse prevention now extends to AV1013 as well.  
The AD50 values for reducing the effects of the 3 mg/kg methamphetamine challenge 
dose did not differ within ibudilast and AV1013 groups between the acutely and chronically 
treated mice, suggesting that peak ability to blunt methamphetamine’s effects was reached by 
two days of b.i.d. administration. This speculation requires the qualification that only a single 
methamphetamine dose (3 mg/kg) was tested, and administration of these drugs was not given 
for longer than seven days. Similarity between these AD50 values also suggests that tolerance 
to their effectiveness did not develop, a desirable feature in a potential pharmacotherapeutic.  
Several additional observations strengthen the interest in these drugs. In the present 
study, repeated administration of methamphetamine-induced sensitization to its locomotor 
activity effects was significantly attenuated by 13 mg/kg ibudilast. It has been suggested that 
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sensitization plays a key role in drug addiction in humans (Sax & Strakowski, 2001; Chen et al., 
2009b). For example, three doses of d-amphetamine given to healthy human volunteers 
produces significant increases in eye-blink and locomotor scores, as well as in reported mood 
and subjective drug effects (i.e. euphoria) suggestive of sensitization (Strakowski & Sax, 1998). 
In conjunction with the behavioral effects, the adaptations of specific brain regions implicated in 
the process of sensitization have been associated with reward pathways linked to drug-seeking 
and addiction (Robinson & Berridge, 1993). Thus, a compound that blunts sensitization may 
have additional merit for consideration as a pharmacotherapy for drug abuse. Furthermore, 
because the neurocircuitry, neurotransmitter, and neuronal receptor systems activated in 
reinstatement models of drug abuse are similar to those systems involved in the process of 
sensitization (Steketee & Kalivas, 2011), the potential usefulness of these drugs in treating 
methamphetamine relapse is even further enhanced.  
Summary 
The present study identified that both ibudilast and its analog, AV1013, are able to 
attenuate methamphetamine-induced locomotor activity in mice. Given AV1013's impotency to 
affect PDE activity, these results suggest that glial cell modulation alone may be sufficient for 
attenuating these methamphetamine effects. Treatments for stimulant abuse targeting 
conventional mechanisms have generally proven unsuccessful.  The present results are 
consistent with others suggesting that modulating glial cell activity with drugs could provide a 
novel, and perhaps fruitful target for treating methamphetamine abuse.  
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Chapter III  
Results from Chapter III reported that methamphetamine was established as a positive 
reinforcer and was self-administered under vehicle pretreatment conditions characterized by an 
inverted U-shaped curve relating infusion numbers to dose, with significantly more 
methamphetamine infusions being obtained at the intermediate dose (0.03 mg/kg/inf) during 
testing of all drugs, and at the highest dose (0.1 mg/kg/inf) during testing of ibudilast and 
AV1013, relative to those obtained of saline. Ibudilast (10 mg/kg), AV1013 (10 and 30 mg/kg) 
and minocycline (60 mg/kg) significantly reduced total 0.03 mg/kg/inf methamphetamine 
infusions compared to vehicle pretreatment conditions. These results suggest that modulating 
glial cell activity, and consequent neuroinflammatory processes, can modulate abuse-related 
effects of methamphetamine. 
All three compounds, ibudilast, AV1013, and minocycline; reduced infusion rates for 0.03 
mg/kg methamphetamine self-administration. None of the test drugs increased infusion rates of 
0.001 mg/kg/inf, the lowest tested dose of methamphetamine and dose that was not self-
administered under vehicle conditions. These observations suggest that the infusion-rate 
reducing effects of these drugs at the 0.03 mg/kg/inf dose of methamphetamine was not 
attributable to the test drugs "enhancing" the effects 0.03 mg/kg/inf methamphetamine to be 
functionally experienced as a higher dose (and thus, advancing it along the descending limb of 
the dose-effect curve). Instead, the data suggest that the effects promoting methamphetamine 
self-administration were diminished at 0.03 mg/kg/inf by the test compounds. None of the 
compounds, however, affected infusions maintained by the highest self-administered 
methamphetamine dose (0.1 mg/kg/inf).  There are several possible levels of explanation for the 
lack of effect on 0.1 mg/kg/inf methamphetamine-maintained behavior, the first being at the 
neurochemical level.  Methamphetamine’s effects on glial cell activation and induction of pro-
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inflammatory signals have been well established (Yamaguchi et al., 1991; Nakajima et al., 
2004b; Goncalves et al., 2008). Additionally, methamphetamine’s glial cell activation is 
associated with changes in behavior (Miguel-Hidalgo, 2009). In the present study, rats self-
administered methamphetamine at an average of 3.7-4.5 mg/kg/2-h session when given access 
to the 0.1 mg/kg/inf dose, and an average of 2.74-3.2 mg/kg/2-h session methamphetamine at 
the 0.03 mg/kg/inf dose.  Self-administration of both doses are likely high enough to produce 
pro-inflammatory conditions, as it has been shown that a single dose of 1 mg/kg 
methamphetamine administered subcutaneously produces a significant enhancement of 
cytokine and chemokine induction in mice (Loftis et al., 2011). However, perhaps 0.1 mg/kg/inf 
methamphetamine produces a glial response "insurmountable" by the tested doses of ibudilast, 
AV1013, or minocycline. For instance, as the dose of methamphetamine increases, it may 
activate glial cells faster and promote more cytokine transcription to induce its 
neuroinflammatory effects. Thomas et al. (2004a) noted that there was a dose-dependent effect 
of methamphetamine on microglial activation in the mouse striatum. Thus, the test compounds 
may not be effective against those processes recruited at higher doses.    
Relative potency analysis revealed that ibudilast was ~6 times more potent than 
AV1013, and ~13 times more potent than minocycline in reducing self-administration of 
methamphetamine. These data are consistent with my previous report that ibudilast is ~4-7 
more potent in reducing methamphetamine-induced hyperlocomotion in mice than AV1013 
(Snider et al., 2012). These findings also support that while glial cell modulation is sufficient to 
attenuate some methamphetamine-induced behaviors, ibudilast’s PDE inhibition activity may 
have acted in combination with glial suppression.  
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Summary 
The present study established methamphetamine self-administration at levels likely 
great enough to induce glial activation and pro-inflammatory signaling.  Ibudilast, AV1013, and 
minocycline, three compounds that attenuate glial activity, all reduced self-administration of 0.03 
mg/kg/inf methamphetamine. While the mechanism of these effects has yet to be definitively 
identified, the previously published data and the present report, strengthen the linkage between 
glial cell activation, neuroinflammation, and the behavioral effects of abused drugs.  
Clarifying Ibudilast's Behavioral Mechanism of Action and Defining the Limits of its 
Effectiveness 
Ibudilast attenuated rates of self-administration at the self-administered dose of 
methamphetamine that maintained the highest baseline response rate (0.03 mg/kg/infusion), 
and did not significantly affect self-administration of another self-administered dose that 
maintained a lower baseline rate (0.1 mg/kg/infusion). This raises the possibility that there was a 
response-rate determinant of ibudilast's effectiveness. Also, although ibudilast was effective in 
attenuating the locomotor activity and reinforcing effects of methamphetamine, it could not be 
assumed that it would attenuate all effects of methamphetamine. Because of these two 
observations, tests were conducted to determine if ibudilast's effects on methamphetamine self-
administration were attributable to response rate determinants, and other tests were conducted 
to determine if its range of effectiveness and specificity in attenuating methamphetamine's 
effects. 
A possible behavioral mechanism for the effectiveness of ibudilast for reducing 0.03 
mg/kg/inf but not 0.1 mg/kg/inf methamphetamine self-administration may be attributable to a 
rate dependent effect. Dews (1955) reported that a dose of pentobarbital that increases low 
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reinforced rates of responding can also decrease high rates of responding. Thus, a drug’s effect 
on behavior can be a function of the baseline response rate.  In the present study, total 
responses (and infusions) emitted during the sessions in which responding was maintained by 
0.03 mg/kg/inf methamphetamine were greater than that maintained by 0.1 mg/kg/inf 
methamphetamine. Thus, it may be argued that the pre-treatment compounds differentially 
affected responding because baseline responding (i.e. total responses and infusions obtained 
under vehicle-treatment conditions) differed between methamphetamine doses to start. 
However, this explanation is unlikely because when response rates were specifically matched in 
rats maintained by 0.03 and 0.1 mg/kg/inf methamphetamine during Rate Dependency Analysis 
tests, 10 mg/kg ibudilast still did not reduce response rates for 0.1 mg/kg/inf methamphetamine. 
Furthermore, the response rate reductions at 0.03 mg/kg/inf methamphetamine were not likely a 
result of non-specific behavioral suppression because total infusions (and consequently, 
response rate) following pretreatment with ibudilast did not differ from baseline rates at either 
the lowest or highest tested methamphetamine doses in the present study (and they would have 
been if there was non-specific behavioral suppression) nor did ibudilast or AV1013 significantly 
suppress locomotor activity in mice when tested alone under similar dosage regimens (Snider et 
al., 2012). Ibudilast has been reported, however, to produce transient sedation and decreased 
reactivity to touch in the Irwin test in Wistar (Han) rats (Ledeboer et al., 2006). 
In observing the effectiveness of ibudilast reducing methamphetamine self-
administration, the question emerges regarding the degree to which ibudilast's effectiveness is 
restricted to methamphetamine-maintained responding. Considering that ibudilast is a PDE 
inhibitor with likely broad-ranging effects, and that its modulation of glial activity could also have 
broad-ranging down-stream effects, ibudilast is unlikely to be solely specific in affecting 
methamphetamine-maintained as opposed to other reinforcer-maintained responding. It is 
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important, if only from a drug developmental view, to begin to characterize the range of 
reinforced behavior ibudilast can affect. Given these considerations, the effects of ibudilast on 
banana pellet maintained-behavior were examined. It was hypothesized that the baseline 
strength of behavior (i.e., the efficacy of the reinforcer) could determine whether or not ibudilast 
reduced responding. This was somewhat suggested by the observation that ibudilast reduced 
responding maintained by 0.03 mg/kg/inf methamphetamine, and not at the higher dose of 0.1 
mg/kg/inf, and often the higher the dose of a self-administered drug, the greater the reinforcing 
efficacy (Griffiths et al., 1979). To ensure similar baseline strengths of banana- and 
methamphetamine-maintained responding, a behavioral economic approach was used to help 
equate them.  The baseline reinforcing strength (α level) of both non-nutritive banana flavored 
cellulose pellets (banana pellets) and methamphetamine self-administration were successfully 
equated. The baseline reinforcing strengths of these two commodities were generated while 
both reinforcers were controlled within closed economies.     
When tested on a FR1 schedule, all compounds that significantly attenuated 0.03 
mg/kg/inf methamphetamine-maintained responding also attenuated banana pellet 
consumption, with the exception of 10 mg/kg AV1013.  These findings possibly suggest that an 
intermediate dose of AV1013 may be the best potential pharmacotherapeutic as it is the most 
selective for methamphetamine-induced behaviors without affecting non-drug-maintained 
behavior. The initial hypothesis asserted that none of the test compounds would alter food-
maintained behavior because banana pellet consumption does not inherently induce glial cell 
activation and neuroinflammatory activity. There are at least two opposing conclusions that 
could be drawn from the gathered results.  First, all three test compounds affected both 
methamphetamine and food maintained behavior, thus glial cell attenuation could reduce 
behavior maintained by many reinforcer types through a similar mechanism. Mild chronic food 
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restriction (85% body weight restriction), however, does not cause glial cell activation; in fact, 
chronic food restriction attenuates age-related astrocyte and microglial activity (Morgan et al., 
1999).  Hence, it is likely that the test compounds are not attenuating a banana pellet-induced 
inflammatory action to reduce reinforcer-maintained behavior. Furthermore, while the animals 
used for this study had a history of methamphetamine self-administration and abstinent human 
methamphetamine abusers show protracted microglial activation (Sekine et al., 2008), the 
activation is negatively correlated with time of abstinence (Sekine et al., 2008) and can return to 
baseline levels in rodent subjects in as little as seven days (Thomas et al., 2004c).   
A second conclusion that could be drawn from the behavioral economic study results is 
that all three of the test compounds are exhibiting non-specific effects in which all behavior is 
suppressed. As discussed above, while there was no significant effect on locomotor activity in 
mice by ibudilast or AV1013, ibudilast (7.5 and 10 mg/kg) did significantly suppress response 
rates for food pellet delivery in the drug discrimination studies. Minocycline (56 mg/kg) causes 
locomotor activity suppression at 100 mg/kg i.p. (Kofman et al., 1990) and suppresses response 
rates for food pellet reinforcer delivery in a drug discrimination paradigm but response rates are 
only moderately affected by 32 mg/kg minocycline (Munzar et al., 2002). Symptoms such as 
light-headedness, headaches and nausea have all also been reported as side effects of high 
doses of minocycline in humans (Gump et al., 1977). However, disentangling the relationship 
between methamphetamine’s, or any drug’s, specific effects on drug maintained behavior and 
those of “non-specificity” is complex at best. The importance of determining this specificity 
should be based on the usefulness of the drug’s outcome as a potential pharmacotherapeutic.  
If a particular compound reduces drug self-administration by anesthetizing the animal, 
disentangling that relationship is a vital component to determine for the progression of that 
compound as a therapeutic tool. However, there are commonly prescribed 
  
122 
 
pharmacotherapeutics that engender non-specific effects (i.e. side effects). For example, 
methadone is a widely utilized pharmacotherapeutic agent that has been used to help treat 
opiate dependence for almost 50 years (Dole & Nyswander, 1965). Methadone maintenance 
treatment also significantly suppresses food intake in rhesus monkeys, in fact with greater 
specificity than it suppresses heroin self-administration (Mello et al., 1983).  Thus, it may be 
argued that suppression of food intake does not necessarily eliminate a compound from 
consideration as a potential therapy, but rather adds important information to its 
pharmacological profile to be considered in future studies.  
 
Can Baseline Strength Determine Sensitivity to a Drug's Effect 
To evaluate the assumption that a drug would differentially affect reinforced behavior 
when differential baseline strengths were involved, 45 mg food pellets were used as the 
reinforcer when subjects were maintained at three different body weight conditions (85, 90 and 
100% BW).  Initial food pellet reinforcer demand curves indicated that the α level for food when 
maintained at 85% BW produced significantly more demand than when animals were 
maintained at 90% and 100% BW, indicating that the baseline strength (reinforcing efficacy of 
food pellets) at 85% was significantly stronger. When minocycline (30 & 60 mg/kg) was 
administered, there was a significant decrease in total consumption of food compared to 
vehicle, however there was no significant effect of body weight condition.  Likewise, 10 mg/kg 
buspirone produced similar results in significantly decreasing total consumption of food 
independent of body weight condition.  
The differences between the α levels obtained at 85, 90%, and 100% BW conditions 
during the initial reinforcing strength assessment, while statistically significant, displayed a 
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narrow window in demand between which to see differential effects of drug on food-maintained 
responding. Thus, widening the window between the initial demand conditions was 
hypothesized to allow for a better evaluation of differential drug effects. When animals’ percent 
body weight was increased to 115%, they were re-tested under two intermediate doses of 
buspirone.  Again, while the demand for food between the 85% and 115% body weight 
conditions was statistically different, there was no main effect of body weight condition under 
buspirone treatment. The possibility of being below threshold for detecting differences under 
these conditions remains a plausible possibility, however. Any attempt at widening the range 
between α values by manipulation of body weight was precluded by concerns of maintaining the 
animals’ health. A more thorough evaluation of the possibility that baseline strength can be a 
determinant of the sensitivity to a drug's effect (while having a broad range between α values) 
should involve reinforcers not directly essential for health, although this would likely necessitate 
specialized reinforcer delivery equipment that was not available during the present tests.   
General Conclusions 
While seemingly intuitive to assess the effects of test compounds on responding 
maintained by a non-drug reinforcer (i.e. non-nutritive banana pellets) in this manner, the 
limitations of using banana pellets as a reinforcer may preclude further analyses using this 
approach.  For example, animals were observed to respond for but not necessarily eat all 
earned banana pellets during a given session, even while maintained at 85% of their free-
feeding body weight.  Thus, it could be argued that the animals’ responding was maintained by 
conditioned reinforcers other than the banana pellet delivery. However, the purpose of 
generating α levels for methamphetamine and banana pellet maintained responding was to 
approximate the baseline strength of responding for two distinct reinforcers.  Whether those 
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reinforcers were the primary reinforcers themselves (i.e. methamphetamine or banana pellets) 
or conditioned stimuli does not matter. Baseline strengths for methamphetamine and banana 
pellet maintained responding were also matched under incongruent experimental stimuli (i.e. 
active lever, lights, tones), to reduce the probability conditioned stimuli from a 
methamphetamine self-administration history would confound response strengths. Actual 
consumption of the banana pellets was inconsequential to the question posed. The test 
compounds were still assessed against two different reinforcer types while they were 
maintained under similar reinforcing strength regardless of what unconditioned or conditioned 
stimuli the animals were responding to or as a result of.   
Secondly, while differences between α levels for pellet delivery at different body weights 
was significantly different in tests with nutritive food-pellets as the reinforcer, the range of α 
levels was relatively tight perhaps limiting detection of differential drug effects. Widening the 
differences in initial baseline strength would require further food restriction and/or a pre-feeding 
procedure that might compromise the health of the animals or add confounding variables.  
An assessment of any test compounds’ effects on food maintained behavior is still a 
valuable addition to basic information surrounding a potential pharmacotherapy.  Thus, as an 
alternative approach, food (or food-like) reinforcers may be examined concurrently with 
methamphetamine in a choice procedure. Test compounds could then be assessed for their 
ability to re-allocate methamphetamine maintained responding to food maintained responding.  
For example, when cocaine and food are concurrently available, administration of monoamine 
releaser compounds produce right-ward shifts in the cocaine choice dose response curve 
(Negus, 2003; Banks et al., 2011) indicating a reduction in cocaine maintained behavior when 
food is also available. This approach could be developed by first determining whether the two 
reinforcers in question interact with one another before posing the choice. Those interactions, in 
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behavioral economic terms could include two commodities acting as complements, substitutes 
or independents. 
Behavioral economics provides ways for describing interactions between two reinforcers 
such as drug and food in choice procedures (Hursh, 1978; Elsmore et al., 1980; Bickel et al., 
1995). Two reinforcers available concurrently may act as substitutes, complements, or 
independent reinforcers (Hursh, 1980; Hursh et al., 2005). The two reinforcers are considered 
substitutes if consumption of commodity B increases with an increase in price of commodity A 
(Hursh, 1980). Reinforcers are complements when consumption of commodity B decreases with 
increases in the price of commodity A (Hursh, 1980; Hursh & Roma, 2013) indicating that one 
reinforcer affects the reinforcing strength of the second reinforcer. Finally, the price of each 
independent reinforcer has no effect on the consumption of the other (Hursh, 1980; Hursh & 
Roma, 2013). In order to ascertain the specificity of a test compound on attenuating only 
methamphetamine’s reinforcing strength, and not food, the two reinforcers would first need to be 
matched in initial baseline strength and assessed as substitutes, complements, or independent 
reinforcers in a behavioral economic paradigm. This would theoretically allow for an initial 
baseline in which reinforcing strength is equated and interactions between the two commodities 
are noted and controlled for. Then, administration of the test compounds during concurrent 
choice of both reinforcers might elucidate whether the test compounds can re-allocate 
responding to and from drug to food-maintained behavior and interactions of substitutes or 
complement reinforcers does not confound a shift in choice.  
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Chapter V 
Rats trained to discriminate 1 mg/kg methamphetamine from saline emitted 
progressively more methamphetamine-lever responses as methamphetamine dose increased 
until at the training dose and above, nearly 100% of lever presses were emitted on the drug-
associated lever. These results are consistent with previous reports of methamphetamine drug 
discrimination in rats. Methamphetamine drug discrimination is well established, and 
methamphetamine is known to substitute for other stimulants such as ephedrine, cocaine, 
methylphenidate, d-amphetamine (Schechter, 1997b; Bondareva et al., 2002; Sevak et al., 
2009). Further, SKF77434 (a partial D1 agonist), SCH39166 (selective D1 antagonist), 
varenicline (nicotinic agonist), pentobarbital, aripiprazole, and clomipramine (serotonin re-
uptake inhibitor) all attenuate methamphetamine or amphetamine drug discrimination (Tidey & 
Bergman, 1998; Gatch et al., 2005; Lile et al., 2005; Desai & Bergman, 2010). Furthermore, and 
most pertinent for the present studies, nefiracetam and rolipram, two PDE inhibitors, reduce 
methamphetamine drug discrimination in rats (Yan et al., 2004; Yan et al., 2006). Given that 
ibudilast also engenders PDE inhibitory activity, ibudilast was hypothesized to attenuate 
methamphetamine’s discriminative stimulus properties. 
While drug discrimination procedures conventionally utilize a single test drug 
administration during test sessions (Brady & Balster, 1980), cumulative dosing procedures, in 
which multiple administrations of test drug occur between periods of reinforcer availability within 
a single test session, are also used (Walker & Young, 1993). Direct comparison of these two 
types of procedures produce similar dose response relationships and ED50 values for drug-
paired lever responding (Schechter, 1997a). Cumulative dosing testing procedures thus allows 
for rapid data collection and flexibility between procedure types. Similarly, in the present study, 
there were no significant differences between ED50s of methamphetamine generalization 
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between the acute and cumulative dosing procedures. Thus, the cumulative dosing procedure 
was utilized to assess ibudilast’s effects on methamphetamine drug discrimination. 
Ibudilast did not significantly alter methamphetamine drug discrimination when the 
animals were trained with 1 mg/kg methamphetamine. There are several possibilities for why 
this might be the case including both neurochemical and behavioral explanations.  
First, drug discrimination is proposed as a pre-clinical model for the subjective effects of 
a drug (Schuster, 1976; Brady & Balster, 1981). The present study hypothesized that 
methamphetamine’s glial and related neuroinflammatory effects are involved with 
methamphetamine’s discriminative stimulus effects, and these stimulus effects could be 
reduced by attenuating the associated glial effects with the chosen test compounds. Given the 
present results, it remains possible that while methamphetamine-induced neuroinflammation 
may be involved with some aspects of abuse-related behaviors, such as locomotor sensitization 
and self-administration, it may not be involved with methamphetamine's discriminative stimulus 
effects. The drug discrimination procedure can be used to determine the mechanism by which 
drugs of abuse produce their interoceptive effects (Balster, 1990).  Thus, perhaps the proposed 
indirect neurochemical mechanism through which glial cell modulation affects 
methamphetamine-induced behavior (see below) is separate from affecting interoceptive cues. 
In addition to its glial cell modulatory and anti-inflammatory activity, ibudilast is also a non-
selective PDE inhibitor for PDEs 3, 4, 10, and 11 (Kishi et al., 2001; Gibson et al., 2006). 
Rolipram and nefiracetam, two selective PDE4 inhibitors, have been reported to attenuate 
methamphetamine drug discrimination (Yan et al., 2006). While ibudilast is not more selective 
for PDE4 over the others, it has relatively similar binding affinity to that of rolipram at all PDE4 
isotypes (Gibson et al., 2006). Thus, ibudilast’s selectivity is likely not the reason it did not affect 
methamphetamine discrimination while rolipram and nefiracetam were reported to do so. 
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Behaviorally, previous literature has shown that it is plausible to have a disconnection in 
effects between self-administration and drug discrimination involving the same compound 
because the two procedures are measuring different pharmacological effects (Woolverton & 
Balster, 1982). Experimenter-administrated test compounds, such as used in drug 
discrimination procedures, compared to actively self-administered drug, such as in typical self-
administration procedures, can elicit different behavioral, neurochemical, and even proteomic 
differences (Jacobs et al., 2003). Thus, these potential differences could explain the dissociation 
between ibudilast significantly affecting self-administration yet not drug discrimination in the 
present study. Finally, drug discrimination training and tests with ibudilast occurred using a 1 
mg/kg methamphetamine training dose in the present study. However, the training dose utilized 
during a drug discrimination procedure can be a pivotal component of the assay.  For example, 
progressively lowering a PCP training dose produces marked decreases in the ED50 for 
stimulus generalization and parallel leftward shifts of the dose response curves indicative of 
greater stimulus generalization at lower training doses (Beardsley et al., 1987). Further, an 
antagonist can more readily disrupt discrimination of a particular drug when trained at a low 
training dose (Picker et al., 1993). Yan et al (2006) trained animals to discriminate 0.5 mg/kg 
methamphetamine and tested under 0.2 mg/kg methamphetamine conditions. Thus, in order to 
better compare ibudilast's to rolipram and nefiracetam’s effects on methamphetamine drug 
discrimination, the subjects were re-trained in the present study at lower methamphetamine 
training doses (0.56 and 0.3 mg/kg).  
Rats re-trained at 0.56 mg/kg methamphetamine were probed with 10 mg/kg ibudilast 
pretreatment at the 0.56 training dose and there were no significant effects on discrimination. 
Further analysis with the cumulative dosing procedure revealed that under ibudilast’s vehicle 
conditions, the training dose was the lowest methamphetamine dose to completely occasion the 
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0.56 mg/kg discriminative stimulus. Generating the entire dose response curve allowed for the 
possibility that 0.3 mg/kg methamphetamine might produce partial generalization to the training 
dose, in which case ibudilast would have been tested to determine if it could reduce 
generalization. However, 0.3 mg/kg produced near zero methamphetamine appropriate lever 
responding eliminating the opportunity to continue testing ibudilast under those conditions.  
Finally, the remaining animals were retrained at 0.3 mg/kg methamphetamine. While the 
animals eventually acquired the discrimination, performance during their training sessions were 
not as stable or consistent as compared to when animals were trained at 1 mg/kg 
methamphetamine. These findings are consistent with previous reports in that progressively 
lower doses of a training dose increase the number of training sessions required to acquire the 
discrimination and the number of errors occurring on training days following acquisition 
(Beardsley et al., 1987). Generalization test results indicated that 0.56 and 1 mg/kg 
methamphetamine, doses higher than the 0.3 mg/kg training dose, failed to produce full 
generalization to the 0.3 mg/kg training stimulus, and this uncharacteristic result of well-trained 
discriminative performance suspended enthusiasm to proceed with ibudilast testing.  
In sum, ibudilast did not significantly affect methamphetamine generalization when 
involving cumulative dosing procedures when rats were trained at 1 mg/kg methamphetamine, 
or when tested with an acute dose of 0.56 mg/kg methamphetamine when animals were 
retrained at 0.56 mg/kg.  Stimulus control was not stable enough to warrant further testing with 
animals trained at either 0.56 or 0.3 mg/kg.   
Potential mechanisms connecting methamphetamine, PDE, inflammation, and behavior 
How methamphetamine promotes neuroinflammation precisely is not yet known.  
Reactive oxygen species, substance P, and dopamine quinones contribute to 
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methamphetamine-induced cellular damage and apoptosis (Fleckenstein et al., 1997; Zhu et al., 
2006). As a result of the damaged cells and neurotoxicity, astrocytes and microglia become 
activated and elicit an immune response and increase pro-inflammatory cytokine production 
(Kita et al., 2008; Clark et al., 2012). While cell damage and death is a common catalyst for 
inflammation induction, methamphetamine’s effects on inflammatory pathways can also 
temporally occur before dopamine cell terminal pathology (LaVoie et al., 2004).  Furthermore, 
there is growing evidence that psychostimulants can activate both astrocytes and microglial 
cells directly through a variety of mechanisms (Beardsley & Hauser, 2014). Thus, 
methamphetamine-induced inflammation can occur at non-neurotoxic levels and independently 
of cell damage. One mechanism that has been proposed for methamphetamine-induced 
inflammation via the nuclear transcription factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) (Shah et al., 2012).  Methamphetamine’s release of excitatory neurotransmitters 
activates the metabotropic glutamate receptor, mGluR5. mGluR5 is described to activate the 
intracellular signaling pathway, AKT/PI3K, that downstream induces the release of NF-κB, 
which, in turn, translocates to the nucleus to promote transcription of inflammatory cytokine 
proteins such as TNFα, IL-6 and IL-8 (Shah et al., 2012).  
Bacterial lipopolysaccharide (LPS) is a gram-negative endotoxin that stimulates 
inflammation via toll-like receptor-4 (TLR-4) (Chow et al., 1999). Methamphetamine and LPS 
both induce inflammation through the AKT/PI3K pathways and induce NF-κB to translocate to 
the nucleus and promote transcription of inflammatory cytokines (Ojaniemi et al., 2003; Shah et 
al., 2012).  Methamphetamine exacerbates LPS’s inflammatory signal (Liu et al., 2012a). These 
effects are likely attributable to both compounds acting via NF-κB, MAPK, and AKT/PI3K 
pathways (Liu et al., 2012a). Ibudilast and AV1013 antagonize macrophage migration inhibitory 
factor (MIF) (Cho et al., 2010), a pro-inflammatory factor essential for TLR-4 function and 
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inflammatory response (Roger et al., 2001).  If LPS and methamphetamine’s inflammatory 
signals are similar, ibudilast and AV1013’s antagonism of the TLR-4 receptor via modulation of 
MIF may be one mechanism in which these compounds are reducing cytokine production and 
inflammation.  Furthermore, ibudilast reduces nuclear translocation of p65, a subunit of NF-κB, 
potentially suggesting a mechanism for ibudilast’s reduction of MIF (El-Hage et al., 2014). 
AV1013's minimal PDE inhibitory effects could contribute to its lower efficacy relative to ibudilast 
in attenuating methamphetamine induced locomotor activity in mice and on-going self-
administration in rats. AV1013's lower efficacy in these assays could be due to reduced potency 
at the drugs' glial targets. AV1013 is a less potent inhibitor of MIF with a Ki = 74.9 (± 8.5) μM 
than is ibudilast, which has a Ki of 30.9 (± 2.8) μM (Cho et al., 2010). Given this, AV1013 may 
be less effective in reducing methamphetamine activity due to a combination of decreased 
potency at both PDE and glial targets. Interestingly, morphine’s inflammatory response occurs 
when the glycoprotein, MD-2, forms a complex with TLR-4 and induces inflammation similar to 
LPS (Wang et al., 2012a), thus providing evidence for ibudilast’s mechanism of action in 
reducing opioid-induced inflammation and behavior as well.  
Minocycline also inhibits pro-inflammatory action of microglia without affecting the anti-
inflammatory functionality of the cells (Kobayashi et al., 2013). Minocycline’s proposed 
mechanism also includes interaction with LPS and the NF-κB pathway.  Minocycline prevents 
LPS induced degradation of Iκbα, an inhibitory factor, which ultimately prevents NF-κB 
translocation to the nucleus and induction of inflammatory cytokine production (Nikodemova et 
al., 2006). Minocycline also decreases binding of NF-κB to DNA which disrupts transcription 
(Bernardino et al., 2009). Thus, all three test compounds are hypothesized to inhibit 
inflammation and methamphetamine-induced behaviors via a similar neurochemical pathway. 
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How attenuation of glial cell activation and neuroinflammatory activity translates into 
modulating methamphetamine's behavioral effects is also unknown. However, stimulant-
activated glial cells can respond, as a result, to influence the behavioral effects of the drug 
(Beardsley & Hauser, 2014). One proposed mechanism involves the ability of glial cells to 
regulate neurotransmission and synaptic strength by affecting the cell surface delivery and 
retention of glutamatergic NMDA and AMPA receptors (Eroglu & Barres, 2010). Interestingly, an 
up-regulation of TNFα, elicited from activated astrocytes, increases AMPA receptor expression 
on the cell surface and increases NMDA and AMPA receptor-mediated synaptic currents 
(Beattie et al., 2002; Stellwagen & Malenka, 2006) that improves synaptic efficacy. Conversely, 
blockade of TNFα has the opposite effect (Beattie et al., 2002). Therefore, methamphetamine-
induced increases in TNFα could indirectly increase the concentration of AMPA receptors and 
their activation. In contrast, ibudilast and AV1013's attenuation of TNFα levels would inhibit 
delivery of these receptors preventing signaling and synaptic change. Excessive activation of 
both AMPA and metabotropic glutamate receptors may play a role in behavioral sensitization 
and in the rewarding properties of stimulants such as cocaine and methamphetamine (Wolf, 
1998). Thus, the blockade of these processes may be a link to suppressing the effects of 
stimulant drugs. 
What about PDE inhibition?  
Increases in cAMP, by a PDE inhibitor like rolipram for example, reduce microglial 
activation as well (Atkins et al., 2007). TNFα levels may also be affected via cAMP production, 
which reduces further TNFα synthesis (Kast, 2000; Shames et al., 2001). Thus, under ibudilast 
treatment, increasing cAMP and inhibiting TNFα synthesis both work to reduce further glial 
activation. Consistently, elevations in inflammatory cytokines such as TNFα and IL1-β reduce 
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the level of cAMP in microglia that can be reversed by PDE inhibition (Ghosh et al., 2012) 
suggesting that PDE inhibition can be a potential therapeutic target even after the initial 
inflammatory response has occurred.   
Amphetamine derivatives, including methamphetamine and MDMA, have been identified 
as agonists for an orphaned GPCR, the rat trace amine receptor (TAAR1), and work to up-
regulate cAMP release (Bunzow et al., 2001).  TAAR1 is widely distributed and co-expresses 
with both DAT and D2 receptors on DA neurons (Xie & Miller, 2007; Espinoza et al., 2011).  
Cells incubated in 8-Bromo-cAMP mediated a PKA-dependent up-regulation in DAT uptake of 
extracellular substrates (Batchelor & Schenk, 1998; Page et al., 2004) indicating cAMP’s 
importance in DAT functionality. Further, MDMA was suggested to auto-inhibit dopaminergic 
transmission via recruitment of TAAR1 (Di Cara et al., 2011) suggesting that TAAR1 is a 
negative modulator of DAT (Xie & Miller, 2007). Interestingly, TAAR1 knockout mice exhibited 
significantly more sensitization to amphetamine than wild type mice and TAAR1 decreased the 
firing rate of DA neurons in the VTA suggesting that TAAR1 is also a negative modulator of the 
behavioral effects of amphetamines (Lindemann et al., 2008). With ibudilast administration it 
remains a possibility that an increase in cAMP, given its PDE inhibitory activity, might act to 
recruit TAAR1 receptors to negatively modulate methamphetamine’s neurochemical and 
behavioral effects. In sum, perhaps ibudilast's PDE inhibition and glial modulatory effects are 
working in conjunction to produce the observed results. 
 
Future Directions 
Ibudilast and AV1013 are suggested to inhibit the p65 subunit of NF-κB which 
subsequently inhibits its translocation to the nucleus and subsequent pro-inflammatory release 
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(El-Hage et al., 2014).  However, is there a molecular correlation between inflammatory activity 
expression and behavior? The literature has suggested that a single bolus dose of 1 mg/kg 
methamphetamine administered subcutaneously produces a significant enhancement of 
cytokine and chemokine induction in mice (Loftis et al., 2011).  If separated into individual 
treatment groups, an important future direction would be to examine the ability of daily 
methamphetamine self-administration to produce cytokine and chemokine induction, as well as 
the ability of the test compounds ibudilast, AV1013, and minocycline to reduce that induction in 
vivo. Further analysis of these hypotheses would include an examination of the molecular time-
course of methamphetamine’s induction of glial cell activation, the test compounds’ ability to 
reduce it, and whether a tolerance to the immune reduction occurred following chronic 
treatment. 
In order to further clarify the range of behavior, beyond that modified by 
methamphetamine, that these glial cell modulators attenuate it would be important to expand 
upon the banana pellet and food-maintained behavior studies. The banana pellet studies 
suggested that the test compounds do not just solely reduce methamphetamine-affected 
behavior.  The second control procedure attempted to examine drug effects on differential 
reinforcer demand, however there were health-related and potentially behavioral limitations 
using food reinforcement. An expansion of this line of study might include testing alternative 
reinforcers when baseline reinforcing efficacy is matched to that of self-administration.  For 
example, would ibudilast attenuate a reinforcer that is not consumable such as intracranial self-
stimulation (ICSS)? Another advantage to using ICSS would be the ability to differentially control 
a wider range of baseline strengths of behavior by altering the frequency of stimulation.  
 Finally, in addition to the development of a potential pharmacotherapeutics for treating 
drug-abuse behavior, there may also be some validity in exploring the possibility of alternative 
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interventions such as healthy diet regimens to reduce inflammatory activity in the CNS.  Thus, 
would altering an abuser’s diet and nutrition be enough to reduce drug abuse behavior? The 
literature suggests that dibenzocyclooctadiene lignans from the fruit of Schisandra wilsoniana, a 
plant grown in Asia, attenuates agonist-induced action of the TLR2/4 receptor on microglia by 
inhibiting MAPK and NF-κB pathways (Park et al., 2013).  More readily recognizable foods 
available in the US, including pomegranate (Rojanathammanee et al., 2013) onion, oregano, 
and red sweet potato, also show the ability to reduce microglial activation even following 
standardized “cooking” preparation (Gunawardena et al., 2014). Cinnamon and fresh ginger 
also exhibit anti-inflammatory activity and attenuate microglial activation via the NF-κB pathway 
(Ho et al., 2013a; Ho et al., 2013b). Thus, while an alteration in an addict’s diet may likely not 
produce full abstinence, perhaps different types of nutrition programming used in conjunction 
with behavioral and/or pharmacological therapies could be beneficial in sustaining abstinence 
and reducing the risk of relapse. 
 Finally, the growing literature regarding the linkage between glial cell modulators 
affecting stimulant abuse behavior has initiated the study of both ibudilast and minocycline in 
clinical trials.  Minocycline significantly reduced the “feel good drug effects” and “I feel high” 
subjective ratings of d-amphetamine in an outpatient procedure using non-dependent healthy 
volunteers (Sofuoglu et al., 2011). Furthermore, ibudilast is now in Phase IIb clinical trials to 
assess its safety and efficacy in treatment seeking methamphetamine dependent volunteers 
half of whom are also HIV positive. This trial will also be sufficiently powered to ascertain 
whether ibudilast can significantly improve methamphetamine abstinence over the two-week 
treatment period (Johnson & Iwaki, 2014). 
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Conclusions 
 Methamphetamine’s induction of glial cell activation and neuroinflammatory activity 
causes effects in the periphery, CNS, and on behavior.  The present dissertation supports 
evidence that there is a linkage between glial cell modulation and abuse-related behavior. The 
glial cell modulators ibudilast and AV1013 were observed to significantly attenuate 
methamphetamine-induced locomotor activity and sensitization in mice. In addition, ibudilast, 
AV1013, and minocycline significantly attenuated methamphetamine self-administration in rats. 
The range of abuse-related behavior that ibudilast could affect, however, had limits in that it did 
not alter methamphetamine’s discriminative stimulus effects.  
Each of these three assays illustrates a different component of drug abuse and thus all 
three were important to assess as a collection.  The results suggest that glial cell modulation 
affects drug abuse-related behaviors associated with methamphetamine-induced hyperactivity, 
sensitization and drug seeking, however they do not suggest a linkage with the subjective cues 
of methamphetamine intoxication.  Furthermore, studies utilizing a behavioral economics 
approach indicated that these glial cell modulators may also affect behavior maintained by 
alternative reinforcers, such as non-nutritive banana pellets, in which case further studies may 
be warranted to assess the extent to which these compounds affect behavior maintained by 
other reinforcers. In summary, compounds that modulate glial cell activation and 
neuroinflammatory activity appear to be associated with some methamphetamine abuse-like 
behaviors, and while there is more to understand regarding these mechanisms, compounds 
such as those tested may provide novel targets for potential drug abuse pharmacotherapeutics.  
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